

INDEX

A

- American Oil Chemists Society (AOCS), 220, 221
- Amylopectin, 12–13
- Amylose, 12
- Anaerobic co-digestion, FVW, 104–106
- Anaerobic digestion, FVW
 - biodegradation waste management, 103–104
 - choice of temperature, 101
 - potential for material recovery, 102
 - reaction scheme, 101
- Apogossypol, 225
- Apple pomace
 - for fatty acid production, 78
 - for heteropolysaccharide-7 production, 79
 - for lactic acid production, 78–79
- Aspergillus niger*, 73–74

B

- Bacillus licheniformis*, 194
- Balsamic vinegar. *See* Traditional balsamic vinegar (TBV)
- Barrel cask, TBV production process
 - aging
 - definition, 163
 - physical ripening time, 166–168
 - residence time, 164–166
 - configuration, 160
 - process streams types, 159
 - refilling procedure
 - degree of freedom (DOF) analysis, 163
 - Fickian model, 161–162
 - mass transfer, 161
 - vectorial concentration model, 162–163
 - residence time (RT), 160–161
 - yield, 161
- Beer brewery waste, 97
- Beetroot, coloring agents, 86
- Bioadsorbents for wastewater treatment
 - dyes adsorption, 97–98
 - metal ions biosorption, 94–97
- Biodiesel production, 107–108

- Biopolymeric nanostructured particles
 - hydrolyzed protein, 194
 - polysaccharides, 194
 - protein–polysaccharide mixtures, 194–195
 - whole proteins, 193
- Borohydride, 222–223
- Bound gossypol (BG), 220, 221, 229, 231, 232

C

- Candida utilis*, 71
- Carboxymethylchitin, 91, 92
- Carotenoids, seafood wastes, 91
- Cauliflower, FVW, 83–84
- Ceratocystis fimbriata*, 75
- Chemoinformatics
 - chemical space exploration, 35–36
 - computational methods, classification and definition, 35
 - definitions, 34
 - in food chemistry
 - chemical space comparison, 41
 - physicochemical properties
 - distribution, comparison, 42
 - toxicity, 40
 - food-related components
 - molecular docking, 49–52
 - molecular similarity, 43–47
 - pharmacophore model, 47–48
 - QSAR and QSPR, 48–49
 - molecular databases and chemical space
 - Distributed Structure-Searchable
 - Toxicity (DSSTox), 38
 - DrugBank, 39
 - generally recognized as safe (GRAS)
 - compounds, 38
 - MMSINC database, 39
 - National Cancer Institute (NCI)
 - database, 39
 - Protein and Bioactive Peptide Sequences (BIOPEP), 39
 - SuperScent, 39
 - molecular descriptors and
 - physicochemical properties, 36–37

Chenopodium quinoa, 19

Cotton and cottonseed products, 216–218

Cyanoborohydrate, 223

D

Dairy industry wastes, 65–66

Dairy wastes

aerobic treatment, 111–116

anaerobic treatment, 108–111

Differential scanning calorimetry (DSC), 14

Docosahexaenoic acid (DHA), 15

E

Eicosapentaenoic acid (EPA), 15

European Landfill Directive, 60

F

Fermentation industry wastes, 64–65

Fermentation, TBV production process

acetic acid bacteria

ecological studies, 157–158

oxidation products, 158–159

scalar fermentation, 154–156

yeast and alcoholic fermentation

product, 157

zygosaccharomyces, 156

Food chain management (FCM)

for sustainable food system development,
116

food market focus, 118–119

integrated product development and
sustainability, 118

market-oriented research, 117–118

user-oriented innovation in food
sector, 117

Food materials structuring process

electrospraying, 190–191

homogenization, 186–188

microfluidization, 188

milling, 186

rapid expansion of supercritical solution
(RESS), 191–192

ultrasound, 188–190

Food-related components,

chemoinformatics

molecular docking

Autodock, 49, 52

improvement areas, 49

Protein Data Bank, 49

QSAR models, 50–51

molecular similarity

fusion methods, 43

G-protein coupled receptor (GPCR), 44

odor-structure relationships, 45–46

OpenEye scientific software
(OpenEye), 45

stereochemical theory, 45

pharmacophore model, 47–48

QSAR and QSPR, 48–49

Food waste processing

FCM, sustainable food system
development, 116

food market focus, 118–119

integrated product development and
sustainability, 118

market-oriented research, 117–118

user-oriented innovation in food
sector, 117

fruit-and-vegetable wastes (FVWs),
63–64

multifunctional food ingredient
production, 82–93

recovering added-value products,
69–82

green production processes, development

food production, holistic approach,
61–62

green production strategy, 62–63

waste management hierarchy, 60–61

problems and opportunities, 58–60

anaerobic digestion (AD), 59

CO₂ emissions, 59

low levels of suspended solids and
dissolved materials, 59

restrictions on waste, 60

sources and characterization

dairy industry, 65–66

fermentation industry, 64–65

fruit-and-vegetable wastes (FVWs),
63–64

meat and poultry industry, 67–68

olive oil industry, 64

seafood by-products, 68–69

using eggshell, 98

vegetable residues for wastewater
treatment

dyes adsorption, 97–98

metal ions biosorption, 94–97

waste treatment

aerobic treatment of dairy wastes,
111–116

anaerobic treatment of dairy wastes,
108–111

- of aqueous food industry waste streams, 100
- biodiesel production, 107–108
- bioprocessing of FVWs, 100–107
- whey, added-value products, 98–100
- Free gossypol (FG), 221, 229, 231, 233
- Fruit-and-vegetable wastes (FVWs), 63–64
 - bioprocessing, 100–107
 - multifunctional food ingredient
 - production, 82
 - coloring agents and antioxidants, 84–86
 - dietary fibers, 83–84
 - food preservation, 88–89
 - gelation properties, 87
 - meat waste derivatives, 89–91
 - oil and meal, 88
 - production of biopolymers, films, food packaging, 89
 - seafood waste derivatives, 91–93
 - recovering added-value products
 - SSF of fruit/vegetable by-products, 70–82
 - vegetable industry challenges, 69–70
- Fusarium oxysporum*, 73, 74

G

- Gelatin, 92–93
- Glucosamine, 91–92
- Goldenberry pomace, 88
- Gongronella butleri*, 80
- Gossypol, cotton plant
 - agricultural implication
 - antifeeding activity, 228–229
 - detoxification, 232–233
 - insecticidal activity, 228
 - toxicity, 229–232
 - analyses, 225
 - AOCS methods, 227
 - enzyme-linked immunosorbent assays (ELISA), 227
 - high-performance liquid chromatography (HPLC) method, 226–227
 - near-infrared reflectance, 226
 - biological properties
 - anticancer activity, 237–242
 - antifertility activity, 235–237
 - antimicrobial activity, 247–248
 - antioxidant property, 234–235
 - antiparasitic protozoan activities, 244–247
 - antivirus activity, 242–243
 - plasma cholesterol levels, 248–249
 - clinical implication, 249–251
 - cotton and cottonseed products, overview, 216–218
 - occurrence, 218
 - physiochemical properties, 218
 - apogossypol, 225
 - chemical formula, 219
 - methylation, 224
 - naphthalene rings, 220
 - oxidation, 223
 - ozonolysis, 223–224
 - Schiff base reaction, 221, 222
 - structure, 219
 - tautomeric forms, 220
- G-protein coupled receptor (GPCR), 44
- Grape must production, TBV
 - chemical changes, 153–154
 - cooking time effect, 155
 - physical changes, 154
 - solute concentration, 151–153
- Grape pomace, 75
- Grapes, 85–86

H

- Hydrogen–methane two-stage fermentation, 105
- 5-Hydroxymethyl furfural (HMF), 153
- Hydroxytyrosol, 84
- Hypokalemia, 249–250

L

- Lactic acid bacteria (LAB), 93
- Lipids and lipidic compound, Quinoa
 - docosahexaenoic acid (DHA), 15
 - eicosapentaenoic acid (EPA), 15
 - fatty acid composition, 15, 17
 - polyunsaturated fatty acids (PUFA), 16
 - squalene and phytosterols, 17
- Liposomes, 203
- Lycopene, 81

M

- Meat and poultry industry wastes, 67–68
- Melanoidins, 153, 174
- Molecular databases and chemical space, chemoinformatics
 - Distributed Structure-Searchable Toxicity (DSSTox), 38
 - DrugBank, 39

- Molecular databases and chemical space, chemoinformatics (*cont.*)
 generally recognized as safe (GRAS) compounds, 38
 MMsINC database, 39
 National Cancer Institute (NCI) database, 39
 protein and bioactive peptide sequences (BIOPEP), 39
 SuperScent, 39
- Molecular docking, 49–52
- Molecularly imprinted polymer (MIP) techniques, 201
- Molecular similarity
 fusion methods, 43
 G-protein coupled receptor (GPCR), 44
 odor-structure relationships, 45–46
 OpenEye scientific software (OpenEye), 45
 stereochemical theory, 45
- N**
- Nanosensors and nanotracers
Escherichia coli, 200
 molecularly imprinted polymer (MIP) techniques, 201
 molecular recognition, 199
- Nanostructured materials
 aggregates disruption, 188–189
 biopolymeric nanostructured particles
 hydrolyzed protein, 194
 polysaccharides, 194
 protein-polysaccharide mixtures, 194–195
 whole proteins, 193
 food materials structuring process
 electrospaying, 190–191
 homogenization, 186–188
 microfluidization, 188
 milling, 186
 rapid expansion of supercritical solution (RESS), 191–192
 ultrasound, 188–190
 functionality and applications
 encapsulated food components, 202–205
 food packaging and edible coatings, 201–202
 nanosensors and nanotracers, 199–201
 future of, 206–207
 high-pressure homogenization effects, 188–189
 lipid nanoparticles, 195–196
 microencapsulated food components, 204–205
 microfluidization effects, 188–189
 nanocomposites, 198–199
 nanoscale manipulation, 185
 nanostructured emulsions
 double emulsions, 197
 microemulsions, 197
 simple oil-in-water emulsions, 197
 structuring emulsions, functionality, 198
 nanotechnology and society, 206
Neurospora crassa, 73, 74
- O**
- Oleuropein, 84
 Onion wastes, 85
 OpenEye scientific software (OpenEye), 45
- P**
- Pectin, 87
 Pectin methylesterase, 73
Penicillium decumbens, 73, 74
 Pharmacophore model, 47–48
 Phytosterols, 17
 Polyunsaturated fatty acids (PUFA), 16
- Q**
- QPs. *See* Quinoa proteins
- Quantitative structure–activity relationships (QSARs) models, 35, 48–49
- Quantitative structure–property relationships (QSPRs), 48–49
- Quinoa
 antioxidant capacity, phenolic compounds, and flavonoids, 18
 carbohydrates
 amylopectin, 12–13
 amylose, 12
 differential scanning calorimetry (DSC), 14
 gelatinization properties, 14
 glucose polymers, 11–12
 granule size, 13
 polysaccharides, 12
 thermal properties, 14
 chemical, nutritional, and physical properties, 4–6
 chenopodium species, 2–3
 functional properties

- quinoa flour, 21–23
- quinoa protein, 23
- quinoa starch, 24
 - water-holding capacity (WHC), 21
 - water imbibing capacity (WIC), 21
- lipids and lipidic compound
 - docosahexaenoic acid (DHA), 15
 - eicosapentaenoic acid (EPA), 15
 - fatty acid composition, 15, 17
 - polyunsaturated fatty acids (PUFA), 16
 - squalene and phytosterols, 17
- minerals and vitamins, 19–20
- proteins
 - active biopeptides, 9
 - chemical and nutritional aspects, 6–9
 - structural aspects, 9–10
- pseudocereal, 3
- saponins, 18–19
 - uses of, 24–25
- Quinoa flour
 - emulsifying capacity and stability, 22–23
 - functional properties, 22
 - solubility, 21
- Quinoa proteins (QPs)
 - active biopeptides, 9
 - chemical and nutritional aspects
 - amino acids composition, 6–9
 - protein efficiency ratio (PER), 7
 - structural aspects, 9–10
- Quinoa starch
 - functional properties, 24
 - structure, 11–15

R

- Rapid expansion of supercritical solution (RESS), 191–192
- Residence time (RT), 160–161, 164–166
- Rhizopus oligosporus*, 96
- Rhodopsin, 44

S

- Saponins, 18–19
- Seafood by-products wastes, 68–69
- Seafood wastes, derivatives
 - carotenoids production, 91
 - gelatin production, 92–93
 - glucosamine and carboxymethylchitin production, 91–92
 - marine peptone production, 93
- Solid-state fermentation (SSF),
 - fruit/vegetable by-products

- antibiotics, 81–82
- apple pomace, 70–71
- aroma compounds production, 74–75
- baker's yeast production, 80
- enzymes production, 71–74
- ethanol production, 75–78
- feed protein, 81
- organic acids production, 78–79
- pigments production, 80–81
- polysaccharides production, 79–80
- Squalene, 17
- Supercritical fluid anti-solvent (SAS) process, 191

T

- Thermophilic bioremediation technology, 111–116
- Total gossypol (TG), 221, 233
- Traditional balsamic vinegar (TBV)
 - chemical composition
 - characteristics, 169
 - composition, 174–175
 - furanic compounds, 173–174
 - melanoidins, 174
 - minor compounds, 171–174
 - organic acids, 170–171
 - phenolic compounds, 172–173
 - sugars, 169–170
 - volatile compounds, 171
 - condiments, 139, 141
 - conservative mass balance equation, 151–153
 - consortia, 138–139
 - features, 142–143
 - historical note
 - comprehensive research, 140–141
 - production aspects, 144–145
 - testimonies, 141–144
 - 5-hydroxymethyl furfural, 153
 - legal aspects, 147–148
 - physical properties
 - color and spectrum absorbance, 176–177
 - rheological properties, 176
 - production process
 - barrel set, 159–168
 - cooking technology, 151–154
 - cooking time effect, 155
 - fermentation, 154–159
 - raw material, 149–151
 - semitic languages and italian legislation in European languages, 146

Traditional balsamic vinegar (TBV) (*cont.*)
 traditional *vs.* industrial, 146–147
 various forms, 145
 sensorial aspects, 148
 vinegars, 139–141
Tuna fin gelatin (TFG), 92–93

U

UK's Waste and Resources Action Program
 (WRAP), 59
User-oriented innovation in food sector, 117

V

Vegetable residues for wastewater
 treatment
 dyes adsorption, 97–98

 metal ions biosorption, 94–97
Vinegar. *See* Traditional balsamic vinegar
 (TBV)

W

Waste management strategies, 62–63
Waste recovery, 62
Whey utilization and disposal, 99–100

X

Xanthan gum, 79

Z

Zirconium, 96
Zygosaccharomyces, 156



A

- AAC. *See* Antioxidant activity coefficient
- Acid degree value (ADV) method, 178–179
- Aeluropodeae, 217
- Alcoholic fermentation, 49, 54. *See also*
Fermentation process
- American trypanosomiasis
diagnoses and treatment, 67–68
discovery, 65–66
with food
Brazil, 72–77
Chacao city, 77
history, 64–65
oral route transmission
animals, 69–70
humans, 70–71
T. cruzi strain, 72
phases and symptoms, 67
T. cruzi
control (in food), 78–80
life cycle, 66–67
transmission routes, 68–69
- Antioxidant activity coefficient (AAC), 227
- Aroma extract concentration analysis (AECA), 196
- Aroma extract dilution analysis (AEDA), 196
- Artificial neural networks, 96

B

- Balsamic vinegars of Modena (BVM), 141–144
- Beer, 137–138
- BHA. *See* Butylated hydroxy anisole
- Biomarkers. *See* Milk fat biomarkers
- Boehringer Mannheim kits, 174, 176
- Botrytis cinerea*, 47–48
- Bureau of Dairy Industry (BDI) method.
See Acid degree value method
- Butylated hydroxy anisole (BHA), 230
- BVM. *See* Balsamic vinegars of Modena

C

- Calcium flux mechanisms, 27–28
- Carbohydrate composition, ragi
nonstarchy polysaccharide, 233–236
starch, 231–233
- Cardiovascular diseases (CVDs), 6, 11–13
- Cereals, geographical origin
discriminant analysis, 118
¹H NOESY spectrum, 116–117
- Chagas disease transmission. *See also*
American trypanosomiasis
oral route transmission
animals, 69–70
humans, 70–71
T. cruzi strain, 72
outbreaks with food, Brazil
Barcarena city, 76
Belém city, 74
Catolêdo Rocha, 74–75
Chacao city, 77
Estrela, 73–74
Macaúbas city, 76–77
Pan American Health Organization (PAHO), 73
routes, 68–69
- Chamomile flowers (*Matricaria recutita* L.), 127–128
- CHD. *See* Coronary heart disease (CHD)
- Cheese
compositional analysis
acidity and pH, 172–173
ash, 172
calcium and phosphorus, 173
fat, 171
moisture and total solids, 169, 171
protein, 171–172
salt and chloride content, 172
standard methods, 169–170
- FTIR spectroscopy
NIR and MIR, 197
partial least-squares regression model, 199
principle, 196–197

Cheese (*cont.*)

- sampling techniques, 197–198
- spectra of Cheddar cheese, 198–199
- TruDefender™ FT handheld, 199–200
- geographical origin
 - Emmental, canonical analysis of, 113–114
 - Italian Parmigiano Reggiano *vs.* east European Grana-type samples, 114, 116
 - mozzarella, 113
 - Parmigiano Reggiano, ¹H NMR spectrum of, 114–115
- quality and authenticity, 151–153
- ripening process
 - citrate metabolism assessment, 176
 - lactose and lactate
 - assessment, 174–178
 - lipolysis assessment, 178–180
 - proteolysis assessment, 180–194
 - smaller breakdown products
 - assessment, 194–196
 - sampling techniques, 168–169
- Chemometrics. *See also* Geographical origin of foods; Quality and authenticity of foods
 - artificial neural networks, 96
 - monivariate statistical analysis, 92–93
 - multivariate statistical analysis
 - applications, 93
 - compression technique, 93–94
 - DA and independent component analysis (ICA), 94
 - partial least squares
 - projections, 95–96
- Chromatography, proteolysis assessment
 - GC-FID chromatogram of cheddar, 192, 194
 - IEC and SEC, 190–191
 - RP-HPLC, 191–192
 - water-soluble component extraction, 192–193
- CLA. *See* Conjugated linoleic acid
- Cocoa, 130–131
- Cod liver oil, 128
- Conjugated linoleic acid (CLA), 18
- Copper soaps method, 178
- Coronary heart disease (CHD), 24–26
- CVDs. *See* Cardiovascular diseases
- Cynodontae, 217

D

- Dairy food consumption. *See also* Obesity-related chronic disease
 - CLA effects, 18
 - individual dairy foods effects, 21–23
 - micronutrients effects, 15–17
 - milk composition and percent contribution, 13–15
 - milk-derived peptides effects, 17
 - obesity-related chronic disease
 - and cardiovascular diseases, 11–13
 - and dietary fat, 6–7
 - metabolic syndrome and type 2 diabetes, 10–11
 - and weight management, 8–10
 - saturated fats, 18–20
 - total dairy fats, 20–21
 - trans-fatty acids effects, 17–18
- Dairy products
 - cheese, 151–153
 - milk, 150–151
- Discriminant analysis (DA), 94, 96

E

- Electrophoresis, cheese ripening
 - capillary, 190
 - isoelectric focusing (IF), 189
 - sample preparation and staining, 188–189
 - types and application, 188
- Eleusine coracana*
 - composition
 - AAC, 227
 - α -amylase inhibitor, 242–243
 - benzoic acid, 228
 - BHA, 230
 - caffeic acid, 227
 - carbohydrate, 231–236
 - coumaric acid, 227
 - ferulic acid, 227
 - Folin-Ciocalteu method, 228
 - gallic acid, 228–231
 - mineral, 226
 - nitrogen and calcium, 225
 - nonstarchy polysaccharide, 233–236
 - phenolic acids, 227
 - polyphenol, 227–228, 230
 - protein, 225, 236–243
 - starch, 231–233
 - tannin, 227–228
 - testa, 228
 - total lipids, 225

- trypsin/ α -amylase inhibitor, 242–243
- zinc, 226
- cultivation
 - antiquity, 223
 - expressed sequence tags, 225
 - seed development, 223–224
- glycemic index, 251–252
- herbicides and genetic transformation, 253
- processing and utilization
 - amino acid composition, 247
 - amylase activity, 247
 - flour, 243–244
 - NPU, 246
 - parboiling and decortication, 251
 - PER, 246
 - properties, 244–245
 - sprouting, 249
- taxonomy
 - Chloridoideae, 217–218
 - chromosome number, 218
 - distribution, Africa and India, 221
 - fluorescent *in situ* hybridization, 219
 - inflorescence morphology, 217–218
 - landrace, 221–222
 - linkage map, 222–223
 - restriction pattern analysis, 219
 - sequenced amplicons, 220
 - tetraploid species, 219
- Eleusine indica*, 218–220, 235
- Eragrostidae, 217
- Extra virgin olive oil (EVOO). *See* Olive oil

F

- Fat oxidation mechanisms, 27–29
- Fecal fat excretion mechanisms, 27–28
- Fermentation process
 - alcoholic fermentation, 49, 54
 - pesticides residues, 57–58
 - yeasts, 54–57
- Finger millet. *See* *Eleusine coracana*
- Fish
 - geographical origin, 121–122
 - quality and authenticity, 149–150
- Folin–Ciocalteu method, 228
- Food characterization. *See also* Geographical origin of foods; Quality and authenticity of foods
 - analytical online system, 89–90
 - chromatographic techniques, 89
 - omics techniques, 90
- Fourier-transform infrared (FTIR) spectroscopy

- NIR and MIR, 197
- partial least-squares regression model, 199
- principle, 196–197
- sampling techniques, 197–198
- spectra of Cheddar cheese, 198–199
- TruDefender™ FT handheld, 199–200

G

- Geographical origin of foods
 - cereals
 - discriminant analysis, 118
 - ¹H NOESY spectrum, 116–117
 - chamomile flowers (*Matricaria recutita* L.), 127–128
 - cheese
 - Emmental, canonical analysis of, 113–114
 - Italian Parmigiano Reggiano *vs.* east European Grana-type samples, 114, 116
 - mozzarella, 113
 - Parmigiano Reggiano, ¹H NMR spectrum of, 114–115
 - cocoa, 130–131
 - cod liver oil, 128
 - EU regulation, 96–97
 - fish, 121–122
 - green tea, 126–127
 - honey
 - Corsican and non-Corsican, 120–121
 - hierarchical PLS-DA, polyfloral, 119–120
 - meat
 - canonical analysis, 123, 125
 - ¹H HRMAS and TOCSY spectrum, 123–124
 - mustard oil, 125
 - olive oil
 - canonical LDA, 107–108
 - classification, 106
 - ¹³C NMR DEPT, 111–112
 - ¹H and ¹³C NMR spectra, 108–109
 - ¹H NMR spectroscopy and PCA, 106–107
 - LDA, Lazio provinces, 108, 110
 - PCA, Lombardia and Veneto bank of Garda lake, 111
 - PDO, PGI, TSG status, 97
 - product quality level, 97–98
 - propolis, 128
 - tomato paste
 - ¹H NMR spectrum, Chinese and Italian triple, 128–129

Geographical origin of foods (*cont.*)
 unsupervised PCA protocol, 130
 traditional food products, 88
 wine
 Apulian and Slovenian, 103
 2D ^1H - ^{13}C GHSQC spectrum, Venosa,
 98, 102
 metabolite content, 104
 physicochemical analysis, 103–104
 PLS-DA, 104–105
 red, 102–103
 trace element analysis and
 chemometrics, 105–106

Grapevine
 cultivation, 44–45
 pathogens
 citrus mealybugs (*P. citri*), 48–49
 downy mildew (*P. viticola*), 46–47
 grape moth (*L. botrana*), 48
 gray mold (*B. cinerea*), 47–48
 powdery mildew (*U. necator*), 47
 vine mealybug (*P. ficus*), 48–49

Green tea
 geographical origin, 126–127
 quality and authenticity, 141

H

Hemicellulose structure, ragi, 234
 Heptadecanoic acid, 3, 23–24
 High resolution-magic angle spinning (HR-
 MAS) spectroscopy, 91

Honey
 geographical origin
 Corsican and non-Corsican, 120–121
 hierarchical PLS-DA of polyfloral,
 119–120
 quality and authenticity
 ^{13}C NMR study, 153
 ^1H NMR spectrum of polyfloral,
 154–155
 TOCSY NMR experiment, 154

L

Lactic acid bacteria (LAB), 174
 Lipolysis, cheese ripening
 colorimetric methods, 178–179
 GC-MS detection, 180
 HPLC, 179
 sample preparation and GC analysis,
 179–180

Lobesia botrana, 48

M

Malolactic fermentation (MLF)
 lactic bacteria, 59–60
 pesticide residues, 60
 Meat
 geographical origin
 canonical analysis, 123, 125
 ^1H HRMAS and TOCSY spectrum of
 Swiss dried, 123–124
 quality and authenticity, 149–150
 Metabolic syndrome and type 2 diabetes
 dairy food intake, 10–11
 obesity-related chronic disease, 5
 Micronutrients effects, 15–17
 Milk-derived peptides effects, 17
 Milk fat biomarkers
 CHD, 24–26
 pentadecanoic acid and heptadecanoic
 acid, 23–24
 stroke, 26
 type 2 diabetes mellitus, 26
 MLF. *See* Malolactic fermentation
 Monovariate statistical analysis, 92–93
 Multivariate statistical analysis
 applications, 93
 compression technique, 93–94
 discriminant analysis (DA) and
 independent component analysis
 (ICA), 94
 partial least squares projections,
 95–96
 Mustard oil, 125

N

Net protein utilization (NPU), 246
 NMR. *See* Nuclear magnetic
 resonance (NMR)
 Nonstarter lactic acid bacteria (NSLAB),
 174, 176
 NPU. *See* Net protein utilization
 NSLAB. *See* Nonstarter lactic acid bacteria
 Nuclear magnetic resonance (NMR). *See also*
 Geographical origin of foods; Quality
 and authenticity of foods
 energy absorption, 90–91
 HR-MAS spectroscopy, 91
 MRI, 91–92
 SNIF, 92
 Nutrigenomic effects mechanism,
 27, 29–30

O

- Obesity-related chronic disease
 - calcium flux mechanisms, 27–28
 - cardiovascular diseases, 6
 - dairy food components
 - CLA effects, 18
 - micronutrients effects, 15–17
 - milk composition and percent contribution, 13–15
 - milk-derived peptides effects, 17
 - saturated fats, 18–20
 - total dairy fats, 20–21
 - trans-fatty acids effects, 17–18
 - and dietary fat, 6–7
 - and dietary foods intake
 - and cardiovascular diseases, 11–13
 - metabolic syndrome and type 2 diabetes, 10–11
 - obesity, and weight management, 8–10
 - fat oxidation mechanisms, 27–29
 - fecal fat excretion mechanisms, 27–28
 - individual dairy foods effects, 21–23
 - and insulin resistance, 4
 - metabolic syndrome and type 2 diabetes, 5
 - milk fat intake, biomarkers of
 - CHD, 24–26
 - pentadecanoic acid and heptadecanoic acid, 23–24
 - stroke, 26
 - nutrigenomic effects mechanisms, 27, 29–30
 - satiation mechanisms, 27, 29
- Olive oil
 - geographical origin
 - canonical LDA, 107–108
 - classification, 106
 - ¹³C NMR DEPT, 111–112
 - ¹H and ¹³C NMR spectra, 108–109
 - ¹H NMR spectroscopy and PCA, 106–107
 - LDA, Lazio provinces, 108, 110
 - PCA, Lombardia and Veneto bank of Garda lake, 111
 - quality and authenticity
 - ¹³C NMR spectroscopy, 147
 - ¹H and ¹³C NMR, 148
 - LDA, Sicilian extra virgin, 147–148
 - ³¹P NMR spectra, 148–149

P

- Pappophoreae, 217
- Partial least squares discriminant analysis (PLS-DA), 95–96, 104–105, 114, 116, 119–120
- Pentadecanoic acid, 3, 23–24
- PER. *See* Protein efficiency ratio
- Pesticide effect. *See also* Wine fermentation, pesticide effect
 - lactic bacteria, MLF, 60
 - maximum residue limits, grape and wine, 53
 - registered pesticides, 49–52
 - yeasts, fermentation process, 54–57
- Planococcus citri*, 48–49
- Planococcus ficus*, 48–49
- Plasmopara viticola*, 46–47
- Propolis, 128
- Protected designation of origin (PDO), 88, 97
- Protected geographical indication (PGI), 88, 97
- Protein composition, ragi
 - amino acid, 236–237
 - α -amylases, 241
 - carboxyesterase and ferulic acid esterase, 240
 - prolamins, 238–239
 - protease activity, 239
 - pyrophosphatase activities and glycerolphosphatase, 240
- Protein efficiency ratio (PER), 246
- Proteolysis, cheese ripening
 - analysis scheme for, 181–182
 - chromatography, 190–194
 - electrophoresis, 188–190
 - fluorimetric and colorimetric methods, 187
 - nitrogen analysis, extraction and fractionation methods, 182–184
 - reactive compounds and formol titration, 186
 - schematic diagram, 181
 - trichloroacetic acid (TCA), 185
 - ultrafiltration, 186
 - water-soluble extracts (WSE), 182, 185

Q

- Quality and authenticity of foods
 - beer, 137–138
 - BVM and TBVM
 - ¹H NMR spectrum, 143–144

Quality and authenticity of foods (*cont.*)

- PCA, 142
- coffee, 154
- dairy products
 - cheese, 151–153
 - milk, 150–151
- fish and meat, 149–150
- fruit juice, 143–145
 - ^1H NMR spectra, 145–146
 - PCA, 145
 - SNIF-NMR, 144
- honey
 - ^{13}C NMR study, 153
 - ^1H NMR spectrum, 154–155
 - TOCSY NMR experiment, 154
- olive oil
 - ^{13}C NMR spectroscopy, 147
 - ^1H and ^{13}C NMR, 148
 - LDA, Sicilian extra virgin, 147–148
 - ^{31}P NMR spectra, 148–149
- papers dealing NMR and chemometric characterization, 131–133
- vanilla, 154, 156
- vegetables
 - green tea, 141
 - potato, 138–139
 - rice, 141
 - watermelons, 139
 - wheat, 139–141
- wine
 - antioxidants, 137
 - fermentative performance of yeast strains, 136–137
 - ^1H NMR spectra of red wine, 134, 136
 - metabolite content of grape berries, 134

R

Ragi. *See also Eleusine coracana*

- carbohydrate composition
 - nonstarchy polysaccharide, 233–236
 - starch, 231–233
- glycemic index, 251–252
- protein composition
 - amino acid, 236–237
 - α -amylases, 241
 - carboxyesterase and ferulic acid esterase, 240
 - prolamins, 238–239
 - protease activity, 239
 - pyrophosphatase activities and glycerolphosphatase, 240

Ripening, cheese monitoring

- lactose, lactate, and citrate metabolism
 - assessment
 - acetic acid measurement, 176
 - analysis, 174–175
 - Boehringer Mannheim kits, 174, 176
 - citrate quantification, 176
 - diacetyl and acetoin quantification, 176–177
 - gas chromatographic methods, 177–178
 - high-performance liquid chromatography (HPLC) method, 177
- lipolysis assessment
 - colorimetric methods, 178–179
 - GC-MS detection, 180
 - HPLC, 179
 - sample preparation and GC analysis, 179–180
- proteolysis assessment
 - analysis scheme for, 181–182
 - chromatography, 190–194
 - electrophoresis, 188–190
 - fluorimetric and colorimetric methods, 187
 - nitrogen analysis, extraction and fractionation methods, 182–184
 - reactive compounds and formol titration, 186
 - schematic diagram, 181
 - trichloroacetic acid (TCA), 185
 - ultrafiltration, 186
 - water-soluble extracts (WSE), 182, 185
- smaller breakdown products assessment
 - biogenic amines, 196
 - headspace analysis, 195
 - lactones and methyl ketones, 195
 - pathways, 194–195
 - SPME, 195–196

S

- Satiation mechanisms, 27, 29
- Saturated fats, 18–20
- Site specific natural isotope fractionating (SNIF)-NMR technique, 92
 - authenticity of fruit juice, 144–145
 - authenticity of mustard oil, 125
 - geographical characterization of wines, 105–106
- Sporoboleae, 217

T

- TBVM. *See* Traditional balsamic vinegars of Modena
- Tomato paste, concentrated
 ^1H NMR spectrum, Chinese and Italian triple, 128–129
 unsupervised PCA protocol, 130
- Total dairy fats, 20–21
- Traditional balsamic vinegars of Modena (TBVM), 141–144
- Traditional specialty guaranteed (TSG), 88, 97
- Trans-fatty acids effects, 17–18
- Trypanosoma cruzi*. *See also* American trypanosomiasis
 control (in food)
 food contamination, 78
 freezing and refrigeration, 79
 good manufacturing practices (GMP), 80
 integrated pest management (IPM), 80
 microwaves and ionizing radiation, 79
 sanitization and pasteurization, 79
 standardized operational procedures (SOPs), 80
 life cycle, 66–67
 strain influence, 72
- Trypsin/ α -amylase inhibitor, 240–241
- Type 2 diabetes, 5, 10–11

U

Uncinula necator, 47

V

- Vanilla, 154, 156
- Vinegar, BVM and TBVM, 141–144

W

- Wine
 geographical origin
 Apulian and Slovenian, 103
 $2\text{D } ^1\text{H-}^{13}\text{C}$ GHSQC spectrum, 98, 102
 metabolite content, 104
 physicochemical analysis, 103–104
 PLS-DA, 104–105
 red, 102–103
 trace element analysis and chemometrics, 105–106
- quality and authenticity
 antioxidant, 137
 fermentative performance of yeast strains, 136–137
 ^1H NMR spectra of red wine, 134, 136
 metabolite content of grape berries, 134
- Wine fermentation, pesticide effect
 consumption, 45–46
 fermentation process
 alcoholic fermentation, 49, 54
 pesticides residues, 57–58
 yeasts, 54–57
- grapevine cultivation, 44–45
- grapevine pathogens
 citrus mealybugs (*P. citri*), 48–49
 downy mildew (*P. viticola*), 46–47
 grape moth (*L. botrana*), 48
 gray mold (*B. cinerea*), 47–48
 powdery mildew (*U. necator*), 47
 vine mealybug (*P. ficus*), 48–49
- malolactic fermentation
 lactic bacteria, 59–60
 pesticide residues, 60
- maximum residue limits, grape and wine, 53
- registered pesticides, 49–52

Z

Zoysiaeae, 217

INDEX

A

- Acute toxoplasmosis, 6
- Alaska pink salmon, 139
- Alaska pollock gelatin, 138–139
- Animal feed
 - C. difficile*, 60
 - E. coli* O157:H7, pathogen transmission, 72–73
 - rat feeding experiments, 38
- Asthenia, 7
- Atlantic cod, 138
- Atlantic salmon, 138

B

- Bacteriophage
 - high-level shedders, 81–82
 - preharvest control, 92–93
- Bill and Melinda Gates Foundation (BMGF), 23
- Biofortification
 - anthropometric measurements and blood tests, 43
 - Burkina Faso, 44–45
 - cereal, 42–43
 - CMF, 44
 - definition, 23
 - lysine plus threonine, 42
 - micronutrient deficiency, 46
 - PDCAAS, 45–46
 - QPM, 44
 - transferrin and hemoglobin levels, 43
 - wheat bread, 43
- Biosorghum project, 23–24
- Bradyzoites, 3–5

C

- Carcass contamination
 - C. difficile*, 60–61
 - E. coli* O157:H7
 - fecal shedding and hide prevalence, 70, 89
 - probability, 81
- Carp skin gelatin, 139
- C. difficile* infection (CDI), 54

- Cerebral biopsy, 10
- Cerebral toxoplasmosis, 9–10
- Clostridial spores, 60
- Clostridium difficile*
 - animal feed, 60
 - detection, food
 - bacteriologic culture, 55
 - enrichment broths, 55–56
 - recovery rates, 55, 57
 - environmental strains/organisms, 57, 60
 - food contamination, 60–61
 - genotypes, 61–62
 - human colonization, 62–63
 - isolation, 54
 - meat and meat products, 57–59
- Cold-water fishes, 129–130
- Collagen
 - α -chains, 122–123
 - amino acids, 123
 - β - and γ -chain, 123
 - fibrils, 121–122
 - gelatin conversion
 - alkali and acid process, 125
 - drying and grinding process, 126
 - extraction method, 125–126
 - pretreatment process, 125
 - removal of unwanted materials, 124
 - hydroxyproline, 123
 - isoelectric point, 137
 - molecular structure, 122
 - molecules arrangement, 121–122
 - stabilization, hydrogen bonds, 123–124
 - structural protein, 25
 - triple helix structure, 122
 - tropocollagen, 122
 - types, 124
- Cow's milk formula (CMF), 44

D

- DDG. *See* Dried distillers grain with/without solubles
- Direct/indirect fecal–oral exposure, 75
- Dried distillers grain with/without solubles (DDGS), 84–85

E

- Electrolyzed oxidizing water, 74
- Enterobacteriaceae*, 93
- Escherichia coli* O157:H7
 - animal stress
 - catecholamine norepinephrine, 87
 - heat stress, 88
 - immune response, 87
 - livestock response, 88
 - microbial food safety risk, 86
 - practical implications, 87
 - weaning, 87
 - antimicrobial carcass interventions, 97
 - bacterial diarrhea, 68
 - beta-agonists, 88–89
 - diet effects, shedding and persistence
 - barley grain, 84
 - cattle fed barley *vs.* cattle fed cracked, 84, 86
 - distillers grains, 84
 - energy-dense grain rations, 84
 - gastrointestinal tract and fecal incidence, 86
 - potential effects, 83–84
 - ruminal fluid, 83
 - ruminant animals, 82–83
 - WDGS and DDGS, 84–85
 - fecal shedding, 70
 - feedlot cattle, 89
 - high-level shedders
 - bacteriophage, 81–82
 - cattle hide contamination, 81
 - chain of events, 81–82
 - colonization, 81
 - feedlot pens, 80
 - mathematical modeling, 80–81
 - super-shedders, 80, 82
 - ionophores, 89
 - modes of transmission, 69
 - outbreak, water, 69
 - preharvest control
 - bacteriophage, 92–93
 - brown seaweed product, 95
 - chlorate, 93–94
 - cottonseed, 94
 - esculetin and esculin, 95
 - manure and cattle pen surface treatments, 95–97
 - neomycin sulfate, 94
 - probiotics/direct-fed microbials, 91–92
 - rumen modifiers, 94
 - vaccines, 90–91

- risk factors, 98
- seasonality of shedding
 - cattle feeds, 77
 - cooler temperatures, 77–78
 - heat stress, cattle, 78
 - human foodborne disease, 80
 - melatonin, 78
 - percentage of samples, 78–79
 - physiological responses, animal, 78
 - prevalence, 77
- sorbitol fermentation, 70
- sources and transmission, cattle
 - animal feed, 72–73
 - drinking water, 73–75
 - feces, manures, and soils, 75–76
 - flies, 71–72
 - on-farm ecology, 70
 - potential reservoirs/vehicles, 70–71
 - prevalence, 71
 - transportation and lairage, 98–99

F

- Fecal–oral transmission, 75
- Feedlot calves, 61
- Fish gelatin
 - chemical characteristics
 - amino acid composition, 134
 - peptide size, quality, 134–135
 - common and potential sources, 129–130
 - effects of processing conditions
 - alkali and acid treatments, 135–137
 - extraction temperature and duration, 137–138
 - gelatin extraction flowchart, 135–136
 - storage and transportation, 138
 - physical attributes
 - gel strength, 130–132
 - melting and gelling temperature, 132–133
 - viscosity, 131–132
 - quality *vs.* mammalian gelatins, 138–139
- Freeze drying method, 140
- Frequency sweep tests, 133

G

- Gelatin
 - biopolymers, 120
 - characteristics, 127
 - chemical composition, 120
 - collagen–gelatin conversion
 - alkali and acid process, 125

drying and grinding process, 126
 extraction method, 125–126
 pretreatment process, 125
 removal of unwanted materials, 124

gelatin market, 128
 gelation mechanism, 126
 industrial applications, 128–129
 manufacturing, raw material, 127–128
 parent molecule, collagen
 α -chains, 122–123
 amino acids, 123
 β - and γ -chain, 123
 fibrils, 121–122
 hydroxyproline, 123
 molecular structure, 122
 molecules arrangement, 121–122
 stabilization, hydrogen bonds, 123–124
 triple helix structure, 122
 tropocollagen, 122
 types, 124
 quality determination, 139–140

Gelatin hydrolysate, 134
 Gelation mechanism, 126
 Gel strength
 bloom jar, 130–131
 bloom strength, 130
 different instruments and probes,
 131–132
 measurement, standard method, 130

Glucocorticoid dexamethasone, 87
 Grand Challenges in Global Health, 23

H

Headache, 7
 Heat drying method, 140
 High-level shedders
 bacteriophage, 81–82
 cattle hide contamination, 81
 chain of events, 81–82
 colonization, 81
 feedlot pens, 80
 mathematical modeling, 80–81
 super-shedders, 80, 82

Houseflies, 71–72
 Hydroxyproline, 123–124, 134

I

Isoionic point, 137

K

Kafirin–tannin complexation, 42

L

Leishmania gondii, 3
 Lymph node enlargement, 7

M

Mediterranean Intensive Oxidant Study
 (MINOS), 27
 Multivariate regression analysis approach, 7
 Muscle mass
 amino acids, 26–27
 death, human starvation, 27
 maintenance, 28
 malnutrition, 26
 metabolism, genesis, 26
 MINOS (see Mediterranean Intensive
 Oxidant Study)
 obesity relationship, 27
 protein loss, 28
 rapid starvation/dietary protein
 depletion, 26

N

Neomycin sulfate, 94
N-(*n*-butyl) thiophosphoric triamide
 (NBPT), 96

O

Ocular toxoplasmosis, 8, 10
 Oocysts sporulation, 5
 Osteopenia, 27

P

Parasitophorous vacuole, 4
 Pharmaceutical gelatin, 129
 Preharvest control
 bacteriophage, 92–93
 brown seaweed product, 95
 chlorate, 93–94
 cottonseed, 94
 esculetin and esculin, 95
 manure and cattle pen surface treatments,
 95–97
 neomycin sulfate, 94
 probiotics/direct-fed microbials, 91–92
 rumen modifiers, 94
 vaccines, 90–91

Proline, 123–124, 134, 139
 Protein content and composition
 PDCAAS calculation, sorghum, 33, 36
 sorghum *vs.* other cereals, 32, 34–35
 tryptophan, 36

- Protein digestibility
 changes, protein body, 39
 cross-linking, kafirin prolamin proteins,
 36–37
 diets, 38, 41
 disulfide bonding, 36
 grain improvement, 37
 gruels, 38
 high-*vs.* normal-lysine sorghum, 37
 nutritional parameters, 38
 rat feeding experiments, 38
 sorghum lines, 39–40
 transgenic biofortified sorghum, 41–42
 wet cooked sorghum, 36
- Protein Digestibility Corrected Amino Acid
 Score (PDCAAS)
 biological value prediction, 31
 calculation, sorghum, 31–33
 protein quality, 32, 34–35
 transgenic biofortified sorghum, 42
- Protein Efficiency Ratio (PER), 31
- Pulsed-field gel electrophoresis (PFGE)
C. difficile genotypes determination,
 61–62
 patterns, 72

Q

- Quality Protein Maize (QPM), 44

R

- Rheological method, 132–133
 Ribotyping, 61–62

S

- Sorghum protein
 biofortification
 anthropometric measurements and
 blood tests, 43
 Burkina Faso, 44–45
 cereal, 42–43
 CMF, 44
 definition, 23
 lysine plus threonine, 42
 micronutrient deficiency, 46
 PDCAAS, 45–46
 QPM, 44
 transferrin and hemoglobin levels, 43
 wheat bread, 43
 human health
 amino acids classification, 24–25
 cereal, 29

- 1985 FAO/WHO/UNU *vs.* 2002
 WHO/FAO/UNU requirements,
 28–29
 fat, 26
 indispensable amino acids, 24
 meta-analysis, 28
 muscle mass, 26–28
 nitrogen and amino acid needs, 28
 nitrogen-containing compounds, 25
 nutrition security planning, 28
 pregnancy and lactation period, 30
 protein types, 25
 safe level protein recommendation, 29
 scoring patterns, amino acid, 30
 quality
 chemical mutagenesis, 39
in vitro pepsin method, 41
 lysine-rich protein synthesis, 40
 and measurement, 31–32
 protein body change, 39
 protein content and composition, 32,
 34–36
 protein digestibility, 36–39
 sorghum lines, 39–40
 sorghum *vs.* other cereals, 34–35, 40–41
 stunted and underweight children,
 Africa, 22–23

- Stress and strain sweep tests, 133

T

- Tachyzoites, 3–4
 Tannins, 42
 Temperature sweep tests, 133
 Thermoreversible gels, 127
 Thymol, 96
 Tilapia skin gelatin, 138
 Time sweep tests, 133
Toxoplasma gondii. *See also* Toxoplasmosis
 control in foods, 13–14
 life cycle
 asexual developmental cycle, 3–4
 felines, 3
 interaction, host cells, 3–4
 sexual phase, 5
 stagespecific markers, 4
 Toxoplasmosis
 congenital toxoplasmosis, 2
 discovery, 3
 laboratory diagnosis and treatment
 cerebral toxoplasmosis, 9–10
 differential diagnosis, 10
 DNA detection, PCR, 9

IgG and IgM antibodies detection, 9
immunocompetent *vs.*
 immunocompromised patients, 9
ophthalmologic examination, 10
serologic tests, 9
misdiagnosis/underdiagnosis, 2
outbreaks, 12–13
pathogenesis and human infection
 spectra
 asymptomatic infection, 7
 immunodeficiency, 8
 infection, pregnancy, 6–7
 interferon-gamma (IFN- γ) production,
 8
 ocular toxoplasmosis, 8
 risk factors, 7–8
transmission
 cyst infection, ME-49 strain, 11

 foodborne transmission, 5
 food ingestion, 11
 oocysts ingestion, 5
 sausage samples, 11
 tachyzoite, 5–6
 undercook meat, 11
 unpasteurized milk, 11
Trimester, 6–7

U

Unpasteurized milk, 11, 69

W

Water dessert gels, 128
Water troughs, 73–74
Wet distillers grain with solubles (WDGS),
 84–85

INDEX

A

- Acetaldehyde
 accumulation, 160
 concentrations, 162
 free and bound SO₂, 160–161
- Adulteration, 59, 99
- Alcoholic fermentation, 4
- Allergens, 205
- Amperometric detection, 98
- Aroma, wine
 effects, 172–177
 oxidation, 158–159
- Artificial effervescence, 27
- Artificial neural networks (ANNs),
 91–92
- Artificial tongue
 adulteration and food falsification, 59
 analytical techniques
 impedance spectroscopy, 68–69
 potentiometry, 67
 voltammetry, 68
 beverage differentiation, 65
 chemometrics
 classification and class-modeling,
 83–93
 exploratory analysis, 79–83
 multivariate experimental design,
 71–73
 preprocessing, 73–78
 regression techniques, 93–96
 validation, 96–98
 environmental analyses, 64
 food science
 aging process, 103
 amperometric detection, 98
 ANN models, 100
 biosensors, 103
 commercial electronic tongue, 105
 cross-validation approach, 104–105
 glucose and ascorbic acid
 determination, 104
 hybrid sensor, 99
 impedance measurements, 98
 pasteurization processes, 106
 PCA, 98–99
 potentiometric ion-selective sensors,
 104
 potentiometric sensors, 103, 106
 predicting sensorial attribution, 100
 pulse voltammetry, 101
 sensorial analysis, 100–102
 SIMCA models, 99–100
 square wave and cyclic voltammetry,
 98
 tea analysis, 104
 water monitoring approaches, 103
 wine
 adulterations, 99
 age prediction, 101
 characterization, 98
 food taste properties, 66
 historical aspects, 62–63
 liquid food, 64–65
 nonspecific analytical responses, 60
 pharmaceutical technology studies, 64
 production phase, 58
 qualitative approach and quantitative
 applications, 63
 research-and-development, 58
 sensations, mammals, 60
 terminology, 61–62
 vanguard analytical strategies, 59
 variability amount implications, 58

B

- Beverages. *See* Champagne and sparkling
 beverages
- Biofilms, 130
- Biosensors, 103
- Bubble
 bubbling regimes, 23–24
 bursting process
 avalanches, 51–53
 flower-shaped structures, 48–49
 hexagonal pattern arrangement, 47–48
 high-speed photography, 43–44

- Bubble (cont.)**
 schematic transversal representation, 50–51
 shear stresses, 49–50
 surface active molecules, 45–47
 close-up time sequence and mechanism, 25
 growth
 characteristics, 28–29
 high-speed photography and strobe lighting, 28
 pressure, 30–31
 microbubbles, 151
 micrometric gas bridge establishment, 26
 size
 carbon dioxide content, 33–34
 gravity acceleration, 32–33
 pressure, 33
 significant difference, 34
 temperature dependence, 32
 two gas pockets, 26
- Bubble nucleation process, champagne**
 artificial effervescence, 27
 bubbling instabilities
 bubbling regimes, 23–24
 close-up time sequence and mechanism, 25
 micrometric gas bridge establishment, 26
 two gas pockets, 26
- cellulose fibers**
 bubbling frequency, 20–22
 CO₂ dissolved concentration, 19–20
 conditions, 18
 real gas pocket trapping, 18–19
 structural levels, 15–16
 critical radius, 12–13
 natural effervescence, 13–15
- C**
- Cabernet Sauvignon wine, 169**
- Cell intraction, photosensitizers**
 biofilms, 130
 cytotoxic species, 125
 electron microphotographs, *Bacillus cereus*, 128
 fungal cells and yeasts, 127, 130
 gram negative bacteria, 127, 129
 gram-positive bacteria, 127–128
 killing effects, 129
 metabolic pathways, 127
 modes of light delivery, 133
 photoactive fullerene derivatives, 132
 spore formation, 130
 viruses and structures, 131–132
- Champagne and sparkling beverages**
 bubble growth
 characteristics, 28–29
 high-speed photography and strobe lighting, 28
 pressure, 30–31
 bubble nucleation process
 artificial effervescence, 27
 bubbling instabilities, 23–27
 cellulose fibers, 15–23
 critical radius, 12–13
 natural effervescence, 13–15
 bubbles bursting process
 avalanches, 51–53
 flower-shaped structures, 48–49
 hexagonal pattern arrangement, 47–48
 high-speed photography, 43–44
 schematic transversal representation, 50–51
 shear stresses, 49–50
 surface active molecules, 45–47
 bubble size
 carbon dioxide content, 33–34
 gravity acceleration, 32–33
 pressure, 33
 significant difference, 34
 temperature dependence, 32
 chemical composition, 8–9
 CO₂ dissolved gas molecules
 blending, 4
 first alcoholic fermentation, 4
 second alcoholic fermentation, 5–6
 flute vs. coupe
 champagne serving, 36–37
 CO₂-dissolved concentrations, 37–38
 time series data recordings, 39–40
 pressure under the cork, 6–8
 temperature, role of, 42–43
 uncontrolled champagne cork, 9–12
- Chemometrics**
 classification and class-modeling
 artificial neural networks, 91–92
 class-modeling techniques, 92–93
k-nearest neighbors, 85–86
 linear discriminant analysis, 86–89
 quadratic discriminant analysis, 88
 soft independent modeling of class analogy, 90–91
 unequal class models, 88, 90

- column autoscaling, 76–77
 - column centering, 76
 - exploratory analysis
 - clustering, 82–83
 - principal component analysis, 79–82
 - multivariate experimental design
 - experimental factors, 71
 - factorial scheme, 71–72
 - regression techniques
 - ordinary least squares, 93–94
 - partial least squares, 94–96
 - row preprocessing
 - effectiveness, 73–74
 - exploratory analysis, 79–83
 - first and second order derivation, 75–76
 - forward and backward currents, 76
 - signal compression and variable reduction
 - SELECT, 78
 - wavelet transform, 77–78
 - signal variations, 75
 - standard normal variate transform, 75
 - validation
 - cross validation, 97
 - repeated evaluation set, 98
 - single evaluation set, 97
 - strategy, 96–97
 - Codex Alimentarius Commission (CODEX), 59
 - CO₂ dissolved gas molecules, beverages
 - blending, 4
 - bubbling environment, 35
 - first alcoholic fermentation, 4
 - flute *vs.* coupe
 - champagne serving, 36–37
 - time series data recordings, 39–40
 - vessel influence, 37–38
 - second alcoholic fermentation, 5–6
 - temperature, role of, 42–43
 - Cross validation (CV), 97
 - Cyanogenic glycosides, 205
 - Cytotoxic species
 - photoexcitation, photosensitizer, 125
 - PS-excited triplet reaction, 125–126
 - ROS, 126
- E**
- Effervescence process
 - artificial effervescence, 27
 - natural effervescence
 - lumen, 13
 - mechanism, 14
 - time sequence, 15
 - visual aspects, 38
 - Electronic tongue, 103. *See also* Artificial tongue
- F**
- Fatty acids, 198–200
 - Food and Agricultural Organization (FAO), 59
 - Food falsification, 59
 - Food processing, maroma milk
 - amino acid composition, 215–216
 - chemical composition, 215
 - fermented milk products, 217–218
 - preprocessing treatment, 216
 - small-scale method, 216–217
 - thermal treatment, 216
 - oil, 218
 - protein-rich morama flours
 - amino acid composition, 221
 - dry heating process, 222
 - physico-chemical and protein-related functional properties, 223
 - preparation, 218–219
 - processing procedure, 220
 - proximate composition, 219–220
 - uses, 222
- G**
- Glucose and ascorbic acid, 104
 - Glutathione, 163
- H**
- Hybrid sensor, 99
- K**
- k*-Nearest neighbors (*k*-NN), 85–86
- L**
- Linear discriminant analysis (LDA), 86–89
- M**
- Malachite green, 137
 - Methylene blue (MB)
 - European blood transfusion, 138
 - photoactive dyes, 136–137

- Microoxygenation (MOX)
- acetaldehyde
 - accumulation, 160
 - concentrations, 162
 - free and bound SO₂, 160–161
 - aroma effects, 172–177
 - microbiological considerations, 179–181
 - microbullage delivery, 151–152
 - mouthfeel effects, 177–179
 - oxygen spatial considerations, 153–154
 - polymer membrane, oxygenation
 - procedures, 152–153
 - red wine color effects and polyphenol development
 - antioxidant assays, 170
 - Cabernet Sauvignon wine, 169
 - chemical and instrumental analyses, 172
 - color intensity, 164
 - color properties, 166
 - HPLC analyses, 165
 - Monastrell wine, 166–167
 - pigment composition, 165
 - polymeric pigments and color density, 168
 - red wine maturation, 158
 - SO₂ influence and wine antioxidants, 162–164
 - wine oxidation processes
 - oxygen in wine, 154–155
 - polyphenol-mediated, 155–157
 - wine aromas, 158–159
- Monastrell wine, 166–167
- Morama bean (*Tylosema esculentum*)
- allergens, 205
 - ash content, 196
 - availability, 232–233
 - carbohydrate/dietary fiber, 202
 - chemical composition, 195–196
 - cultivation, 235–236
 - cyanogenic glycosides, 205
 - dietary use, 233
 - economic importance, 189
 - fatty acids, 198–200
 - geographic distribution and description, 190–192
 - health benefits, 206, 208–212, 233–234
 - lipids, 196, 198
 - market, 236–237
 - milk
 - amino acid composition, 215–216
 - chemical composition, 215
 - fermented milk products, 217–218
 - preprocessing treatment, 216
 - small-scale method, 216–217
 - thermal treatment, 216
 - minor chemical components
 - minerals, 203
 - phytoestrogens, 203–204
 - vitamins, 203
 - moisture, 196
 - oil, 218
 - pests and diseases, 192
 - phenolic compounds, 205–207
 - phytosterols, 198, 201
 - potential marketing strategies
 - commercialization strategies, 229–230
 - competition, 225
 - conjoint analysis, 228–229
 - consumer purchasing characteristics, 225–227
 - market size and characteristics, 224
 - retail environment, 224–225
 - protein, 201–202
 - protein-rich morama flours
 - amino acid composition, 221
 - dry heating processes, 222
 - physico-chemical and protein-related functional properties, 223
 - preparation, 218–219
 - processing procedure, 220
 - proximate composition, 219–220
 - uses, 222
 - seed morphology, seedling development and growing stages, 192
 - soil organic matter, 195
 - soil pH, 193–195
 - staple food, 234
 - triacylglycerols, 198
 - trypsin inhibitor, 204–205
 - values, 231–232
 - varieties and classification, 193
- MOX. *See* Microoxygenation
- MRM, 92–93
- Multivariate design of experiments (MDOE)
- chemometrics, 69
 - experimental factors, 71
 - factorial scheme, 71–72
- Multivariate range modeling (MRM), 92–93

N

- Natural effervescence
 - lumen, 13
 - mechanism, 14
 - time sequence, 15

O

- Ordinary least squares (OLS), 93
- Oxidation processes
 - photosensitized oxidation, 123
 - wine
 - aldehydes, 156
 - aromas, 158–159
 - condensation processes, 157
 - oxygen, 154–155
 - polyphenol quinones, 156

P

- Partial least squares (PLS), 94–96
- Pasteurization, 106
- PDT. *See* Photodynamic treatment
- Pests and diseases, 192
- Phenolic compound, 205–207
- Phenothiazinium dyes, 136
- Phloxine B, 137
- Photoactive dyes
 - antimicrobial properties, 134
 - cationic polymer poly (vinyl amine), 138
 - cationic porphyrin derivatives, 134
 - endogenous porphyrins, 135
 - malachite green, 137
 - MB, 136–137
 - medical and therapeutic applications, 133
 - phenothiazinium dyes, 136
 - phloxine B, 137
 - porphyrin derivatives, 135
 - rose bengal, 137
 - TBO, 136
- Photodynamic treatment (PDT)
 - application and principles, 123
 - cell inactivation, PSs
 - biofilms, 130
 - electron microphotographs, *Bacillus cereus*, 128
 - fungus cells and yeasts, 127, 130
 - gram negative bacteria, 127, 129
 - gram-positive bacteria, 127–128
 - killing effects, 129
 - metabolic pathways, 127
 - modes of light delivery, 133

- photoactive fullerene derivatives, 132
- spore formation, 130
- viruses and structures, 131–132

- cytotoxic species
 - photoexcitation, photosensitizer, 125
 - PS-excited triplet reaction, 125–126
 - ROS, 126
- effects, 120

- environmental cleaning and disinfection
 - biofilm destruction and inactivation, 140
 - food-grade PSs, 140
 - immobilized photoactive dyes, 139
 - inactivate pathogens, 141
 - photobleaching, 142–143
 - self-cleaning materials, 143
 - virus inactivation, 138

- photoactive dyes (*see* Photoactive dyes)
- photochemical reaction, 122
- photophysical reaction, 121
- photosensitized oxidations, 123
- photosensitized reactions, 122

Phytosterols, 198, 201

PLS. *See* Partial least squares

Polyphenols

- oxidation processes
 - aldehydes, 156
 - condensation processes, 157
 - polyphenol quinones, 156
 - wine aroma, 158
- red wine maturation, 150

Porphyrin derivatives, 135

Potentiometric ion-selective sensors, 104

Potentiometric sensors, 103, 106

Principal component analysis (PCA)

- pattern recognition tools, 104
- red wine, color effects, 169
- voltammograms, 80

Protein-rich morama flours

- amino acid composition, 221
- dry heating processes, 222
- physico-chemical and protein-related functional properties, 223
- preparation, 218–219
- processing procedure, 220
- proximate composition, 219–220
- uses, 222

Q

Quadratic discriminant analysis (QDA), 88

R

- Red wine
 - color effects
 - color development, 166
 - PCA projection, 169
 - polymeric pigments, 168
 - polyphenol antioxidant measures, 170
 - wine color parameters, 165, 167–168
 - maturation, 158

S

- Sangiovese wine, 168
- Soft independent modeling of class analogy (SIMCA), 90–91
- Sulfur dioxide
 - antioxidants
 - free SO₂, 162
 - glutathione, 163
 - quinone reduction processes, 163
 - wine-aging processes, 163
 - free and bound SO₂, 160–161

T

- Triacylglycerols, 198
- Trypsin inhibitor, 204–205

U

- Unequal class models (UNEQ), 88, 90

W

- Wine
 - adulterations, 99
 - age prediction, 101
 - antioxidants
 - free SO₂, 162
 - glutathione, 163
 - quinone reduction processes, 163
 - wine-aging processes, 163
 - characterization, 98
 - color parameters
 - in Cabernet Sauvignon, 169
 - in Morfastrell wine, 166–167
 - in Sangiovese wine, 168
 - oxidation processes
 - aromas, 158–159
 - oxygen, 154–155
 - polyphenol-mediated, 155–157
 - red wine (*see* Red wine)
- World Health Organization (WHO), 59

INDEX

A

- AFM. *See* Atomic force microscopy
- Atomic force microscopy (AFM)
- carrageenan gelation mechanism
 - components, 222
 - ι -carrageenan, 224–225
 - κ -carrageenan, 222–223
 - rheological behaviour, 223
 - side-by-side aggregation, 225–226
 - casein micelle structure and
 - nanorheology
 - carrageenans, 220
 - decomposition, 218
 - description, 218
 - graphite surface, 221
 - HOPG, 218, 220
 - milk, 217
 - pressure-treated, 219
 - rheological properties, 220–221
 - surface tension-based model, 222
 - Young moduli, 221
 - description, 202
 - food structure, 206
 - gelatin nanostructure and elastic property
 - alkaline and acid pretreatment, 212
 - ampholyte macromolecules, 208
 - annular pores, 212, 214
 - Catfish skin, 208–210
 - dependence, viscoelastic parameters, 217
 - elasticity determination, 215
 - error-signal mode images, 211
 - fibril structure, 212, 214
 - force-distance curves, 212, 215
 - high-friction layer, 207
 - hydrolysis, 207
 - pretreatment, 212–214
 - viscous response, 216
 - Young's modulus calculation, 216
 - gellan gum gelation
 - acyl contents and cations, 227–228
 - continuous network structures, 230
 - description, 226
 - κ -carrageenan, air, 226–227
 - molecular assemblies, 228–229
 - potassium and sodium cation, 230
 - interface phenomenon
 - displacement processes, 235–236
 - DPPC monolayer structures, 237
 - interfacial rheology characteristics, 237
 - Langmuir–Blodgett techniques, 234
 - phospholipids, 235
 - surfactants/proteins, 234
 - nanofabrication, 202
 - principles
 - cantilevers, 205
 - commercial tips, 206
 - contact mode, 203
 - dynamic imaging mode categories, 204–205
 - interaction force and physical properties, 205
 - noncontact techniques, 204
 - operating modes, 204
 - sharp tip scanning, 202–203
 - tip-to-sample distance, 203
 - starch nanostructure and degradation
 - mechanism
 - glucoamylase–amylose complexes, 233
 - glucoamylases, 231
 - molecule types, 230–231
 - potato and rice amylose, 231–232
 - SBD, 231–232, 234

B

- Botanical and geographical origin
 - discrimination, honey*
 - aliphatic acid
 - capillary electrophoresis (CE), 116
 - chromatographic methods, 115
 - enzymatic methods, 114
 - IC-CD method, 115
 - uses, 113–114
 - amino acids
 - lavender and eucalyptus, 101
 - linear discriminant analysis, 99–100

Botanical and geographical origin
 discrimination, honey (*cont.*)
 nitrogen content, 98
 pollen and proline, 99
 aroma compounds
 definition, 101–102
 volatile concentrations and isolation,
 102–103
 carbohydrates
 chromatography methods, 104–105
 fructose and glucose, 103–104
 HMF, 104
 Lithuanian honeys, 104
 maltose, 104
 enzyme activity
 amylase types, 105–106
 description, 105
 diastase, 106
 storage, 107
 fermentation products, 107–108
 flavonoids
 flavanones and flavanones/flavanols,
 108–109
 patterns, 110
 Portuguese and Spanish samples, 109
 quinoline alkaloids, 108
 minerals and trace elements
 ion chromatographic (IC) technique,
 112
 metal content, 113
 potassium, 112–113
 phenolic compounds
 Folin–Ciocalteu method, 117–118
 HPLC, 118
 hydroxybenzoic and hydroxycinnamic
 acids, 116–117
 polyphenols, 116
 pollen analysis, 110–112
 proteins, 98
 stable isotopes
¹³C values, 120
 honey proteins values, 118–119
 isotope ratio mass spectrometry, 121
 radioactive isotopes, 118
 SIRA, 119–120
 Bovine somatotropin (bST), 65–66
 bST. *See* Bovine somatotropin

C

CA. *See* Codex alimentarius
 CIP. *See* Cleaning-in-place
 Cleaning-in-place (CIP)

energy, milk plants, 76
 high heat operations, 59
 procedures, 76
 process, 57
 Codex alimentarius (CA), 90

D

Dairy proteins
 casein, 174
 extrusion texturized (*see* Extrusion
 texturized dairy proteins)
 functional properties
 caseinates, 177
 conformational state, β -LG folding,
 179
 emulsification and foaming, 177
 extrusion texturization, 178
 molecular simulations, apoprotein, 178
 thermal denaturation, whey, 177
 health benefits
 casein-derived phosphorylated
 peptides, 176
 casein types, 175
 whey protein, 176–177
 sweet whey, 174–175
 ultra filtered and dried WPC, 175
 Detection methods regulation, food
 allergenic ingredients
 banana
 high specificity, 167
 latex-fruit syndrome, 166
 ELISA (*see* Enzyme-linked
 immunosorbent assay)
 guideline criteria, validation protocol
 ELISA performance, 153
 quantitative and qualitative, 152
 kiwifruit, 166
 limits of detection (LOD), 147
 meat, 167
 PCR method
 DNA extraction, 156
 target genes, 156–157
 Western blotting and PCR kits, 156, 158
 practical test, monitoring
 decision tree, 163–164
 outline, local government inspection
 center, 159, 163
 quantitative analyses, ELISA kits, 159
 reference material and calibrator
 procedure, preparation, 149
 protein concentration determination,
 151

- raw materials and extraction methods, 149–150
 - SDS-PAGE, 150–151
 - specifications and standardization, 149
 - soybean
 - ELISA, 163, 165
 - high specificity, 165
 - threshold, 147–148
 - validation
 - buckwheat, 161
 - egg, 160
 - evaluation method, interlaboratory, 157, 159
 - homogeneity test, 157, 159
 - milk, 160
 - model processed foods, 156–157
 - peanut, 162
 - protocol criteria, 148
 - shrimp/prawn, 162
 - wheat, 161
 - walnut, 165–166
 - Western blotting, egg and milk
 - flowchart, 156
 - specificity, 155
- E**
- ELISA. *See* Enzyme-linked immunosorbent assay
 - Environmental protection agency (EPA)
 - CO₂ emissions, 56
 - GHG emissions, 79
 - Enzyme-linked immunosorbent assay (ELISA)
 - allergenic ingredients detection
 - antibodies, 153
 - commercial kits, 155
 - FASPEK KIT[®], 154
 - FASTKIT ELISA Ver.II[®], 153
 - retorted and canned foods, 154
 - limits of detection, 147
 - processed foods., 153
 - EPA. *See* Environmental protection agency
 - Extrusion texturized dairy proteins
 - cheese analogs, 193
 - development
 - coextrusion, 190–191
 - cold extrusion, 191
 - corn meal and WPI, 192
 - extrudate expansion, 188–189
 - functionality, 189–190
 - supercritical fluid extrusion, 191
 - high-fibre products, 193–194
 - meat analogs and extenders, 193
 - nutritional bars, 194
 - processing
 - definition, 179
 - flavor, 187–188
 - functionality, 186–187
 - proteins, 181–186
 - single-screw, 179
 - soy proteins and gluten, 181
 - temperature, 180
 - thermal denaturation, 180
 - transmission electron microscopy (TEM), 181
 - twin-screw extruders, 179–180
 - puffed snacks
 - corn starch levels, 193
 - high-protein corn meal products, 192
 - whey, 192
 - whey and soy crisps, 194
- F**
- FCV. *See* Feline calicivirus
 - Feline calicivirus (FCV)
 - chlorine, 18
 - inactivation, 17
 - resistance, 12–14
 - survival, 16–17
 - Fluid milk production
 - EPA, 43
 - FAO estimation, 43–44
 - food processing industries, 44
 - GHG emissions
 - atmospheric concentration, 42–43
 - on-farm, 62–70
 - processing plants, 70–79
 - LCA
 - components, 45–46
 - LCIA, 46
 - milk supply chain, 46–62
 - plants, 70–79
 - sustainable development, 44–45
- G**
- Gibbs–Marangoni mechanism, 234
 - Greenhouse gas (GHG) emissions, 52–61
 - See also* On-farm GHG emission, mitigation; Processing plants and GHG emission mitigation
 - carbon dioxide estimation
 - electricity usage, 55–56

Greenhouse gas (GHG) emissions, 52–61
See also On-farm GHG emission, mitigation; Processing plants and GHG emission mitigation (*cont.*)
 farm, 54
 manure storage, 55
 carbon footprint, 56
 methane emissions estimation
 dairy cows, 53
 fermentation pathways, 53
 microorganisms, 54
 milk processing plant
 benchmarking, 58
 CIP operations, 59
 HTST pasteurization, 57
 refrigerants loss, 59
 SEC, 57–58
 nitrous oxide estimation
 crop production, 52
 direct and indirect, 53
 soils, 53
 packaging
 gallon containers, 60–61
 plastic bottles, 59
 retail, 61
 transportation
 and distribution, packaged milk, 61
 farm to processing plant, 56

H

Hertz model
 elastic deformation, 215
 force–distance curves, 222
 Highly ordered pyrolytic graphite (HOPG)
 casein micelles, 218, 220
 milk/ κ -carrageenan mixtures, 220
 High-performance liquid chromatography (HPLC)
 detectors, 116
 and GC, 115
 honey
 amino acids, 100
 authentic honeys, 105
 enantiomeric ratios, 100
 polyphenols, 116
 oligosaccharide profile, 105
 phenolic acids, 115
 polyphenolic compounds, 118
 solid phase extraction (SPE), 114
 High pressure homogenization (HPH), 74–75

High-temperature short time (HTST)
 pasteurization
 GHGs, 72
 heat demand, 77
 milk nutrition, 75
 replacements, 73
 temperature, 57
 UHT, 73
 HMF. *See* Hydroxymethylfurfural
 Hole-in-the-pipe (HIP) model, 52
 Honey
 analytical techniques, 93–94
 authentication
 additives and water removal, 95–96
 botanical origin and mislabeling, 96–97
 geographical origin and mislabeling, 97
 industrial processing, 93, 95
 CA, 90–91
 chemical composition and analytical methods, 98–121
 definition, 90
 hesperetin and methyl anthranilate, citrus honey, 121
 marker compounds
 abscisic acid, heather honey, 121
 3-aminoacetophenone, chestnut honey, 122
 hesperetin and methyl anthranilate, citrus honey, 121–122
 minerals and elements analysis, 92
 mislabeling and adulteration, 91
 protein, identification, 92–93
 HPH. *See* High pressure homogenization
 HPLC. *See* High-performance liquid chromatography
 HTST. *See* High-temperature short time
 Hydroxymethylfurfural (HMF)
 adulteration, 104
 content value, 107

I

IC–CD. *See* Ionic chromatography–conductivity detection
 Ionic chromatography–conductivity detection (IC–CD), 115

J

Japan food allergen labeling regulation
 characteristics, 146–147
 detection methods, ingredients

banana, 166–167
 ELISA, 153–155
 guideline criteria, validation protocol,
 152–153
 kiwifruit, 166
 limits of detection (LOD), 147
 meat, 167
 PCR method, 156
 practical test, monitoring, 159, 163
 reference material and calibrator,
 149–151
 soybean, 163–165
 threshold, 147–148
 validation study, 156–157,
 159–162
 walnut, 165–166
 Western blotting, egg and milk,
 155–156

Food Sanitation Law, 144–145

immediate-type, assessment

anaphylaxis cases, 144
 cases, 1998–1999, 142
 cases, 2001–2002, 143
 food sanitary law, 140
 questionnaire, 141
 survey, 141

ingredients, MHLW, 145

mandatory and recommended stages,
 145

patient evaluation

characteristics, surveyed subjects,
 168
 comprehension and understanding,
 169
 incidence, accidental intake, 169
 questionnaire, 167

L

LCA. *See* Life cycle analysis

LCIA. *See* Life cycle impact assessment

Life cycle analysis (LCA)

application, 46
 components, 45
 fluid milk supply chain
 dairy products, 46
 GHG emissions, 47–48
 goal and scope, 48–49
 inventory analysis, 49–61
 LCIA, 61–62
 technique, 44

Life cycle impact assessment (LCIA), 46

M

Melissopalynology, 110

Milk supply chain, LCA

dairy products consumption, 46–47
 GHG emissions, 47–48
 goal and scope definition
 boundaries, 48–49
 ECM formula, 49
 inventory analysis
 crop/milk production, 50
 distribution, 51–52
 GHG emissions sources, 52–61
 milk processing, 51
 packaging, 51
 retail/consumer, 52
 transportation, 50–51
 LCIA, 61–62

MNV. *See* Murine norovirus

Murine norovirus (MNV)

disinfection, 11
 inactivation, 18
 removal, fruits and vegetables, 17–18
 resistance, 12–14, 17

N

Norovirus (NoV)

description, 2

fomite contamination

epidemiological links, 15
 MNV and FCV, 10–14

food handlers

characteristics, 15–16
 poor personal hygiene practices, 15
 transmission control, 16

genetic types and outbreak association

GI and GII genotypes, 7
 GII.4 cluster, 3, 7

infection, 3

open reading frames, 2

person to person

closed/semiclosed settings, 8–9
 GII.4, 8
 hospitals, 9
 hotels/schools, 9
 human volunteer studies, 7–8
 infection control measures, 10
 prevention and limitation, 9–10

reports, outbreak, 4–6

water and food

calicivirus survival, 16
 chemical treatment, 17–18

- Norovirus (NoV) (*cont.*)
 cooking, 20
 fruits and vegetables, 20
 MNV and FCV, 16–17
 shellfish, 19–20
 temperature control, 17
 waterborne, 18–19
- NoV. *See* Norovirus
- O**
- On-farm GHG emission, mitigation
 carbon dioxide
 NT methods, 69
 SOC, 68–69
 methane
 anaerobic digestion, 67
 biochar, 68
 bST uses, 66
 digesters types, 67–68
 feeding practices, 64
 management practices, 66–67
 manure management, 67
 methanogenesis process, 65–66
 oil and oilseeds, 64–65
 probiotics, 65–66
 propionate precursors, 66
 thermochemical conversion, 68
 models, predictions, 69–70
 nitrous oxide
 N inputs, soil, 62–63
 practices, 63–64
- P**
- Pollen analysis
 authentication, botanical origin honey,
 111–112
 melissopalynology, 110
 royal jelly, 110–111
 usage, 97
- Processing, extrusion texturized dairy
 proteins
 definition, 179
 flavor
 carbohydrates and lipids, 187
 retention, 187
 vitamins, 188
 functionality
 foaming and digestibility, 186
 partial denaturation, 187
 physical properties, WPI, 186
 proteins, effect
 amino acids, 181
 denaturation and aggregation, whey,
 182
 digestibility, 184
 disulfide bonds, 181–182
 electron-density mapping, 185
 electron micrographs, WPI, 183
 extrusion melt temperatures, 182–183
 Fourier transforms, 186
 insolubility test, 182
 polyacrylamide gel electrophoresis,
 182
 SDS-PAGE, 184–185
 spatial spectral analyses, 185
 single-screw, 179
 soy proteins and gluten, 181
 temperature, 180
 thermal denaturation, 180
 transmission electron microscopy (TEM),
 181
 twin-screw extruders, 179–180
- Processing plants and GHG emission
 mitigation
 CIP procedures, 76
 energy information data, 71
 energy management systems
 CHP, 78
 dairy industry, 76
 pinch technology, 77
 fluid milk process, 72–73
 implementation
 energy efficiency, 70–71
 tools, 71
 LCA and GHG audits, 72
 packaging
 LCA, 78
 milk containers manufacture, 78–79
 recycled HDPE resin, 78
 pasteurization technologies
 bacto-fugation and HPH, 74
 CIP operation, 74
 HTST and UHT, 73–74
 sustainability, 75–76
 transportation, 79
- R**
- Rennet casein, 174, 190
- S**
- SEC. *See* Specific energy consumption
 SIRA. *See* Stable isotopic ratio analysis

INDEX

A

- Alcoholic fermentation, Vin Santo
 analytical and organoleptic, yeast
 madre, 90–91
 microorganisms, 88
 non-*Saccharomyces*, 88–90
S. cerevisiae strains, 89
vinsantaia, 90
 grape drying, microbial population
 apiculate yeasts, 81
 Greco Bianco and Mantonico Bianco, 82
 lactic acid bacteria, 81
 Malvasia and Zibibbo grapes, 82–83
 microflora, 80–81
 yeasts, 81–82
 madre addition
 description, 83
S. cerevisiae, 83–84
 sensory attributes, 84, 85
Zygosaccharomyces, 83
 passito, 80
 Picolit, 82
 starter inoculum
 Italian passito wines, 84
 mixed, 88
 non-*Saccharomyces*, 87–88
 passito wines, 85
Saccharomyces, 85, 86
Saccharomyces yeast, 84
S. cerevisiae, 84–85
S. cerevisiae and *S. bayanus*, 86
S. uvarum, 86
T. delbrueckii and *Z. bailii*, 88
Z. rouxii strain, 88
vinsantaia, 80
 Amarone wine
 alcoholic fermentation and maceration
 advantages, starter strains, 297
 anthocyanin extraction and color
 stabilization, 299
 botrytized, 299
 "cap", 298
 chemical–physical change, 299
 environmental condition, 296
 grape maceration, 298
 hexanols, 298–299
 nutrients release, 297
 phenolic compounds, anthocyanins
 and tannins, 297–298
 prefermentative cold maceration,
 298–299
 starter yeast strains, 297
 strains sequence, 297
 sulfur dioxide and volatile acids,
 296–297
 temperatures, 297
 yeast flora, 297
 area, production
 characterization, 289
 Eastern part, 289
 hills, 288
 natural boundaries, 288
 rainfall, 289
 soils and Prun stone, 289
 temperatures, 289
 valley and Garda Lake, 289
 winds, 289
 biotechnology
 grape dehydration phase, 302–303
 stages, 302
 winemaking process, 303
 grapevine cultivars
 Corvina, 290
 Corvinone, 290
 genetic heritage, 290
 indigenous varieties, 289
 Molinara, 291
 Rondinella, 291
 varietal composition, 291
 varietal transplantations, 291
 history
Acinatico, 286
 occurrence, 286
Recioto wine, 287
 sensory attributes, 287–288
 significance, 286
 stuck fermentation, 287

- Amarone wine (*cont.*)
 sweet food/beverage, 287
 tastes, 287
 technology, 286–287
 as “very bitter”, 287
 malolactic fermentation
 autochthonous *O. oeni* strains, 300
 LAB, 299
Leuconostoc oenos, 300
 ribotyping and macrorestriction profile
 analyzes, 300
 maturation, cooperage
 “aging”, 300
 ambient temperature and humidity,
 301
 autolysis, yeast cells, 301
 clarification, 301
 fragrance, 301
 humidity control, 301
 oak cooperage, 301
 “protective colloids”, 302
sur lees maturation, 302
 tannins and aldehydes, 300–301
 wood porosity, 300–301
 production
 grape selection, 291–292
 postharvest grapes drying, 292–295
 sensory characteristics, 296
- Amontillado sherry
 characterization, 27
 odor-active compound, 31–32, 33
 two-stage process production, 27
- Apple vermouth
 cider, 265
 flow sheet, preparation, 266
 PCA and descriptive analysis, 266–267
- B**
- Biotechnology, amarone
 grape dehydration phase
 hermo-hygro-metric conditions, 302
 infection, *B. cinerea*, 302–303
 stages, 302
 winemaking process
 aging, 303
 cold and alcohol tolerance, 303
 sensory individuality, 303
- Botrytized wines
 aging and stabilization
Botrytis glucan, 189
 calcium mucate crystals, 189
Cladosporium cellare, 188, 189
 premium sauternes, 188
 Szamorodni, 188
 Tokaji aszú, 188
- biogenic amines
 formation, 192
 histamine contents, 192–194
 malolactic fermentation, 192
 occurrence, 193
 Tokaji aszú, 194
- Botrytis cinerea*, 148
 fermentation
 chemical composition, 179–185
 technique, 186–187
 yeasts, 176–179
- grape processing
 cold pressing technology, 174–175
 decanting, 175–176
 maceration, 175
 oxidation, 174
 puttonyos aszú, 175
 sulfiting, 175
- harvest, production, 173–174
- health promoting attributes
 antioxidant capacity, 191
 polyphenols, 190
 red wines, 190
 resveratrol, 190
 Sauvignon/Sémillon grapes, 192
 Tokaji aszú, 189–190
- and late-harvest wines, 148
- mycotoxins
 OTA, 194, 195
Penicillium and *Aspergillus* species,
 195
 Prädikat wines, 195
- noble rot
 effects, juice composition, 165–170
 grape microbiota, 170–172
 induction and control, 172–173
 infection, *B. cinerea*, 161–162
 process and conditions, 163–165
 sweet, 159–160
 technological and analytical parameters
 French, Australian, South African and
 Californian, 152
 Hungary, Germany and Austria, 150
- types
 German and Austrian, 157–158
 passito wines, 160–161
 Sauternes and French styles, 158–159
 Tokaji aszú, 149–156
- Bottle-aged port, 139

C

- “Camara de Lobos”, 211
- Canteiros, Madeira wines, 213–214
- Carbonic maceration (CM) wines
 - berry fermentation, 2
 - distinctive sensory characteristics
 - aging and shelflife, 4
 - aroma compounds, 4
 - color depth and tannic sensation, 3–4
 - esters, 4
 - foxy and raspberry aromas, 4
 - economy, 5
 - grape berries, AM
 - activation and termination, 13
 - anoxia, 12–13
 - cell exploitation, 11
 - CO₂, 12
 - cytoplasmic enzymes, 11–12
 - intracellular fermentation, 11
 - sequence, 12
 - grape-berry ripening, 13
 - history
 - description, 3
 - dessert grapes, 2–3
 - French Academy of Agriculture, 3
 - winemaking process
 - devatting, pressing, 8, 9
 - diffusion fermentations, 11
 - fermentation, 9–11
 - grape harvesting, transportation and vating, 6–7
 - maceration-fermentation step, 7–8
 - steps, 5, 6
- Chemical composition, port wine
 - polyphenols
 - anthocyanins and flavan-3-ols, 138
 - color composition, 138
 - oxidative cycloaddition products, 138
 - phenolic compounds, 137–138
 - red wine, 137
 - volatiles
 - aroma, young port, 138–139
 - bottle-aged port, 139
 - dichloromethane extract, Touriga Nacional, 141
 - old tawny port wines, sulfur compounds, 142
 - oxidative reaction, 141–143
 - oxygen, free SO₂, pH and time/temperature, 140–141
 - sulfur compounds, young ports, 142
 - temperature and pH, 139–140

- young ports, 140
- Chemical composition, sherry wines
 - alcohols
 - acetaldehyde, 24–25
 - ethanol, 24
 - glycerol, 25
 - flor yeast, 23–24
 - nitrogen compounds
 - amino acids, 25
 - S. cerevisiae*, 25
 - organic acids, 26
 - polyphenols
 - amontillado-type, 27
 - chromatograms, 27, 28
 - fino-type sherries, 26
 - LDA, 27–29
 - oloroso-type, 26–27

D

- Douro Demarcated Region (DDR)
 - Entrepoto of Gaia, 121
 - grape varieties
 - blue-black, 127
 - climatic conditions, 125–126
 - red and white, 126, 127
 - Tinta Amarela, 128
 - Tinta Barroca, 128
 - Tinta Roriz, 128
 - Tinto Cão, 128
 - Touriga Franca (*see* Touriga Franca)
 - Vitis vinifera*, 126–127
 - location, 122
 - Lower Corgo, 122–124
 - rabelo boats, 121
 - socalcos-terraced vineyards, 120
 - soil and climate
 - characterization, 125
 - rock formation, 124
 - schistous, 125
 - temperature, 125
 - Upper Corgo, 123, 124
 - Upper Douro, 123, 124

E

“Estufagem”, 213

F

- Fermentation, botrytized musts
 - chemical composition
 - aroma, 182–183, 184
 - carbonyl compounds, 182

Fermentation, botrytized musts (*cont.*)
 gas chromatography–olfactometry, 183
 high sugar content, 179–182
 nitrogen deficiency, 182
 odorants, 183
 traditional wines, 179, 180
 volatile thiols, 183, 186
 technique
 carbonyl compounds removal, 187
 cessation, 186–187
 dimethyldicarbonate (DMDC), 187
 fermentors, 186
 temperature control, 186
 Tokaj aszú, 187
 yeasts
 alcoholic, 177
 cryotolerant, 177–178
 molecular identification methods, 178
 non-*Saccharomyces* species, 176
 population dynamics, 176
 starter cultures, 179
S. uvarum strains, 178
 taxonomy, 178
 technological traits, 179

Fino sherry
 aroma, 29–30
 biological aging, 30
 and oloroso wines, 27
 phenolic aldehydes, 27
 volatile compounds, 31

Flavoring, vermouth
 aging and finishing, 264
 bottling, 264
 fortification and blending, 264
 herbs and spices
 flavorants classification, 260
 plant part used, 261
 methods
 alcoholic infusion, 263
 concentrates, 263
 direct extraction, 263
 macerating, 263–264

G

German and Austrian botrytized wines
 Ausbruch, 158
 Auslese, 157
 beerenauslese (BA) and
 trockenbeerenauslese (TBA), 157
 Ruster Ausbruch, 158
 Schloss Johannisberg vineyards, 157
 vinification technology, 157–158

H

“Hippocratic wine”, 254

I

Italian Vin Santo

chemical and organoleptic characteristics
 alcohol content, 47
 color, 63
 composition, 62
 ethanol and sugar concentration, 47, 61
 flavor and taste, Tuscany, 65
 inoculated, volatiles compounds, 65
 residual sugar, 50–61
 styles characterization, 63
 sweet and sweet style, 62
 Tuscany, 61, 62
 Vigoleno, Barbieri, 62, 63
 volatile compounds, 62–63, 64
vs. white and red wines, 63–65
 classification and style
 nonaromatic passito wines, 46, 48
 passito wines, 46, 47
 sweetness and alcohol content, 47

J

Jaune wines, 21–22

L

Lactic acid bacteria (LAB), 299

M

Madeira wine making

amino acids and biogenic amines
 chemical structure, 237
 concentration, 237–238
 nitrogen source, 236–237
 putrescine and cadaverine, 237

authenticity

physicochemical parameters, 242–244
 quality certificates, 242
 statistics analysis, 242–244

grape varieties

poios, 211
 Tinta Negra, 210–211
 vineyards, 211
Vitis vinifera varieties, 210–211

history

discovery, America, 209
 Germany, 210
 Napoleonic Wars, 210

- Portuguese explorations, 209
 - production and export, 210
 - quality control, 210
 - United States, 210
 - mineral composition, 238
 - organic acids, 236
 - parameters
 - analytical, 217
 - physiochemical subdivisions, 215–216
 - polyphenols, table
 - antioxidant capacity, 241
 - beneficial effects, 238, 240
 - biosynthesis, 239
 - chemical structures, 241
 - concentration, 243
 - metabolites, 239–240
 - nonflavonoid phenolic compounds, 239, 240
 - Palheiros red wine, 242
 - protocatechuic acid, 242
 - production and marketing
 - evolution, 214
 - V. vinifera* L. grapes, 214–215
 - specificity
 - baking process, “Estufagem”, 213
 - characteristics, 212
 - harvesting, 211
 - sweetness and divisions, 211–212
 - unit operations, 212
 - wooden casks support, “Canteiros”, 213–214
 - volatile and aroma compounds
 - constituents, 218–228
 - evolution, aging, 228–232
 - extraction techniques and analytical methodologies, 216–218
 - impact odorants, 232–235
 - Mango vermouth, 265
 - Mead production
 - description, 102
 - fermentation
 - alcohol content, 111–112
 - calcium alginate gels/pectate, 113–114
 - heat treatments, 112
 - honey, 113
 - honey pH, 112–113
 - microorganism, 110–111
 - optimization, 113
 - organic acid content, 113
 - production steps, 112
 - rate, 115
 - sugar content, 111
 - temperature and salt concentration, 113
 - flavorants, 115–116
 - honey
 - composition and physicochemical properties, 103–107
 - definition, Portuguese law, 103
 - description, 103
 - microbiota, 109–110
 - quality indicators, 107–109
 - postfermentation adjustments and maturation
 - aging, 114
 - bentonite, 114
 - brandy and alcohol content, 114
 - HMF and phenolic contents, 115
 - shelf life, 115
 - sturdy bottles, 115
 - sugar content, 114
 - production, 110–115
 - scientific and technical research, 102
 - yeast strain, 115
 - Montilla-Moriles wines
 - pedro ximenez, 34
 - two-stage aging process, 21
- N**
- “Noble late harvest”, 160
 - Noble rot, botrytized wines
 - effects, juice composition
 - acidity, 167
 - aroma composition, 169, 186
 - berry sugars, 166
 - cysteine-S-conjugates, 169–170
 - exocellular proteolytic enzymes, 167
 - galacturonic acid, 166–167
 - γ - and δ -lactones, 169
 - glycerol production, 166
 - nitrogen compounds, 168
 - polymerized quinones, 169
 - polysaccharides, 168
 - sugar content, 166–167
 - terpenols, 169
 - grape microbiota
 - acetic acid, 171–172
 - biocontrol agent, 171
 - Candida* species, 170–171
 - lactic acid bacteria, 172
 - Penicillium* and *Aspergillus* species, 171
 - Saccharomyces* species, 171
 - induction and control

Noble rot, botrytized wines (*cont.*)

- field inoculation, 172
- inoculation, 172
- spore suspensions, 172
- weather condition, 172–173

infection, *B. cinerea*

- conidiophore and conidia, 161
 - cutinolytic activity, 162
 - flowers and leaves, 162
 - polyphageous, 161–162
- process and conditions
- conidial germination, 165
 - micropore formation and wound, epidermis, 164
 - mycelia and conidiophores, 163–165
 - peristomal microfissures, 163
 - phytoalexins production, 165
 - pourri roti, 163–165
 - pourry plein, 163

O

Odor activity values (OAVs)

- odor thresholds, 225–226
- spider-web, odorants, 226, 227

Oloroso sherry

- benzoic and cinnamic acids, 27
- characterization, 26–27
- Z-whisky lactone, 31

P

Passito wines, 160–161

Physiochemical characteristics, vermouth

- apple
 - alcohol, 274
 - sugar levels, 274
- dry and sweet
 - composition, 272
 - plum, 273
- mango, composition, 271, 272
- minerals, 275
- sand pear base wine and sweet, 273
- viscosity, 275
- wild apricot, spices level, 273, 275

Plum vermouth

- alcohol concentrations, 267–268
- spices and herbs, 267

Pomegranate vermouth, 269

Port wine

- benefit
 - IVDP, 129
 - quantities, 130

- scoring system, 129–130
- vineyards classification, 130

chemical composition

- polyphenols, 137–138
- volatiles, 138–143

DDR (*see* Douro Demarcated Region)

description, 120

IVDP, IP, 121–122

production

- alcohol and sugar content, 130
- blending, 132
- bottle aging, 133
- grape crushing, 131, 132
- racking and fining, 131–132
- red port, 130–131
- spirit, 131
- vats/balseiros, 132, 133
- wood casks, 132
- young wine, 131

types

- age indication, 137
- colheita/data de colheita, 137
- color, 135
- crusted, 136–137
- LBV, 136
- reserve, 137
- rosé, 135
- ruby, 135
- sugar content, classification, 133–134
- sweetness, alcohol content and color, 133
- tawny, 135
- traditional, 136
- vintage, 136
- vintage cellar, 134
- white, 135

Production, amarone wine

- “aging”, 296
- alcoholic fermentation, 295, 296
- grape selection
 - alcohol content, 291–292
 - arele* and *fruttaio*, 292
 - harvested clusters, 292
- maceration, 295
- malolactic fermentation, 296
- maturation, 296
- postharvest grapes drying
 - climatic data database, 295
 - dehydration and weight loss, 292–293
 - fungal invasion, 293–294
 - gray rot, 293–294

- lofts, 295
 - loose moisture, 293–294
 - noble rot, 293–294
 - trays role, 294–295
 - sensory characteristics, 296
 - transformation and crushing, 295
- R**
- Red ports, 135
- S**
- Sand pear vermouth
 - dry and sweet versions, 268–269
 - preparation, 268
 - Sauternes botrytized wines, 158–159
 - “Sélection de Grains Nobles” (SGN), 159
 - Sensory quality, vermouth
 - astringency and bitterness
 - sucrose, 278
 - time-intensity measurements, 276–278
 - flavor profiling
 - evaluation methods, 279
 - PCA, 279–280
 - quantitative descriptive analysis (QDA), 279
 - sweetness and viscosity, 278–279
 - wild apricot, levels
 - alcohol, 277
 - spices, 277
 - sugar, 276
 - Sherry wines
 - aroma and sensory characteristics, aging
 - acetaldehyde, 29–30
 - α -butyrolactone and pantolactone, 30–31
 - esters, 30
 - fino wines, 31
 - flor yeasts, 30
 - lactones, oak, 31
 - odor-active compounds, 31–32
 - odor activity value (OAV), 31
 - sotolon, 30
 - volatile compounds, 29
 - wood lactone, 31
 - chemical composition, biological and oxidative aging
 - alcohols, 24–25
 - flor yeast, 23–24
 - nitrogen compounds, 25
 - organic acids, 26
 - polyphenols, 26–29
 - flor film microbiota
 - amino acids, urea and ammonium ions, 23
 - biological aging, 22
 - enzyme activity, 22–23
 - lactic acid bacteria, 23
 - physiological and molecular characterization, 22
 - making process
 - biological aging, 20
 - categories, 21
 - flor yeast, 19–20
 - jaune, 21–22
 - rocío, 21
 - solera and criadera, 20
 - steps, 19
 - sweet wines, 21
 - solera and criaderas system, 18
 - technology
 - accelerated biological aging, 32–33
 - drying condition, 34
 - organic grapes, 34–35
 - velum, 18–19
- T**
- Tamarind vermouth, 269
 - Tinta Amarela, 128
 - Tinta Barroca, 128
 - Tinta Negra Madeira wines
 - ethyl hexanoate and octanoate, 226
 - volatile compounds, 226
 - Tinta Roriz, 128
 - Tinto Cão, 128
 - Tokaji aszú
 - biogenic amine, 194
 - chemical composition, 156
 - curative powers, 189–190
 - Esszencia/Essencia, 155
 - Fordítás, Máslás and Szamorodni, 155
 - γ - and δ -lactones, 169
 - glycerol production, 166
 - grape cluster, aszú and shriveled berries, 154
 - harvest, 154
 - juice extraction, 175
 - noble-rotted grapes, 149
 - oak barrels, 155
 - vineyards, 149–154
 - Touriga Franca
 - description, 127
 - wine characterization, 128

Touriga Francesa. *See* Touriga Franca

Touriga Nacional

blue-black grapes, 127

Vitis vinifera, 126–127

V

Vermouth

base wine preparation

requirements, 258

sweetening and color intensification,
258

brandy distillation

fermentation, 259

fractions, 260

Saccharomyces bayanus, 259–260

categories, 252–253, 256

dry (French)

alcohol content, 257

base, 257–258

Europe, 257

fortifying alcohol, 257–258

Martini and Rossi, 258

flavoring, base wine

aging and finishing, 264

bottling, 264

fortification and blending, 264

herbs and spices, 260

methods, 260–264

history

France, 254

Piedmont (Italy), 254

rosé vermouth, 254–255

sweet and dry versions, 254

Vinum Hippocraticum, 254

wormwood, 253

legal requirements, 280

medicinal and aromatic value

oxidative stress, 255

properties, 255

nongrape fruits, preparation

apple, 265–267

mango, 265

plum, 267–268

pomegranate, 269

sand pear, 268–269

tamarind, 269

wild apricot, 269

quality

physiochemical characteristics,
270–275

sensory quality, 276–280

steps, production, 258, 259

sweet (Italian)

American, 256

California, 256–257

France, 256

muscat flavor, 256

pH addition, 257

Vinho do Porto. *See* Port wine

Vin Santo

alcoholic fermentation

analytical and organoleptic, yeast,
88–91, 89

apiculate yeasts, 81

Greco Bianco and Mantonicco Bianco, 82

lactic acid bacteria, 81

madre addition, 83–84, 85

Malvasia and Zibibbo grapes, 82–83

microflora, 80–81

passito, 80

picolit, 82

starter inoculum, 84–88

vinsantaia, 80

yeasts, 81–82

barrel maturation

aging, 92

commercial yeast, 93

gross lees, 91

madre, 93

organoleptic characteristics, 93

oxidation, 92

oxygen, 92

phases, aging, 91

phenolic compounds, 92

sensorial characteristics, 94

sugar metabolism, 91

temperature, 91–92

vinsantaia, 91, 93

definition, 42–43

description, 42

drying, grapes

and aroma compounds, 77–79

factors, 76–77

metabolism, 76

techniques, 75–76

grape varieties

passito wines, 74–75

terpene aromas, 73–74

Italy

alcohol content, 44

chemical and organoleptic
characteristics, 47–65

classification and style, 46–47

color, 44

- definitions, 43, 44
 - and European Union regulation, 66–67
 - nonaromatic passito wines, 48
 - passito wines grape drying system, 47
 - production areas, 43
 - sugar concentration, 43–44
 - origin history, 45–46
 - pressing and barrel filling
 - “caratelli”, 80
 - juice quality, 79–80
 - temperature, 80
 - production
 - areas, 42
 - Florence, 73
 - and marketing, 67–73
 - in Tuscany, 68, 69, 71
 - Vigoleno, 71
 - Santorini
 - PDO Santorini, 45
 - taste, 45
 - white grape varieties, 45
 - Volatile and aroma compounds, Madeira wine
 - constituents
 - compositional parameters, 219
 - ethyl hexanoate and octanoate, 226
 - furan compound values, 235
 - higher alcohols, 226
 - monoterpenoids, 219–224
 - multivariate analysis, 225–226
 - OAVs, 225–226
 - odor-active, 218–219
 - odor descriptors and threshold, 219
 - odor thresholds, 220, 225–226
 - PCA and SLDA, 224–225
 - prefermentative, fermentative and post fermentative, 219
 - profile, varietal origin, 225
 - short-chain aldehydes and alcohols, 227
 - spider-web, odorants, 226, 227
 - V. vinifera*, 224
 - evolution, aging
 - chemical families, 232
 - γ -decalactone, 229
 - FAEE and EE concentration, 230
 - heterocyclic acetals, 229–230
 - linear correlation, concentration and age, 230
 - Malvasia wines, aged 1 and 25, 230, 231
 - 3-methylbutan-1-ol and 2-phenylethanol content, 230
 - oak aromas, 228–229
 - potential age markers, 230–232
 - sensory attributes, 228
 - temperature and time, baking, 232
 - extraction techniques and analytical methodologies
 - compound analysis, low concentrations, 216–218
 - gas chromatograph detectors, 218
 - GC X GC, 218
 - legal limits, 216
 - SPME and SPDE, 218
 - wine matrix complexity, 216–218
 - impact odorants, 232–235
- W**
- Wild apricot vermouth
 - evaluation, 269
 - preparation
 - extract, 270
 - flow sheet, 271
 - Winemaking process, CM
 - anaerobic metabolism, grape berries, 6
 - devatting, pressing, 8, 9
 - diffusion fermentations, 11
 - fermentation, 9–11
 - grape harvesting, transportation, and vating, 6–7
 - maceration-fermentation step, 7–8
 - steps, 5, 6
 - “Wine of hospitality”, 45

SOC. *See* Soil organic carbon

Soil organic carbon (SOC)

carbon storage, 68

sequestration, 69

Specific energy consumption (SEC), 57–58

Stable isotopic ratio analysis (SIRA), 119, 121

T

Texturized WPI (TWPI)

digestibility, 184

functionality, 186

spatial spectral analyses, 185

Triple Bottom Line, 44

TWPI. *See* Texturized WPI

U

UHT. *See* Ultrahigh temperature

Ultrahigh temperature (UHT)

milk, 73

pasteurization, 57

process, 73

Unifloral honey, 111

W

Whey protein isolate (WPI)

extruded, fat mimic, 194

extrusion melt temperatures, 183

heat-treated, 184

microstructural changes, 182–183

physical properties, 186

solubility, 190

twin-screw extrusion, 179

WPI. *See* Whey protein isolate

INDEX

A

- AAA Ca. *See* Active absorbable algal calcium
- AAS. *See* Amino acid score
- ACE. *See* Angiotensin I-converting enzyme
- Activated partial thromboplastin time (APTT)
- prolongation, 236–237
 - TT pathways, 236–237
- Active absorbable algal calcium (AAA Ca), 49
- Adequate intake (AI), 375
- Alginates, 91–92
- Alkaline phosphatase (ALP), 430
- Amino acid score (AAS), 308–309
- Angiotensin I-converting enzyme (ACE), 318
- Antiallergic benefit, marine algae
- allergy, 268
 - compounds, 268–269
 - therapeutic inhibitors
 - macroalgae, 269
 - microalgae, 272–273
 - phlorotannins, 270
 - polysaccharides, 270–271
- Antiallergic compounds
- phlorotannins, 270
 - polysaccharides
 - marine algae, 270–271
 - porphyran, 271
- Anticancer compounds, marine macroalgae
- brown algal species, 215
 - carotenoids, 220–221
 - functional foods, 221–222
 - metabolites, 214–215
 - phlorotannins, 218–220
 - plants and terrestrial microorganisms, 214–215
 - sulfated polysaccharides
 - carrageenans, 217–218
 - fucoïdan, 216–217
 - monomeric units, 215–216
 - ulvans, 218
 - synthetic drugs and natural products, 214
- Anticancer effect, SPs
- apoptosis *in vitro*, 397
 - tumor cell proliferation, 397
- Anticoagulant effect, marine algae
- bioactive substances, 236–237
 - blood coagulation system, 236
 - description, 236
 - heparin, 236, 241
 - organisms, 236
 - phlorotannins, 237–239
 - PT, 241
 - Sargassum thunbergii*, 241
 - SPs, 237, 240
- Anti-human immunodeficiency virus (HIV) activity
- AIDS, 257
- DT1 and DT2, 262–263
- gp120 and gp41, 256
- lectins
- BCA, 262
 - description, 261
 - Griffithsin, 261–262
- macroalgae, 262
- phlorotannins
- 6,6'-bieckol, 258
 - Ecklonia cava*, 258
 - Ishige okamurae*, 258
 - tannins, 257
- polysaccharides
- Adenocystis utricularis*, 260
 - effects, 259
 - fucans, 259–260
 - GFP and GLP, 260
 - Schizymenia dubyi*, 260
 - SPMG, 260–261
 - therapeutic agents, 256
- Antioxidant effect, SPs
- ABTS radical scavenging, 394–395
- antioxidant activity, 394–395
- marine algae, 394
- natural antioxidants, 395
- ROS, 394
- structural features, 394–395

- Antiviral effect, SPs
 algal sulfated polysaccharides, 395–396
 fucoidan, 396
in vitro and *in vivo* infections, 396
 inhibitory effects, 396
 marine algal polysaccharides, 395–396
- APTT. *See* Activated partial thromboplastin time
- Asthma
 characteristics
 airway wall, 282–283
 inflammation, 281–282
Ecklonia cava, 278–279
 factors, 279
 macroalgae
 Ecklonia cava, 281–282
 Eisenia arborea, 281–282
 red algal, 282
 mechanism, 280
 microalgae
 blue-green algae, 282–283
 use, 282–283
 remedies and failures, 281
 symptoms, 278

B

- Biofilm, chronic infection prevention
 agricultural soil enrichment, 404
 anti-biofilm agents, 408
 bacterial cells, 405–406
 bacterial interactions, 405
 carbon-neutral electricity, 407–408
 chemotherapy, 408–409
 diabetic foot ulcer, 411–412
 environmental dangers, 405–406
 eye infection, 412
 fibrosis-associated infections, 404
 formation, 405
 global wound care expenditures, 409
 health care, 408–409
 histological changes, 405–406
 immunity, 412–413
 kidney relevance, 411
 metabolic waste products, 407
 otolaryngologic diseases, 412–413
 periodontal diseases, 409–410
 physiology/growth state, 406–407
 planktonic cells, 407–408
 proinflammatory cytokines, 408
 quorum sensing, 406–407
 surface attachment, 405–406
 synthesis and degradation, 405–406
- wound inflammation, 410
- Biological activity, SPs
 description, 328–329
in vitro studies
 animals and cell model, 330
 anticoagulant, 329
 antioxidant, 329
 properties, 329
 sulfate groups, 329–330
- Bisphosphonates
 adverse side effects, 419
 osteoporosis, 419
- Bone mineral density (BMD), 420
- Bone morphogenic proteins (BMPs), 430

C

- Ca-mineralization, osteoblastic differentiation
 abnormal bone homeostasis, 430
 ALP levels, 434–436
 anti-inflammatory effects, 431
 BMPs, 430
 CMAP, 432, 433
 fucodiphlorethol G, 434
 fucoidans, 434–436
 marine algae therapeutic potential
 bone tissue engineering applications, 437–438
 diet with calcium supplement, 438
 marine compounds, 431
 marine organisms, 430–431
 microalgae and macroalgae, 431
 novel marine metabolites, 431
 osteoblasts and osteoclasts, 430
 phlorotannins, 432–434
 triphlorethol-A, 434
- Capsosiphon fulvescens*-polysaccharides (Cf-PS)
 antioxidant activities, 180
 cell proliferation, 180–181
 description, 180
 ERK1/2 activation, IEC-6 cells
 cross talk model, signaling pathways, 186, 188
 EGFR transactivation, 185–186
 MAPK protein expression, 185
 proliferation, 185, 186
 Wnt signaling, 186, 187
- IEC-6 cell proliferation
 agarose gel electrophoresis, 181–182
 microscopy analysis, 181–182, 183
 MTS assay, 181–182, 183

PCNA protein expression, 181–182, 183
 sea vegetables, 181
 signaling pathways, 180–181
 Wnt signaling components
 cell proliferation and division, 182
 expression measurement, 184
 IEC-6 cells, 184
 time-course experiment, 182

Cardiolam, 94

Cardiovascular diseases (CVD)
 lipids, 344
 risk, 340

Carotenoids
 astaxanthin and fucoxanthin, 220–221
 biological activities, 221

Carrageenans
 antioxidant and antitumor activities,
 217–218
 l-carrageenan, 217–218

Chlorophyta, 73–74

Coccolith matrix acidic polysaccharide
 (CMAP), 432

Cyclooxygenase-2 (COX-2), 343

D

Dietary Reference Intakes (DRIs), 375

Diet with calcium supplement
 bone mineral loss, 438
 ingredients, 438
 mineral-rich supplement, 438
 osteoporosis, 438

E

EAs. *See* Essential amino acids

EGFR. *See* Epidermal growth factor receptor

Eicosapentaenoic acid (EPA)
 ALA conversion, 341
 DHA, 343

Epidermal growth factor receptor (EGFR)
 signaling pathway, 185
 transactivation, 185–186

ERK1/2. *See* Extracellular signal-regulated
 kinase 1/2

Essential amino acids (EAAs)
 levels, 307–308
 ratio, 307–308

Estimated Average Requirement (EAR),
 375

Extracellular signal-regulated kinase
 1/2 (ERK1/2)
 activation, IEC-6 cells

cross talk model, signaling pathways,
 186, 188
 EGFR transactivation, 185–186
 MAPK protein expression, 185
 proliferation, 185, 186
 Wnt signaling, 186, 187
 pathway, 181

F

Female health, beauty and longevity,
 marine algae on
 anticancer activity
 apoptosis, 43–44
 breast cancer, 43
 cervical cancer, 44
 chemopreventive agents, 45
 estrogen-dependent cancers, 44
 antiobesity activity
 detrimental effects, 46
 foods and pharmaceuticals, 48–49
 fucoxanthin, 48
 soluble, insoluble and total fiber,
 46–48
 synthetic antiobesity agents, 46
 antiosteoporosis activity
 AAA Ca, 49
 description, osteoporosis, 49
 dietary fucoxanthin, 49
 antiviral activity, 45–46
 Asia, 42
 marine organisms, 42
 nutritional value and health benefits, 42
 skin whitening activity
 advantages, 50–51
 tyrosinase inhibition, 50

Fucoidans
 anticoagulant and antithrombotic activity
Ecklonia cava, 168–169
 fermentation process, 169
 heparin, 167–168
 mechanism and molecular interaction,
 168–169
Sargassum fulvellum, 169
 anti-inflammatory activity
 connective tissue destruction, 173
 definition, 172
 LPS-stimulated RAW 264.7 cells, 172
 antiproliferative/antitumor/anticancer
 activity
 biological activities, 169, 170
 chemopreventive agents, 170
 inhibitory effects, 169

Fucoidans (*cont.*)

- antitumor and antimetastatic activities, 217
- antiviral activity, 173
- biological properties, 166–167
- chemical structure, 165
- description, 216–217
- fucoxanthin and phlorotannins, 164
- immunomodulatory activity
 - activated splenocytes, 171
 - dendritic cells, 171–172
 - MMP-9, 172
- industrial applications, 173–174
- Laminaria*
 - anticancer properties, 92–93
 - antioxidant activity, 93
 - antivirus effects, 92
 - cholesterol content, reduction, 93–94
 - molecular mass and sulfate content, 93
 - oligosaccharides, 93–94
- MMPIs (*see* Matrix metalloproteinase inhibitors (MMPIs))
- polysaccharides
 - description, 164–165
 - functional, 164
- purification
 - enzyme-assisted extraction
 - technique, 166
 - marine algae, 165–166
 - solvent extraction process, 166
- restenosis, 173
- seaweeds and bioactive components, 164
- toxicology, 173

Fucoxanthin

- antiangiogenic activity
 - angiogenesis, 121–122
 - pathological conditions, 121–122
 - siponaxanthin, 122
- anticancer activity
 - anti-adult T-cell leukemia effects, 117–118
 - apoptosis, 117
 - pharmaceutical and food industries, 118
 - vs.* siphonaxanthin, 117–118
- anti-inflammatory activity
 - inhibition, proinflammatory mediators, 118–119
 - macrophage function, 118
 - scientific analysis, 118–119
- antiobesity activity
 - adipocyte differentiation, 120
 - advantages, 120
 - description, obesity, 119

- WAT, 119–120
- xanthigen, 119–120
- antioxidant activity
 - applications, 116
 - cytoprotective effect, 116
 - free radical-mediated process, 115
 - radical scavenging, 116
 - synthetic antioxidants, 115
- health beneficial effects, 112, 113
- marine algae
 - food diets and traditional remedies, 112
 - pigmentation, 112–113
- marine organisms, 112
- neuroprotective effect
 - natural and synthetic compounds, 120–121
- neurite outgrowth, 121
- wakame, 121
- osteoclastogenesis, 122–123
- profiles and bioavailability
 - absorption and esterification, 114–115
 - adverse side effects, 115
 - amarouciaxanthin A, 114–115
 - chemical structures, 113–114
 - skin protective effect, 122
- Fucoxanthin-rich seaweed extract (Fx-SEE), 202
- Fx-SEE. *See* Fucoxanthin-rich seaweed extract

G

- Glucose transporter 2 (GLUT2), 209
- GLUT2. *See* Glucose transporter 2
- Glutathione (GSH)
 - description, 150
 - levels
 - JNK inhibitor, 158
 - measurement and analysis, 150, 155
- Green water technique, 79–80
- GSH. *See* Glutathione

H

- Herpes simplex virus (HSV)
 - classification, 246
 - infection, 246
 - reproduction, 246–247
- Histone deacetylases (HDACs), 420–421
- Hizikia fusiformis*-polysaccharide (Hf-PS-1),
 - protective effects
 - botanical products, 145
 - description, 145

ethanol-induced gastric damage, rats
 caspases, 149, 150
 composition, powdered sample, 146, 147
 DNA fragmentation, 149, 151
 electrophoresis bands, 146, 148
 epithelial cells, 148–149
 hemorrhaging, 146–148
 intestinal surface, stomach samples, 146–148
 long-term *vs.* short-term experiments, 146–148
 oxidative stress, 150–151
 pharmaceutical products and side effects, 146
 purification procedures, 146, 147
 seaweed compounds, 146
 gastrointestinal disorders and drugs, 144–145
 IEC-6 cells, ethanol-induced injury
 cell viability assays, 151–152, 153, 154
 downregulation, JNK, 152–157
 IGF-IR and Shc phosphorylation, 151–152, 155
 methanol and ethanol extracts, 144
 seaweeds and extracts, 145
 HPV. *See* Human papilloma virus
 HSV. *See* Herpes simplex virus
 Human papilloma virus (HPV)
 carrageenan, 45–46
 infection and vaccine, 45

I

IEC-6. *See* Intestinal epithelial cell line 6
 IGF-IR. *See* Insulin-like growth factor-I receptor
 Immunostimulating effect, SPs
 anti-inflammatory activities, 397
 immune system, 397
 macrophages, 396–397
 Insulin-like growth factor-I receptor (IGF-IR)
 phosphorylation, 151–152, 155
 signaling pathways, 158
 Intestinal epithelial cell line 6 (IEC-6)
 ERK1/2 activation
 cross talk model, signaling pathways, 186, 188
 EGFR transactivation, 185–186
 MAPK protein expression, 185
 proliferation, 185, 186
 Wnt signaling, 186, 187
 proliferation

agarose gel electrophoresis, 181–182
 microscopy analysis, 181–182, 183
 MTS assay, 181–182, 183
 PCNA protein expression, 181–182, 183
 sea vegetables, 181

J

JNK. *See* Jun N-terminal kinase
 Jun N-terminal kinase (JNK)
 activation, 150–151
 downregulation, ethanol-induced toxicity
 Hf-PS-1's protective mechanism, 155–157
 IGF-IR activation, 152–155
 inhibitor SP600125, 155
 MAPK signaling pathway, 152–155, 156
 phosphorylation, 152–155, 156

K

16 kDa fucoidan, 136–137
 Kelp. *See* *Laminaria*

L*Laminaria*

biological properties
 alginates, 91–92
 cardiolam, 94
 fucoidan, 92–94
 laminarin, 94
 medicinal benefits, 91
 chemical properties
 alginic acid, 90
 biologically active substances, 90
 chromists, 88–90
 medicinal properties, 90
 mineral extraction, 90
 vitamins, 90–91
 description, 86
 life cycle, 88, 89
 nutrients, 86
 physical properties
 fucoxanthin, 87–88
 genomic information, 87–88
 structure, 87
Laminaria japonica (LJ)
 antidiabetic effects
 algal polysaccharides, 205
 aqueous extract (LJE), 206
 diabetes, 205
 glucose absorption, 206–207
 glucose intake, Caco-2 cells, 207–209

- Laminaria japonica* (LJ) (cont.)
 glucose transmission, Caco-2 cells, 207–209
 oral carbohydrate tolerance test, 209
 phloridzin, 207–209
 postprandial blood glucose level, 206–207
 rhizoid, 206
 SGLT1 and GLUT2, 209
 structure, glucose transmission test, 207, 208
 antiobesity effects
 active component, 205
 fucoxanthin, 201
 Fx-SEE, 202
 NSK and TK, 202–203
 obesity, 200–201
 sodium alginate, 202
 TK, 202
 wakame lipids (WLs), 201–202
 description, 200
 use, 200, 210
 Laminarin, 94
 Lipids
 phospholipids and sterols, 11
 PUFAs, 10–11
 LJ. *See Laminaria japonica*
 Low-density lipoprotein (LDL) oxidation, 359
- M**
- MAA. *See* Mycosporine-like amino acids
 Macroalgae
 active components, 452
 alkaline phosphatase (ALP), 450
 apoptotic cell death, 449–450
 bone marrow cell coculture, 449–450
 carotenoid fucoxanthin, 449–450
Ecklonia cava, 281–282
Eisenia arborea, 281–282
 ovariectomized group, 450
 rat femoral-diaphyseal tissues, 449
 red algal, 282
Sargassum fusiforme (SME), 449–450, 451
Sargassum horneri, 449
 MAPKs. *See* Mitogen-activated protein kinases
 Marine algae
 active compounds, 419
 bone tissue engineering applications
 calcium phosphate compounds, 437
Corallina officinalis, 437
 graft materials, 437
 hydroxyapatite ceramic granules, 437
 inorganic calcium sources, 437–438
 microporous structure, 437
 brown macroalgae
 anti-HSV activity, 249–250
 fucoidans, 248–249
 colorectal cancer
 active compounds, 231
 brown algae, 230–231
 description, 229
 development, 229–230
 fucoxanthin, 230
 glycoprotein, 230
 description, 226
 diet with calcium supplement
 bone mineral loss, 438
 ingredients, 438
 mineral-rich supplement, 438
 osteoporosis, 438
 environment, 246
 gastricstomach cancer
Capsosiphon fulvescens, 228
 description, 227
 differences, 227–228
 fucoidan, 228
Laminaria japonica, 228–229
 porphyran, 228
 prevention, 228
 gastrointestinal tract cancer, 227
 green macroalgae, 250
 herpes, 246
 microalgae
 HIV-1, 250–251
Spirulina platensis, 250–251
 mineral extraction, 420
 nutritional value, 226
 pharmaceutical research, 226
 purposes, 226
 red, green and brown, 419
 red macroalgae
 galactans, 247–248
 polysaccharide and xylomannans, 247
Polysiphonia denudate, 246–247
 Marine algal sources
 antibacterial screening
 chlorophyta, 73–74
 macroalgae classification, 73
 phaeophyta, 73
 rhodophyta, 73
 antimicrobial potentials, 72
 bioactive compounds
 bromoditerpenes, 74–75

- halogenated furanones, 75
- lectins, 75–76
- phlorotannins, 74
- sesquiterpenes, 74
- biofilm/antifouling bacteria, controlling, 77, 79
- fish bacterial disease, treatment
 - antibacterial activity, 80
 - drug resistance, 79
 - QS, 79–80
- human pathogenic drug/multidrug-resistant strains
 - antimycobacterial activity, 77, 78
 - methanol extracts, 76–77
 - solvents and extraction method, 76
- infectious agents, 72
- therapeutics, 73
- Marine algal sterols. *See* Sterols
- Marine collagen peptides (MCP), 420
- Marine compound
 - BMD, 420
 - mineral extraction, marine algae, 420
- osteoblast differentiation
 - HDACs, 420–421
 - largazole, 421
 - MCP, 420
 - metaphyseal tissues, 422
 - norzoanthamine, 421–422
 - prevalent chronic inflammatory diseases, 422
- osteoclast differentiation
 - biselyngbyaside, 423
 - bolinaquinone, 423
 - fucoxanthin, 423
 - ikarisoside A, 423
 - inhibitor, 422
 - symbioimine, 423
- Marine edible algae, disease prevention
 - cancer prevention, 36–37
 - food health promotion
 - ancient times, 30
 - daily consumption, 30–31
 - nutrition facts, 30–31, 32
 - human diet and chronic diseases, 30
- MetS
 - description, 34–35
 - prevention, 35–36
- NCDs, 31
- Matrix metalloproteinase-9 (MMP-9), 172
- Matrix metalloproteinase inhibitors (MMPi)
 - fucoidans
 - antiproliferative action, 137–138
 - chemical structure, 135–136
 - Costaria costata*, 137–138
 - inhibitory effects, 137–138
 - 16 kDa fucoidan, 136–137
 - photoaging, 135–136
 - therapeutic ability, 136–137
 - MMPs and TIMPs, 130
 - phlorotannins
 - chemical structures, 131–133
 - dieckol and eckol, 133–134
 - Ecklonia* and *Eisenia*, 135
 - eckol and dieckol, 135
 - formation, 131–133
 - functional groups, 133–134
 - osteosarcoma differentiation, 133–134
 - phloroglucinol, 134–135
 - skin wrinkling, 134–135
 - scientific investigations, 138–139
 - seaweeds/marine macroalgae, 131
- Matrix metalloproteinases (MMPs)
 - cell proliferation and metastasis, 137–138
 - description, 130
 - functional groups, 133–134
 - photoaging, 134–136
- Metabolic syndrome (MetS)
 - description, 34–35
 - prevention
 - high blood pressure, 35
 - wakame, 35–36
- MetS. *See* Metabolic syndrome
- Microalgae
 - antiallergic properties, 272–273
 - blue-green algae, 282–283
 - in vitro* experiments, 448–449
 - marine invertebrates, 447
 - marine resources, 272
 - norzoanthamine structure, 448–449
 - symbioimine structure, 447, 448
 - use, 282–283
- Micro and macroalgal consumption on
 - photoprotection
 - food and fuel, 288
 - macroalgal foods
 - Alaria esculenta* and *Laminaria digitata*, 294
 - blue-green algae, 293
 - irish moss, 293
 - lettuce, 293–294
 - MAA, 293
 - proteins and peptides, 292–293
 - purple laver, 292
 - seaweeds, 293

- Micro and macroalgal consumption on photoprotection (*cont.*)
 marine environment, 288
 microalgal foods
Arthrospira platensis/*Spirulina platensis*, 291–292
Chlorella, 292
Phaeodactylum tricornutum, 292
 photoprotection, 288–289
 UV, photodamage and photoprotection description, 289
 ERK and JNK, 290
 ozone layer, 291
 RNS and ROS, 289–290
- Mineral bioavailability
 definition, 385
 nutrient synergistic/antagonistic interactions, 385
 reciprocal antagonistic/synergic behavior, 386
- Mitogen-activated protein kinases (MAPKs)
 mammalian cells, 185
 protein expression, 150–151, 153, 185
 signaling pathway, 152–155, 156, 185–186
- MMP-9. *See* Matrix metalloproteinase-9
- MMPs. *See* Matrix metalloproteinase inhibitors
- MMPs. *See* Matrix metalloproteinases
- Mycosporine-like amino acids (MAA), 293
- N**
- NCDs. *See* Noncommunicable diseases
- Noncommunicable diseases (NCDs), 31
- Nonshaved kombu (NSK)
 and HFD, 202–203
 and TK, inhibitory activities (*see* Tororokombu (TK))
- O**
- Osteoclast differentiation
 bone loss, 444
 drug resistance, 444–445
 macroalgae (*see* Macroalgae)
 microalgae (*see* Microalgae)
 osteoblasts, *in vitro*
 cell viability, 447
 cervical dislocation, 446
 femoral and tibial bone marrow cells, 446–447
 macrophage colony-stimulating factor, 446
 mouse calvarial cells, 447
 multinucleated cells, 447
 myeloid hemopoietic lineage, 446
 osteoporosis-related fracture prevention, 445
 parathyroid hormone, 445
 pharmacological and nutritional factors, 444
 postmenopausal osteoporosis, 445
 trench-digging cells, 445
- Osteoporosis treatment
 bisphosphonates, 419
 bone formation and resorption, 418
 bone homeostasis, 418
 elderly age, 418
 estrogen therapy, 418–419
 marine algae
 active compounds, 419
 red, green, and brown, 419
 marine compound
 bone mineral density (BMD), 420
 mineral extraction, marine algae, 420
 osteoblast differentiation, 420–422
 osteoclast differentiation, 422–423
 osteoblast and osteoclast cells, 418
 prevention and treatment, 418–419
- Otolaryngologic diseases, 412–413
- P**
- Peptide, marine microalgae
 anticancer activity, 318–319
 antihypertensive activity
 ACE, 318
Chlorella, 318
 antioxidant activity
 hydrolysis, 317
 synthetic, 317
 therapeutic modalities, 317–318
 application, 314–315
 bioactivity
Arthrospira, *Chlorella* and *Dunaliella salina*, 316–317
 description, 316
 cultivation, 314–315
 effects
 alcohol, 319
 bioactive, 317, 319
 NIPP-1 and NIPP-2, 319, 320
 human food sources composition, 315–316

- Peroxisome proliferator-activated receptors (PPAR-a), 341
- Phaeophyta, 73
- Phlorotannins
 - antiallergic effects, 105
 - anticancer effects
 - antiproliferative activity, 104
 - inhibition, cancer metastasis, 104–105
 - antidiabetic effects, 106–107
 - anti-inflammatory effects, 106
 - antioxidant effects
 - bioresource, 99–102
 - free radical scavenging ability, 102, 103
 - oxidative stress, 99–102
 - photoprotective ability, 102–104
 - antiproliferative activity, 219–220
 - classification, 237–238
 - definition, medicinal foods, 98
 - derivatives, 237–238, 239
 - dioxynodehydroeckol, 218–219
 - MMPiS (*see* Matrix metalloproteinase inhibitors (MMPiS))
 - secretion and concentration, 99
 - structures, 98–99, 101
- Phytochemicals
 - flavonoids and carotenoids, 10
 - halogenated compounds, 10
 - phlorotannins/polyphenols, 9–10
 - secondary metabolites, 9–10
- Planktonic cells, 407–408
- Polysaccharides
 - alginate acid, 8
 - carrageenans, 8
 - fucoidan, 9
 - laminarin, 8–9
 - marine algae, 270–271
 - porphyran, 271
 - sulfated, 7
 - ulvan, 9
- Polyunsaturated fatty acids (PUFAs)
 - composition
 - environmental pollution, heavy metals, 347
 - FA profiles, 347–350
 - Fucus serratus*, 347
 - Laminaria japonica*, 347
 - lipid content, 350
 - nitrogen deficiency, 347
 - red seaweeds, 350
 - wild and cultured strains, 347
 - distribution
 - FA compositions, 350
 - TAGs, 350
 - health importance
 - biochemical pathways, 341
 - biological activities, 343
 - cyclooxygenase-2 (COX-2), 343
 - desaturases and elongases, 341
 - diet, 343–346
 - dispensability, 340–341
 - EPA and DHA, 343
 - metabolic transformation, 341
 - pleiothropic metabolic effects, 341
 - ω -6/ ω -3 ratio, 346
- Probiotics, 24–25
- Proteins and amino acid
 - bioavailability, digestion and absorption
 - digestion, 302
 - mucosal cells, 302–303
 - quality, 302
 - transport, 302
 - requirements
 - defined, 299–300
 - nitrogen balance, 300
 - nitrogen status, 298–299
 - pregnancy and lactation, 299–300
 - role
 - cancer, 302
 - deficiency, 301
 - enzymes deficiency, 298
 - nitrogen waste, 301
 - seaweeds, 303–309
- Prothrombin time (PT)
 - APTT, TT, 241
 - prolongation, 241
- PT. *See* Prothrombin time
- PUFAs. *See* Polyunsaturated fatty acids
- Q**
- QS. *See* Quorum sensing
- Quorum sensing (QS)
 - mechanism, 79
 - microalgae, 79–80
- R**
- Reactive nitrogen species (RNS), 289–290
- Reactive oxygen species (ROS), 289–290, 394
- Recommended daily allowances (RDA)
 - vitamin-dependent function, 359
 - vitamin E, 360
 - vitamins B₁ and B₂, 360
- Recommended daily intakes (RDIs)
 - iodine content, 378

Recommended daily intakes (RDIs) (*cont.*)
 macroelements and microelements, 376
 seaweed, 372, 380
 Recommended nutrient intakes (RNIs), 375
 Retinol equivalent (RE), 360
 Rhodophyta, 73
 RNS. *See* Reactive nitrogen species
 ROS. *See* Reactive oxygen species

S

Sea lettuces

culinary use

animals and humans, 59
 Hawaii, Cuba and Philippines, 59–60
 Japan, 59
 laverbread, 60

description, 58–59

fatty acids, 63–65

lipids, 63

minerals

classification, 67
 contents, 67
 iodine, 68

polysaccharides

family, 60–61
 ulvan, 61, 62
 water soluble and insoluble fibers, 60–61

protein and amino acids

bioactive lectins, 62
 compositions, 62, 63
Ulva reticulata and *Ulva lactuca*, 62

seaweeds and health benefits, 58

vitamins

contents, 65, 66
 vitamin B complex, 65–66
 vitamin C, 66
 vitamin E, 66–67

Seaweed

bioactive peptides, sources

ACE-inhibitory peptides, 331
 antihypertensive agents, 333–334
 description, 330–331
 heart diseases, 331
 proteins extraction, 331–332
 wakame, 332–333

dietary fiber and digestive health benefits

colorectal cancer, 23
 description, 21–22
 gastrointestinal inflammation, 24
 probiotics, 24–25
 types, soluble fiber, 22–23

food, 18

human nutrition, enhancement

carbohydrates, 19
 lipids, 20
 minerals, 21
 proteins, 19–20
vs. vegetables, 18–19
 vitamins, 20–21

nutritional assessment

biochemical aspects, 327
 brown and red, 326
 dietary fiber, 327
 environment, 327
 minerals, 327

nutritional health benefits

glycemic control, 26–27
 lipid absorption and cardiovascular
 diseases, reduction, 26
 obesity reduction, 25–26
 phenolic molecules, 25
 sulfated polysaccharides
 biological activity, 328–330
 preparation, 328
 role, 328
 use, 326

Seaweed lipids, nutraceuticals

marine microalgae

DHA production, 351
 human lymphocytes, 350–351
 microalgal lipids, 351
Schizochytrium mangrovei, 351
 thraustochytriacea, 350–351

PUFAs

composition, 347–350
 distribution, 350
 health importance, 340–346

Seaweed minerals, nutraceuticals

bioavailability

definition, 385
 nutrient synergistic/antagonistic
 interactions, 385
 reciprocal antagonistic/synergic
 behavior, 386

concentration factors (CFs), 383

daily requirements

iodine content, 378
 RDIs, 382–383
 zinc and manganese, 380

endogenous factors

cell wall polysaccharides, 383
 diverse affinity, 384
 iodine uptake mechanism, 384
Palmaria palmata, 383–384

exogenous factors

- chemical composition, 384–385
- environmental conditions, 384
- physiology and biochemical composition, 385
- Porphyra vietnamensis*, 384
- sorption mechanism, metals, 385
- human body
 - iodine, 372–373
 - iron, 373
 - manganese, 374–375
 - zinc, 374
- requirements, humans
 - chronic nutrition-related diseases, 375
 - DRIs, 375
 - recommended daily intakes (RDIs), 376
- Seaweeds and functional food development
 - biochemical composition analysis
 - amino acids, 7
 - lipids, 10–11
 - minerals and vitamins, 11
 - peptides, 6–7
 - phytochemicals, 9–10
 - polysaccharides, 7–9
 - proteins, 5–6
 - species and bioactive compounds, 5, 6
 - challenges, 12
 - classification and biochemical composition, 4
 - cultivation and research, 4–5
 - disease prevention
 - consumer awareness, 2
 - definition, 2–3
 - dietary transitions, 2
 - digestive health, 3
 - energy and sports drinks, 3
 - ω -3 fatty acids, 3–4
 - soy protein, 3–4
 - innovations and chronic diseases, 12–13
 - photosynthetic algae, 4
 - phycocolloid industry, 12
 - supply structure, 12–13
- Seaweeds proteins and amino acid composition
 - EAA, 307–308
 - glutamic and aspartic acid, 308
 - hydrolysis, 308
- factors
 - content, red seaweed, 304, 305
 - green and brown seaweed, content, 304, 305
 - polysaccharides, 304–307
 - use, 303
 - value, 304
- nutritional evaluation
 - AAS, 308–309
 - digestibility, 309
 - green and brown seaweed, 306, 309
 - lysine, 309
 - red seaweed, 305, 309
- Seaweed vitamins, nutraceuticals
 - antioxidant activity
 - carotenoids, 365
 - cerebrovascular diseases, 365
 - compounds, 364
 - food industry, 364
 - low lipid content, 365
 - marine algae, 364
 - neutralizing free radicals, 365–366
 - oxidative forms, 364
 - vitamin C dietary intake, 365–366
 - bioavailability and absorption
 - algal vitamin B12, 362
 - fat-soluble vitamins, 361–362
 - food source, 361
 - factors, vitamin contentplant metabolism
 - carotenes content affection, 361
 - concentration-and temperature-dependent processes, 361
 - light and oxygen, 361
 - plant metabolism, 361
 - functions, human body
 - antioxidant activity, 358
 - enzyme cofactors, 358
 - intermediary carbon metabolism, 358–359
 - LDL oxidation, 359
 - provitamin function, 359
 - requirements, human
 - antioxidant activity, 359
 - fat-soluble vitamins, 360
 - RDA, 359
 - vitamins B₁ and B₂, 360
 - vitamin composition
 - A, B₂, B₁₂, 362
 - daily requirements, 362
 - DNA methylation, 363
 - Enteromorpha flexuosa* and *Ulva fasciata*, 363
 - Gracilaria changgi*, 364
 - red and green algae, 363–364
- SGLT1. *See* Sodium-dependent transporter 1
- Sodium-dependent transporter 1 (SGLT1), 209
- SPMG. *See* Sulfated polymannuronate

INDEX

Note: Page numbers followed by "f" indicate figures, and "t" indicate tables.

A

- ACE inhibitor. *See* Angiotensin I converting enzyme inhibitor
- Actinomycetes
 bioactive compounds
 Abyssomicin C, 396
 chronic diseases, 395
 description, 395
 development, 395
 diazepinomicin (ECO-4601), 395–396
 novel secondary metabolites, 396–397, 398f
 sporolides A and B, 396
 thiocoraline, 396
 secondary metabolites
 anticancer agent, 368–370
 anti-tuberculosis (TB) drugs, 368–370
 marineosins, 368–370
 proteasome inhibitor, 368–370
 TNF- α -induced NFkB activation, 368–370
- 3-[4-Amino-2-methyl-5-pyrimidinyl-methyl]-1-(2-chloroethyl)-1-nitrosourea (ACNU), 227–228
- AMPs. *See* Antimicrobial peptides
- Angiotensin I converting enzyme (ACE) inhibitor. *See also* Marine fish-derived bioactive peptides, ACE
 chitosan, 502–503
 side effects, 498
- Anthraquinones
 definition, cancer, 415–416
 marine microorganisms, 416–417
 metastasis, 416
 MMP-2 and -9 expressions
 cytotoxic effect, HT1080 cells, 417, 418f
 investigation, isolated compounds, 418–419
 TIMPs, 419
 TNF- α treatment, 418–419
 signaling pathways, 420
- Anticancer activities, sterols, 265–266
- Anti-HIV activities, sterols, 264–265
- Antihypertensive activity
 Alaska pollack, 254–255
 Atlantic salmon skin, 256
Bacillus licheniformis alkaline protease, 256–257
 bioactive peptides, 241
 bonito bowels autolysate, 255
 diastolic blood pressure, 256–257
 gelatin extraction, 254–255
 noncompetitive mechanism, 254
 peptides, role, 254
 sardine and hair tail meat, 256–257
 shark meat hydrolyze, 256
 source and enzyme use, 251, 252f
 structure–activity relationships, 254
 synthetic drugs, 254
Thunnus obesus, 255
- Antihypertensive peptides, 251
- Anti-inflammation activities, sterols, 262–264
- Anti-inflammatory effects, EPA and DHA, 215–216
- Antimicrobial activities
 bioactive peptides, 241–243
 chitooligosaccharides, 328–330
 sterols, 264
- Antimicrobial peptides (AMPs)
 crustin type, 163
 MNPs, 161–162
- Antioxidant activity
 bioactive peptides, 240
 chitooligosaccharides, 331–332
 Antitumor activity, 330–331
- APS. *See* Astragalus polysaccharides
- Asterina pectinifera*. *See* Starfish PLA2
- Astragalus polysaccharides (APS), 21

B

- Bioactive antimicrobial peptides, 242f
- Bioactive compounds
 actinomycetes, 395–397

Bioactive compounds (*cont.*)

- antibacterial
 - bogorol A, 391
 - multidrug-resistant strains, 391
 - polyketides ariakemicins A and B, 392
 - Pyron, 392
- anti-inflammatory
 - arachidonic acid pathway, 142–143, 142f
 - cyclooxygenase activity, 141–142
 - dysidotronic acid, 142–143, 143f
 - manoalide, 142–143, 143f
- antitumor
 - cryptophycins, 394
 - cycloprodigiosin hydrochloride, 393–394
 - cytotoxic alkaloid, 394
 - salinosporamide A, 394
 - treatment, 393
- antiviral
 - calyceramides A–C, 393
 - exopolysaccharides (EPSs), 393
 - Macrolactin A, 393
 - multipotential uses, 392
 - recreational activities, 392
- Ara-A, 138–139, 139f
- Ara-C, 138–139, 138f
- cyanobacteria, 397–402
- drug-resistant infectious diseases, 391
- extraction, 270
- hypocholesterolemic
 - cholesterol, 144–145
 - cholesterol biosynthesis pathway, 145–146, 145f
 - FXR, 145–146
- identification, 270–271
- industrial development, 390
- marine sponges
 - description, 140
 - secondary metabolites, 140, 141t
- microorganisms, 390
- natural pigments
 - colorants, 146–147
 - Hymeniacidon sanguineum*, 147
- natural sources, 270
- novel antioxidants, 144
- nutraceuticals, 139–140
- sponge collagen, 146
- sponge metabolite production
 - activities, 147
 - cell culture, 147–148
 - mariculture, 147–148

therapeutic importance, 278–279
types, 270–271

Bioactive marine peptides

- fermentation and approaches
 - ACE-inhibitory activity, 87–89, 88t
 - amino acids and cocompounds, 92–96, 97t
 - DPPH levels changes, 92–96, 94f
 - FAS, 89–90, 90f
 - iron–peptide complex, 92, 93f
 - meat based products, 92–96
 - molecular mass distribution, 92–96, 95f
 - MRSPs, 90–91, 91f
 - oligopeptide amino acids, 92–96, 98t
 - proteolytic activation, 91–92
 - shrimp protein, 92
- fish
 - ACE-inhibitory, 83
 - calcium, 79–82
 - MOP, 82–83
 - resources, 79, 80t
- lobster, shrimp and crabs, 83
- mollusks and oysters
 - anticoagulant, 86
 - cytotoxic cyclic peptides, 84–85
 - dolastatin structure, 85, 85f
 - effects, 86
 - HIV-1 protease, 86–87
 - keenamide A, 85, 86f
- squid, clams and sea urchins, 84
- structural properties
 - ACE-inhibitory activity, 76
 - antioxidative, 76–77
 - C-terminus, 77
 - lipid peroxidation, 75–76
 - N-terminus, 78
 - Tyr, Trp and Phe, 78
- Bioactive peptide, invertebrates
 - AD pathogenic mechanism
 - APP processing, 58–59, 59f
 - marine zooplankton, 60–61
 - β -secretase, 59–60
 - antimicrobial activity
 - AMPs, 65–66
 - lobsters, 66
 - antioxidant activity
 - marine zooplankton, 62–64
 - oxidative stress, 61
 - shellfish, 61–62
 - aromatic amino acids, 57–58
 - crustaceans
 - Acaudina molpadioides*, 54–57

- ACE-inhibitory peptides, 54–57, 56*t*
 - description, 48–49
 - hypertensive mechanism
 - RAS, 50
 - renin–angiotensin system, 50, 52*f*
 - marine zooplankton, 54, 55*f*
 - nutraceuticals and pharmaceuticals, 57–58
 - preparation, 49–50, 51*f*
 - purple sea urchin, 64–65
 - shellfish
 - ACE-inhibiting peptides, 52, 53*t*
 - freshwater clam hydrolysate, 52–54
 - N-terminal sequence, 52–54
 - skin pathologies, 67
 - Bioactive peptides development
 - fish proteins, 244–245
 - fish sources, 236–237
 - identification, 236–237
 - isolation, 236–237
 - marine environment, 236
 - production
 - anticancer effect, 243
 - anticoagulant effect, 243
 - antihypertensive activity, 241
 - antimicrobial activity, 241–243
 - antimicrobial peptides, 239
 - antioxidant activity, 240
 - Atlantic cod hydrolysate, 244
 - bone mineralization ability, 244
 - Ca absorbion, 244
 - collagen, 239–240
 - fishes and fermented fish, isolation, 244
 - fish skin gelatin, 239–240
 - separation, 239
 - sources
 - body parts, 239
 - fish bone, 239
 - fish skin collagen and gelatin, 238
 - muscle protein peptides, 238
 - structure–activity relationship, 237–238
 - Biological activities, chitoooligosaccharides, 332–333
 - Bone mineralization, 292, 292*f*
 - Bovine spongiform encephalopathy (BSE), 440
 - BSE. *See* Bovine spongiform encephalopathy
- C**
- Calcitonin gene related peptide (CGRP)
 - blood flow regulation, 486–487
 - microcirculation, 486
 - neurovascular disorder, 486–487
 - Cardiovascular diseases (CVDs)
 - antihypertensive effects, 468
 - ω -3 FAs, 468
 - hypercholesterolemia, 467–468
 - n-3 PUFAs, 214–215
 - Casein phosphopeptides (CPP)
 - CPP II, 291
 - FBP intake, 293*t*
 - CCK. *See* Cholecystokinin
 - CGRP. *See* Calcitonin gene related peptide
 - Chitoooligosaccharides (COSs)
 - biological properties
 - antihypertensive activity, 327–328
 - antimicrobial activity, 328–330
 - antioxidant activity, 331–332
 - antitumor activity, 330–331
 - hydrogen peroxide-induced stress, 332–333
 - inhibit β -secretase activity, 333
 - lipid peroxidation compounds, 332–333
 - neurodegenerative diseases, 332–333
 - chitosan, 322
 - preparation, chitosan
 - chemical hydrolysis, 322–324
 - continuous production, 326–327
 - enzymatic hydrolysis, 324–326
 - safety, 333
 - water-soluble, 322
 - Chitosan
 - applications, 122
 - biocompatibility and allergy
 - crustaceans, 114
 - proinflammatory properties, 114
 - biodegradation, 115–116
 - biological activities, 132
 - cross-linking, bioactive agent, 111
 - description, 122
 - health benefits
 - anti-inflammatory activity, 129–131
 - antimicrobial activity, 128–129
 - antioxidant activity, 125–126
 - biological properties, 131
 - hypocholesterolemic effects, 126–128
 - mechanical strength
 - compression test, 111
 - load–displacement test, 112
 - tensile test, 111
 - MW and DD
 - description, 109–110
 - DNA and siRNA, 110

- Chitosan (*cont.*)
- nanoparticles, 110–111
 - plasma and liver cholesterol levels, 111
 - preparation
 - characteristics, 123
 - crustacean chitin, 123, 124*f*
 - sources, 123–125
- Cholecystokinin (CCK)
- effect, industrial product hydrolysates, 485–486, 485*f*
 - gastrointestinal actions, 482–485
- Chondrocytes, glucosamine, 339–341
- CLA. *See* Conjugated linoleic acid
- Collagen and gelatin
- acid treatment, 500
 - bioactivities, 500
 - biomedical and nutraceutical applications
 - drug carriers, cancer treatment, 501
 - melt-in-the-mouth property, 501
 - fish skin waste, 499–500
 - manufacturing, 499
 - marine-discarded sources, 500
- Conjugated linoleic acid (CLA), 357–358
- COSs. *See* Chitooligosaccharides
- CVDs. *See* Cardiovascular diseases
- Cyanobacteria
- bioactive compounds
 - anticancer effect, 402
 - anti-inflammatory activity, 400
 - antiviral effect, 400–401
 - borophycin, 400
 - cryptophycin, 400
 - cyanovirin-N (CV-N), 397–399
 - isolated compounds, 401*t*, 402
 - lipopeptides, 400
 - secondary metabolites
 - antiproliferative activity, 371–373
 - antitumor activities, 371–373
 - lipopeptide, modification, 371–373
 - pharmaceutical applications, 371–373
 - production, vitamins, 371–373
 - weak cytotoxic activity, 371–373
- Cytotoxic substances
- coral community
 - alkaloids, 178, 179*f*
 - Aplysina*, 178, 178*f*
 - bromotyrosine-derivatives, 178–179
 - Dysidea*, 177–178, 178*f*
 - Laurencia papillosa*, 179–180, 179*f*
 - papillamide, 179–180, 180*f*
 - reefs, 175–176
 - Terpios hoshinota*, 176, 176*f*, 177*f*
 - cyanobacteria
 - bisebromoamide, 180
 - description, 180, 180*f*
 - lyngbyacyclamides, 180–182
 - Lyngbya majuscula*, 180–182
 - description, 172
 - halichondrins
 - antitumor substances, 173
 - description, 172–173, 173*f*
 - and eribulin, 172–173, 174*f*
 - living organisms, 175
 - structure, 175
 - variations, 173–175
 - marine natural products, 172
- D**
- DD. *See* Degree of deacetylation
- Degree of deacetylation (DD), 123–125
- Depolymerized holothurian
- glycosaminoglycan (DHG), 16–17
- DHA. *See* Docosahexaenoic acid
- DHG. *See* Depolymerized holothurian glycosaminoglycan
- Docosahexaenoic acid (DHA), 212–213
- E**
- Eicosapentaenoic acid (EPA), 212–213
- Enzymatic hydrolysis,
 - chitooligosaccharides, 324–326
- EPA. *See* Eicosapentaenoic acid
- F**
- Farnesoid X-activated receptor (FXR), 145–146
- FAS. *See* Fermented anchovy sauce
- FBP II. *See* Fish bone peptides
- Fermented anchovy sauce (FAS), 89–90
- Fish bone peptide (FBP). *See* Teleost fish bone peptide
- Fish bone peptides (FBP) II, 506–507
- Fish collagen
 - amino acids composition, 112, 113*t*
 - biocompatibility and allergy
 - IgE-reactive protein, 114–115
 - jellyfish, 115
 - SC vascular grafts, 115
 - tilapia, 115
 - biodegradation, 115–116
 - cross-linking, stability, 113
 - degeneration temperature, 112–113
 - mechanical strength, 114

Fish muscle protein
 bioactive compounds, isolation, 236–237
 preparation, 243
 utilization, 236

Fish oil
 degradation, 218
 derived n-3 PUFAs, 213
 NF- κ B activation, 217
 soft gel capsules, 212
 source, 212, 218

Fish protein hydrolysates (FPH), 480–481,
 485–486, 489

Fish proteins, bioactivity, 242*t*

FPH. *See* Fish protein hydrolysates

FXR. *See* Farnesoid X-activated receptor

G

GAGs. *See* Glycosaminoglycans

Glucosamine (GlcN)
 biological activities, 346–348
 description, 338–339
 and GlcNAc, MC3T3-E1 cells
 NF- κ B ligand, 345–346
 osteoblastic, 342–343
 osteoblastic differentiation markers,
 343–344
 incorporation, GAG, 342
 osteoarthritis (OA), 338
 pathological change, subchondral bone,
 339
 RANKL expression, 349–350
 synovial fluid GAG, 339
 and uronic acids
 HA-metabolizing enzymes, 342
 human synovial cells and
 chondrocytes, 339–341

Glycosaminoglycans (GAGs), 12–13,
 196–198, 197*f*, 199*f*

H

Halichlorine
 LPS-induced NF- κ B activation
 BAECs, 188–189, 188*f*
 LDL, 188–189
 VCAM-1, 187–188

L-type Ca²⁺ channel
 effect, 189–190, 190*f*
 voltage relationships, 189–190, 190*f*
 structures, 186, 187*f*

Health benefits, chitosan
 anti-inflammatory activity

acute and chronic inflammation,
 129–130
 COX-2 expression, 130–131
 TNF- α and IL-6, 130–131

antimicrobial activity
 DD and MW, 128–129
 food additive, 129
 MIC value, 128

antioxidant activity
 deacetylation, 125–126
 ROS, 125
 treatment, 126

biological properties, 131

hypocholesterolemic effects
 bile acids, 126
 DD and Mv, 126
 digestive system, 127
 hypolipidemic activities, 126–127
 mechanism, 127–128

Hoki bone
 Ca-binding activity, 291
 chemical composition, 289–290
 isolation and biochemical properties,
 290–291

Holostane group structure, 299*f*

Human synovial cells, glucosamine, 339–341

Hyaluronic acid
 HA at 0.25–1mM, 341, 341*f*
 human chondrocytes (SW1353) at
 0.1–1mM, 340, 340*f*
 human synovial cells (MH7A) at
 0.25–1mM, 339–340, 340*f*

Hypertension
 humans, 250
 prevalence, 250
 prevention and treatment, 250

I

ICAM-1. *See* Intercellular adhesion
 molecule-1

iGluR. *See* Ionotropic glutamate receptor

Inflammation
 EPA and DHA effects, 214*f*
 muscle and adipose tissue, 217–218
 obesity, 217–218
 reduction, 216–217

Insulin resistance
 depression, 213
 EPA and DHA, effects, 214*f*
 reduction, 214

Intercellular adhesion molecule-1 (ICAM-1)
 E-selectin, 188–189

- Intercellular adhesion molecule-1 (ICAM-1)
(*cont.*)
VCAM-1, 187–188
- Ionotropic glutamate receptor (iGluR),
373–375
- L**
- LDL. *See* Low density lipoproteins
- Lipase
pelagic fishes, 425
reactions, 424–425
temperatures, 425
- Low density lipoproteins (LDL), 438–440
- M**
- Marine-derived substances (MDSs)
anti-inflammatory effects, 465
antioxidant activity, 466–467
probiotics, 470
- Marine fish-derived bioactive peptides,
ACE
antihypertensive activity
Alaska pollack, 254–255
Atlantic salmon skin, 256
Bacillus licheniformis alkaline protease,
256–257
bonito bowels autolysate, 255
diastolic blood pressure, 256–257
gelatin extraction, 254–255
noncompetitive mechanism, 254
peptides, role, 254
sardine and hair tail meat, 256–257
shark meat hydrolyze, 256
source and enzyme use, 251, 252*t*
structure–activity relationships, 254
synthetic drugs, 254
Thunnus obesus, 255
- antihypertensive peptides, development,
251
- hypertension, 250
- physiological functions, 250
- sources, 250
- synthetic drugs, 250
- Marine invertebrates
description, 154
MNPs, 154–155
phylum bryozoa, 158–159
phylum Cnidaria
corals, 157–158
jellyfish, 158
phylum molluska
abalone, 160
AMPs, 161–162
corn shell, 160–161
description, 159
oyster shells application, 159–160
sea hares, 161
phylum porifera
description, 156
MNPs, 157
use, 156–157
sample collection, 155–156
- Marine microbial enzymes
activities, 424
advantages, 431–432
lipase, 424–425
microorganisms, 424
polysaccharide-degrading enzymes,
426–431
protease, 426
- Marine natural products (MNPs)
marine spongers, 156–157
production, 155–156
source, 157–158
types, 162
- Marine nutraceuticals, dairy products
advantages, 470–471
anti-inflammatory
diseases, 465
effects, MDSs, 465
antimicrobial
activities, chitosan and COS, 469
bacteriocins, 469
milk, 469
minimum inhibitory concentrations,
469, 469*t*
- antiobese
fat catabolism, 467
uncoupling protein 1 (UCP1), 467
- antioxidant
activity, 466–467, 466*t*
MDS, 466–467
prevention, tissue damage, 465–466
- antitumor
anticancer activity, 462, 463*t*
 β -carotene, 462–464
inhibition, cell apoptosis, 462
MMPs, 464–465
- bioactive peptides, 460
 β -carotene, 471–472
carotenoids, 461
CVD, 467–468
description, 458

- ω -3 FAs, 472–473
- final product, 471, 472*t*
- food formulations, 458
- MDSs, 459
- phenolic compounds, 461
- polysaccharides
 - chitin, 460
 - N*-acetyl glucosamines, 460
 - structural role, 459
- polyunsaturated fatty acids, 461
- prebiotics, 470
- probiotics, 470
- Marine phospholipids
 - antiobesity compounds
 - KK-A^y intake, 41–45, 43*f*
 - UCP1, 41–45, 44*f*
 - UCP1 mRNA expression, 41–45, 44*f*
 - WAT, 41–45
 - cancer cell differentiation
 - c-myc mRNA downregulation, 35–37, 37*f*
 - PC, PS, 35–37
 - retinoic acid effects, 35–37, 35*f*
 - TGF β -1 expression, 35–37, 38*t*
 - cancer suppression
 - Agaricus blazei*, 38–40
 - chitosan mucoadhesive function, 41
 - effect, 41, 42*f*
 - liposomes, 38–40, 40*f*
 - squid meal liposome, 41, 42*f*
 - tumor size, 38–40
 - tumor weight, 38–40, 39*f*
 - water extraction, 38–40
- DHA/EPA, 32
- triacylglycerol
 - description, 32–34
 - lipid content, rats serum, 32–34, 33*t*
 - rat fetus brain, fatty acid composition, 32–34, 34*t*
 - SHR rats, 34–35, 34*f*
- Marine probiotics
 - antibiotics, 355
 - antimicrobial and antitumor agents, 359
 - approaches
 - interaction, 358
 - isolation and identification, potential strain, 358–359
 - aquaculture, 355
 - beneficial effects, CLA, 357–358
 - definition, 354
 - food ingredients, 356–357
 - growth, enteropathogens, 357
 - prerequisites
 - advantageous, medicinal uses, 355–356
 - high-quality products, 355–356
 - probiotic strains, 354–355
- Marine sulfated polysaccharides (MSPs)
 - chemical structure, 198–200
 - external fertilization in sea urchins, 198–200
 - interaction with coagulation (co)factors
 - algal molecules, 200–201
 - clinical activities, 200
 - in vitro* anticoagulant assays, 201
 - mammalian GAG, 200
 - plasma proteases, 201
 - SFs and SGs, 196–198, 197*f*, 199*f*
 - structural feature
 - anticoagulant activity, 203*t*
 - influence by sugar type, 201–204
 - influence by sulfation pattern, 205–206
 - preferential conformation binding, 204–205
- Matrix metalloproteinase (MMP-2 and -9)
 - expressions
 - chrysophanol, physcion and emodin
 - cytotoxic effect, HT1080 cells, 417, 418*f*
 - investigation, isolated compounds, 418–419
 - TIMPs, 419
 - TNF- α treatment, 418–419
- MDSs. *See* Marine-derived substances
- Medicinal foods
 - crustaceans
 - COS, 6
 - shell fish, 6
 - shrimp and crab, 6
 - description, 2
 - fish
 - fisheries, 3–5
 - products, 5
 - values, 5
 - marine animal, 2
 - marine species, 2–3, 4*t*
 - mollusks and echinoderms
 - abalones, 7
 - consumption, 7
 - cuttlefish bones, 7
 - octopus and squids, 7
 - oyster shell and juice, 7
 - phytoplanktons, seaweeds/grasses, 2–3
 - seahorse, 7–8
- Metabolic disorders, 216–218

- Metabolite
 description, 186
 halichlorine, 186–190
- Methicillin-resistant *Staphylococcus aureus* (MRSA)
 antimicrobial activity, 373–375
 cell membrane, 366–367
 cytotoxicity, 368–370
- MMP-2 and -9 expressions. *See* Matrix metalloproteinase expressions
- MNPs. *See* Marine sulfated products
- Molecular weight (MW), 123–125
- MRSA. *See* Methicillin-resistant *Staphylococcus aureus*
- MRSPs. *See* Mussel-derived radical scavenging peptides
- MSPs. *See* Marine sulfated polysaccharides
- Mussel-derived radical scavenging peptides (MRSPs), 90–91
- MW. *See* Molecular weight
- N**
- n-3 polyunsaturated fatty acids (n-3 PUFAs)
 anti-inflammatory effects, EPA and DHA, 215–216
 and cardiovascular diseases, 214–215
 eicosapentaenoic and docosahexaenoic acid, 212–213
 EPA and DHA effects, 213, 214f
 fish oil-derived, 213
 health concerns, 218
 hypotriglyceridemic effects, 214
 and metabolic disorders, 216–218
- O**
- O-GlcNAc. *See* O-linked β -N-acetylglucosamine
- O-linked β -N-acetylglucosamine (O-GlcNAc), 12
- Osteoblastic cells, 343–344
- Osteoporosis-modeling rats, 292–294
- P**
- Phospholipase A2 (PLA2)
 BSE, 438–440
 catalysis, 438–440, 438f
 LDL, 438–440
 lysolecithin, 438–440
 starfish
 activity, 440–442
 application, 450–452
 enzymatic properties, 442–445
 structural properties, 445–448
 structure–function relationship, 448–450
 studies, 439t
 types, 438–440
- PLA2. *See* Phospholipase A2
- Polysaccharide-degrading enzymes
 agarases
 acid degradation, 428
 use, 428
 alginate lyases, 427
 amylases, 430
Bacillus circulans, 431
 carrageenases, 428–429
 cellulose and hemicellulose hydrolase
 hydrolysis reaction, 429
 use, 429
 xylanases, 430
 chitinase and chitosanase
 chemical structure, 426–427
 production, 427
 fucoidan, 431
- Polysaccharides
 ascidians
 CS inhibitory effects, 19, 20f
 CSPG, 18
 inflammation, 19
 NF- κ B, 19
Styela plicata, 18–19
 tadpole-type larvae, 18
 chondroitin sulfate, 14
 disaccharides structures, 13–14
 GAGs, 12–13
 nudibranchs
 description, 22
 GAGs synthesize, 24
 mammalian mucus, 24
 mucus functions, 22–23
 sea slugs, 24, 25f
- O-GlcNAc, 12
- sea cucumber
Apostichopus japonicus, 15–16
 body wall, 14–15
 collagen fibrils, 16–17
 CSE, 17
 DHG, 16–17
 GAG, 14–15
 methylation analysis, 16–17, 17t
 physicochemical properties, 15
 sea urchins
 APS, 21

- Astragalus membranaceus*, 21
 hepatocarcinoma, 21–22
 SEP, 21–22
- Protein and peptides, seafood processing
 by-products
 ACE inhibitory, 497–498
 antioxidative activities, 498–499
 bioactive agents, 499
 coagulation factors, 498
 fish muscle, 497
 osteoclasts, 498–499
 tuna backbone, 498
- R**
- RAS. *See* Renin–angiotensin system
 Reactive oxygen species (ROS), 125
 Renin–angiotensin system (RAS), 50
 ROS. *See* Reactive oxygen species
- S**
- Scaffold properties
 chitosan. *See* Chitosan
 diffusivity and permeability, 109
 fish collagen. *See* Fish collagen
 functions, 109
 parameters, 109
 requirements, 108–109
 tissue
 engineering, 108–109
 regeneration, 109
- Sea by-products
 ACE, 480–481
 agro-alimentary French market, 480
 antioxidant peptides
 amino acid sequences, 487–488, 488t
 ascorbic acid, 487–488
 diseases, 487–488
 inhibition, lipid oxidation, 487–488
 CCK secretion stimulating peptides,
 482–486
 CGRP, 486–487
 enzymatic process
 bioactive peptides, 482, 483t
 protein hydrolysates, 481–482
 reaction, 482
 FPH, 480–481
 production, 480
- Sea cucumber. *See* Triterpene glycosides, sea
 cucumbers
- Seafood processing by-products
 application, fish bone
 FBP II, 506–507
 hydroxyapatite, 506–507
 production, calcium, 506–507
 bioactive compounds, 496–497
 chitin and chitosan
 ACE inhibitory activity, 502–503
 antibacterial action, 502
 anticancer activity, 503
 antioxidant activities, 502
 cardiovascular disease, 503
 enzyme immobilization, 503–504
 medical application, 504
 production, 501–502
 collagen and gelatin, 499–501
 fish catch, 496
 protein and peptides, 497–499
 separation and application, fish oil
 gelatin, 504–505
 production, margarine, 505–506
 types, fatty acids, 504–505
 wet and steam rendering methods,
 504–505
- Sebum
 human identification, 225
 secrete, 225
- Secondary metabolites, drug discovery
 actinomycetes, 368–370
 bioactive metabolites, 365
 chemical diversity, 364–365
 collaborative and interdisciplinary
 research, 378
 cyanobacteria, 371–373
 infections, 364, 378
 marine bacteria
 antibacterial, antiviral and cytotoxic
 activities, 366–367
 anticancer agents, 368
 depsipeptides, 366–367
 lysozyme, 366–367
 MRSA, 366–367
 marine fungi
 antiplasmodial activity, 370–371
 cytotoxicity activity, 370–371
 polyphenolic compounds, 370–371
 spirodioxynaphthalene metabolite,
 370–371
 microbial symbionts
 antileukemic agent, 373–375
 bryostatins, 373–375
 iGluR, 373–375
 yellow pigment, 373–375
 mutagenesis techniques, 378–379

Secondary metabolites, drug discovery
(*cont.*)

- natural products
 - bioinformatics approach, 376–377
 - isolation and cultivation, 376–377
 - limitations, 375–376
 - microbial cells, 376
 - oceans, 365
- SEP. *See* Strongylocentrotus nudus eggs
- Shark liver oil
 - components, 225
 - contains, 227
 - and olive oil, 226
 - protective effect, 231
 - squalene source, 224–225
- Squalene and squalane
 - biological roles
 - anticancer, 227–228
 - anti-infectant, 231
 - antioxidant, 226–227
 - detoxifier, 230–231
 - drug delivery agent, 229–230
 - human skin, 225
 - industrial area, 225–226
 - skin care, 228–229
 - synthesis, 225
 - chemical structures, 224–225, 224f
 - components in shark liver oil, 225
 - detoxifying and anti-infectant effects, 231
 - natural sources, 231
 - role, 224–225
 - saturated derivative, 225
 - supplementation, 231
 - triterpene, 224–225
- Squalene gemcitabine, 230
- Starfish PLA2
 - activity
 - estimation, molecular weight, 440–442
 - gel filtration, 440–442
 - marine invertebrates, 442, 443t
 - studies, 439t, 440–442
 - application
 - distribution, DHA and EPA, 450–452
 - fatty acids, phosphatidylcholine and phosphatidylethanolamine, 450, 451t
 - enzymatic properties
 - acetone treatment, 442–443
 - A. pectinifera*, 444–445, 444t
 - gel filtration, 444
 - structural properties
 - amino acid sequences, 445–447, 446f

- characteristic structure, 448
- reaction cycle, 447–448
- structure–function relationship
 - mutation, 449–450
 - polar-group specificity, 448
 - recombinant, 448–449

Sterols

- biological activities
 - anticancer, 265–266
 - anti-HIV, 264–265
 - anti-inflammation, 262–264
 - antimicrobial, 264
- important family, lipids, 262
- marine organisms, 262
- Strongylocentrotus nudus eggs (SEP), 21–22
- Structural feature, MSPs
 - anticoagulant activity, 203t
 - influence by sugar type
 - Echinometra lucunter*, 201–204
 - Strongylocentrotus franciscanus*, 201–204
 - influence by sulfation pattern
 - ascidian DSs, 206
 - Gelidium crinale*, 205
 - 3-linked α -l-fucans, 205–206
 - preferential conformation binding
 - AT-binding site, 204–205
 - heparin-AT-IIa, 204–205
- Sulfated polysaccharides (SPs), 196–198, 197f, 199f

T

Teleost fish bone peptide

- Ca source, 288–289
- hoki bone
 - Ca-binding activity, 291
 - chemical composition, 289–290
 - isolation and biochemical properties, 290–291
- in vitro* and *in vivo* osteogenic effects
 - Ca bioavailability in ovariectomised rats, 292–294
 - osteoblast-like MG63 cell, 292
 - numerous functions, calcium, 288
- Terpenoids, marine fungi
 - building blocks, 410
 - chronic malfunctions, 412
 - diversity
 - meroterpenoids, 410–411
 - natural products, 411
 - health benefits and biological activities
 - antioxidants, 411–412
 - antiproliferative activity, 412

- structures, 410
 - Therapeutic drugs
 - chemical composition, fish
 - carbohydrates derivation, 271–272
 - collagen and gelatin, 272–273
 - compositions, 271
 - minerals, 278
 - protein derivation, 272
 - protein hydrolysate and bioactive peptides, 273–275
 - fat derivation
 - applications, omega-3 fatty acids, 277–278
 - description, 275
 - extraction and purification, 276
 - omega-3 fatty acids, 275–276
 - fish by-products, 270–271
 - marine organisms, 270
 - natural products isolation, 270
 - TIMPs. *See* Tissue inhibitors of matrix metalloproteinase
 - Tissue inhibitors of matrix metalloproteinase (TIMPs), p0045, p0055, 416
 - Triterpene glycosides, sea cucumbers
 - bioactivities
 - anticancer activity, 300–314
 - antifungal activity, 314–315
 - marine organisms, 298
 - PROS and CONS, drug development, 316
 - structure
 - holostane group, 298–299, 299*f*
 - holostane type sea cucumber
 - glycosides, 300
 - isolation, 300, 301*t*
 - nonholostane type glycosides, 300
 - saponins, 298–299
 - structure–activity relationships, 315
- U
- UCP1. *See* Uncoupling protein 1
 - Uncoupling protein 1 (UCP1), 41–45, 44*f*, 467
 - Uronic acids
 - HA-metabolizing enzymes, 342
 - human synovial cells and chondrocytes, 339–341
- V
- Vascular cell adhesion molecule-1 (VCAM-1)
 - expression, 186
 - ICAM-1, 187–188
 - VCAM-1. *See* Vascular cell adhesion molecule-1
- W
- WAT. *See* White adipose tissue
 - White adipose tissue (WAT), 41–45

INDEX

Note: Page numbers followed by "f" indicate figures, and "t" indicate tables.

A

- Acid detergent acid fiber (ADF), 78–79
- ADF. *See* Acid detergent acid fiber (ADF)
- Agar characteristics, 114, 115t
- Age-standardized rate (ASR)
 - CRC, 90–91, 91f
 - mortality/incidence, 92
- Algal polysaccharides, human nutrition
 - biological activities
 - blue-green freshwater algae, 125–126
 - green freshwater algae, 126–127
 - seaweed polysaccharides, 127–132
 - description, 76–77
 - freshwater and seaweed, 77
 - habitats, 100
 - roles, 100–101
 - significance, dietary fiber (*see* Dietary fiber)
- Alginate, 120
- Anticancer activity, dietary fiber
 - CRC, 90–91
 - malignant diseases, 90–91
- Antifungal lab
 - animal feed, 230–231
 - biopreservatives
 - antagonistic compounds, 223
 - antimycotic activity, 224, 225t
 - description, 223
 - prevention, mycotoxin contamination, 223–224
 - bread
 - antifungal components, 224–229
 - fungal spoilage, 224
 - phenyllactic acid, 224–229
 - sourdough, 224–229
 - dairy products, 229
 - fresh fruits and vegetables, 230
 - industrial importance, 232
 - patents distribution, 231, 231f, 232f

B

- BCAA. *See* Branchedchain amino acid (BCAA)
- Biopreservation, 218–219
- Branchedchain amino acid (BCAA), 181–182

C

- Carbohydrates, dietary
 - body weight and composition, 160
 - description, 159
 - index and load, glycemic, 159–160
 - mechanisms, 160–161
- Cardiovascular diseases (CVDs)
 - description, 148–149
 - dyslipidemia, 150–151
 - fiber and protein, 149
 - hypertension, 150
 - hypocholesterolemic effect, 96–97
 - insoluble fibers, 97–98
 - insulin resistance, 151
 - LDL cholesterol, 96
 - lupin (*see* Lupin)
 - macronutrients (*see* Macronutrients)
 - mortality and dietary fiber intake, 95, 95f
 - overweight and obesity, 150, 151–153
 - proportion, 149
 - risk factors
 - blood lipids, 197–198
 - blood pressure, 196–197
 - glucose and insulin, 198–199
 - stressful lifestyle, 151
 - TDF, 96
 - total serum and low-LDL cholesterol level, 94–95
 - water-soluble components, 97
- Carrageenans
 - anticoagulant activity, 131
 - use, 114–117

- Charmat/Granvas method
 CO₂ pressure, 14–15
 pressure and temperature, 14
 riddling and disgorging steps, 16–17
 tank, 14, 15f
 thermal treatment, 16
- Colorectal cancer (CRC)
 ASR, 90–91, 91f
Bifidobacteria, 93–94
 bile acids, 93
 fats and meat intake, 94
 methane, 94
 SCFAs, 92–93
 wheat bran content, 93
- Color, sparkling wines
 compounds
 carbohydrates, 32
 carotenoids, 29–30
 flavonoids, 30–31
 hydroxycinnamates, 31–32
 phenolic, 30
 quinones, 31–32
 sweet, 29–30
 yellow, 31
 vinification
 hydroxycinnamic acids, 32
 laboratory conditions, 32
 phenolic composition, 32–33
 white and red grapes, 29
- CRC. *See* Colorectal cancer (CRC)
- CVDs. *See* Cardiovascular diseases (CVDs)

D

- Dietary fiber
 characteristics
 cellulose, 80
 chitin and chitosan, 83
 fructans, 82
 β-glucan, 81–82
 gums and mucilages, 82–83
 hemicellulose, 81
 lignin, 83
 pectin, 81
 plant cell wall, 80
 resistant starch, 83
 classification, 79, 161
 definition, 77–78
 energy intake control
 effects, 166
 mechanisms, 166
 FAO/WHO scientific update, 79–80

- freshwater algae polysaccharides
 composition, 101–108
- health benefits
 anticancer activity, 90–94
 CVDs, 94–98
 digestive process, 90
 DRI, 89–90, 89f
 time- and cost-consuming research
 process, 88–89
 mechanisms, 166–167
 NDF and ADF, 78–79
 obesity development
 intervention studies, 168
 population studies, 167–168
- physiological effects
 description, 83–84
 fermentation, 85–86
 gut microflora, 86
 hypocholesterolemic and
 hypoglycemic activities, 88
 pH value, colonic environment, 85
 SCFAs, 86–87
 transit time, 88
 types, 84–85
 upper intestine, 84
 water-holding/hydration
 capacity, 84
 possible negative effects, 98–99
 seaweed polysaccharides composition,
 108–124
 TDF, 78–79
- Dietary reference intakes (DRIs), 89–90, 89f
- DRIs. *See* Dietary reference intakes (DRIs)
- Dyslipidemia
 description, 187–188
 fiber
 cardiovascular health, 190
 insulin, 191
 intervention trials, 190–191
 population studies, 190
 protein
 isoflavone, 189–190
 ketogenic diets, 189
 LDL, 189
 plant, 188–189

E

- Elaboration process, sparkling wines
 aging
 enzymatic self-degradation, 17–18
 MET image, 17, 18f

- polysaccharides, 18–19
- protease A, 17–18
- ribonucleotides, 19
- Sur lies*, 17
- yeast cell, 19
- expedition
 - agglomerate corks, 22
 - bottles, 22, 22t
 - disgorging, 20
 - dosage, 20–22
 - filtration and bottling, 19–20
 - riddling, 20
 - sugar content, 20, 21t
- red/white grape, 10–11
- second fermentation
 - champenoise, classic/traditional method, 12–14
 - Charmat/Granvas method, 14–17
 - definition, *prise de mousse*, 12
 - white vinification, 11–12
- Energy balance
 - description, 153
 - disruption, 155
 - expenditure, 154–155
 - foods/nutrients, 154
 - supply and intake, increase, 154
- F**
- FAO. *See* Food and Agriculture Organization (FAO)
- Fat, dietary
 - description, 158
 - role, 159
- Fermentation
 - champenoise, classic/traditional method
 - bottle glass, 14
 - expedition liqueur, 12–14, 13f
 - Charmat/Granvas method
 - CO₂ pressure, 14–15
 - pressure and temperature, 14
 - riddling and disgorging steps, 16–17
 - tank, 14, 15f
 - thermal treatment, 16
 - definition, *prise de mousse*, 12
- Foam, sparkling wines
 - bubbles
 - air/gaseous phase, 24, 24f
 - enologic practices, 26
 - micelle concentration, 24–25, 25f
 - potential interactions, 26
 - surface tension, 24–25, 25f
 - tensioactive molecules, 23, 24
 - viscosity, 25
- carbon dioxide/liquid interphase, 23, 24f
- effervescence
 - carbon dioxide, 28
 - glasses, 29
 - induced homogeneous nucleation, 26–27
 - microcavities, 26–27
 - sensory descriptors, 27–28, 27f
 - tasting cards, 28
- Food and Agriculture Organization (FAO), 221–222
- Food quality and safety
 - chemical preservative agents, 222–223
 - contamination, 221
 - FAO, 221–222
 - fungal spoilage, 222
 - mycotoxin contamination, 222
 - national and international policies, 221
- Freshwater algal polysaccharides
 - biological activities, 125
 - blue-green, 125–126
 - composition
 - amino sugars, 108
 - blue-green and green, 102
 - Chlorella* sp., 101–102
 - Chlorococcales, 101
 - description, 101
 - glucosamine content, 108
 - glucose, 106
 - granules, starch, 106
 - polysaccharides characteristics, 101–102, 103t
 - Spirulina platensis*, 106
 - starch structure, 106
 - starch synthesis, 102
 - green, 126–127
- Fucoxanthin, 120–123
- Furcellaran, 117–119
- G**
- Glucose and insulin
 - description, 198
 - effects, 199
 - lupin flour-enriched diet, 198
 - mechanism, 199
- Green preservatives
 - antifungal activity, 219
 - bacterial antagonism, 231–232
 - biopreservation, 218–219

Green preservatives (*cont.*)
 fermentation processes, 218–219
 food quality and safety, 221–223
 LAB (*see* Antifungal LAB)
 mold spoilage, 219
 mycotoxins, 219, 220*t*

H

Hypertension
 description, 183–184
 fiber and blood pressure, 186–187
 protein and blood pressure
 beneficial effects, 185–186
 intervention studies, 184–185
 mechanism, 185
 population studies, 184
 sources, 184

I

Insulin resistance
 description, 180–181
 fiber, 182–183
 protein
 BCAA, 181–182
 DASH diet, 181
 diets, 181

L

Lactic acid bacteria (LAB). *See* Antifungal lab
 Lipopolysaccharides (LPS), 60
 Low density lipoprotein (LDL)
 cholesterol concentrations, 189, 190–191
 fiber intake, 190
 lupin protein upregulation, 197
 LPS. *See* Lipopolysaccharides (LPS)
 Lungs, sea food processing
 hypersensitivity pneumonitis, 53
 irritant-induced asthma, 52
 occupational allergic asthma, 52
 RADS, 52
 Lupin
 description, 192
 enriched foods
 CVD risk factors, 196–199
 satiation and energy intake, 195–196
 health benefits, 195
 history, Australia, 192
 human food, 195

Lupinus angustifolius, 192–194
 research, 195

Lupinus angustifolius, bioactive components
 fat, 193
 fiber, 193
 nutritional composition, 192, 193*t*
 phytochemicals, 193–194
 protein, 192–193

M

Macronutrients
 carbohydrates (*see* Carbohydrates, dietary)
 description, 157
 fat (*see* Fat, dietary)
 fiber (*see* Dietary fiber)
 protein (*see* Protein, dietary)
 protein and fiber, 180–191
 satiation
 assessment, 158
 energy intake, 157
 food intake, regulation, 157, 158*f*
 hunger, 157–158

Mycotoxins
 antimycotic activity, 224, 225*t*
 contamination, 221–222, 223–224
 food and feed, 219, 220*t*

N

NDF. *See* Neutral detergent fiber (NDF)
 Neutral detergent fiber (NDF), 78–79

O

Occupational allergies, seafood-processing workers
 allergen families, 54–58
 allergenicity and airborne exposure levels
 assessment studies, land and aboard workers, 62, 63*t*
 codfish, 62
 crab-processing workers, 62–64
 crab workers, 62
 fish-processing operations, 62–64
 food processes, 61
 immunological reactivity techniques, 64
 nonthermal processes, 61
 components

- aerosol, 54
 - arthropods, 53–54
 - cross activity, 60
 - description, 48
 - diagnosis
 - definition, hypersensitivity, 66
 - in vitro* and *in vivo* methods, 66
 - immunodiagnostic tests, 68
 - isotypess, immunoglobulins, 66–68
 - mediators, 66
 - sensitization and identification test, 66, 67†
 - environmental factors, 65
 - health effects
 - lung, 52–53
 - skin, 53
 - high-risk work process
 - dermatological symptoms, 51
 - description, 49–51
 - fishmeal production, 49–51, 51f
 - host associated factors, 64–65
 - immune system and inflammatory response
 - agents, 58–60, 59†
 - hypersensitivity, 58
 - LPSs, 60
 - mechanisms, 58, 59†
 - industry, 48–49
 - population, risk, 49
 - prevention, 68–69
 - Organoleptic characteristics, sparkling wines
 - aroma
 - furanic compounds, 34
 - hydrophobicity, 34
 - sulfur components, 33–34
 - Sur lies*, 33
 - volatile compounds, 33
 - yeast, 34
 - color
 - carotenoids and phenolics, 29
 - compounds, 29–32
 - vinification, 32–33
 - foam
 - bubbles, 23–26
 - effervescence, 26–29
 - tensioactive components, 23, 24f
 - Overweight and obesity
 - causes
 - dietary composition, 156–157
 - dietary patterns, 156
 - energy balance concept, 153–155
 - genetic predisposition/susceptibility, 155–156
 - classification, 152
 - description, 151–152
 - health consequences, 153
 - prevalence, 152–153
- P**
- Protein, dietary
 - energy intake control
 - body weight and composition, 170
 - mechanisms, 170–174
 - RDI, 170
 - and fiber
 - dyslipidemia, 187–191
 - hypertension, 183–187
 - insulin resistance, 180–183
 - obesity development
 - intervention studies, 175–179
 - population studies, 174–175
 - protein leverage hypothesis, 179
- R**
- RADS. *See* Reactive airways dysfunction syndrome (RADS)
 - RDI. *See* Recommended dietary intake (RDI)
 - Reactive airways dysfunction syndrome (RADS), 52
 - Recommended dietary intake (RDI), 170
- S**
- SCFAs. *See* Short-chain fatty acids (SCFAs)
 - Seafood allergen families
 - fish, 57–58
 - shellfish, 56–57
 - species, 54–58, 55†
 - Seaweed algal polysaccharides
 - biological activities
 - antibacterial, 132
 - anticoagulant, 131
 - antiobesity, 130–131
 - antitumor, 128–129
 - antiviral activity, 129–130
 - description, 127–128
 - composition
 - agar, 114
 - alginate, 120
 - carrageenans, 114–117

Seaweed algal polysaccharides (*cont.*)

- fucoïdan, 120–123
- furcellaran, 117–119
- laminaran, 109–113
- mannitol, 109
- species, 108–109
- storage, 109
- structural, 113–114
- ulvans, 123–124

Short-chain fatty acids (SCFAs)

- description, 86–87
- production, 87–88

Sparkling wines

champagne, 3

climate and soil conditions

- grape cultivation, 7
- irrigation, 8
- moisture, 7
- rain fall, 7
- vineyards, 7

cultivation techniques, 9

definition and types

- carbon dioxide, 5
- Crémants*, 6
- DO Cava*, 6
- European categories, 5–6
- Italian spumanti, 6
- Schaumwein* and *Qualitätsschaumwein*, 6

elaboration process

- aging, 17–19
- definition, base wine, 10–11
- expedition, 19–22
- red/white grape, 10–11
- second fermentation, 12–17
- transfer and Charmat method, 10–11
- white vinification, 11–12

fermentation process, 5

grape juice, 2

grape varieties

- Champenoise method, 8, 8*t*
- cultivars, 8

phylloxera crisis, 8–9

grapevines, 4–5

liqueur de tirage, 3–4

organoleptic characteristics (*see*

- Organoleptic characteristics, sparkling wines)

production and consumption data

evolution, 35, 35*f*

exportation, 36

forecast, 35, 36*f*

ripening control

alcohol volume, 9, 10

berries, 10

Botrytis cinerea, 10

type, press, 10

vinum titillum, 2

T

TDF. *See* Total dietary fiber (TDF)

Total dietary fiber (TDF), 78–79

U

Ulvans, 123–124

W

White vinification

alcoholic fermentation, 12

juice extracted, 11

oxidation, 12

phenolic compounds, 11

static method/dynamic method, 11

tartaric stabilization, 12

INDEX

Note: Page numbers followed by “*f*” indicate figures, and “*t*” indicate tables.

A

AA. *See* Antioxidant activity (AA);

Arachidonic acid (AA)

Acyl homoserine lactones (AHLs), 271–272

AHLs. *See* Acyl homoserine lactones (AHLs)

ALA. *See* α -Linolenic acid (ALA)

Antibiotics and bacterial resistance

description, 192–193

human and veterinary medicine, 192–193

plant/animal origin, 193

Salmonella strains, 193

Antioxidant activity (AA)

capacity, 106

determination, 108–109

drying process, 107

extraction methods, 107

Antioxidants, medical plants

carotenoids, 86

and oxidation processes, 77–81

phenolic components, 82–85

properties, 124

sources

activity, 87–88, 89*t*

Apiaceae family, 96–97

Asteraceae family, 105

Ginkgoaceae family, 104–105

Lamiaceae family, 88–99

Myrtaceae family, 106

plant preparations, 87

polar solvents, 87

uses, 86–87

Zingiberaceae family, 101–104

vitamins, 85–86

Apiaceae family

caraway, 101

cumin, 99–100

fennel, 100–101

Arachidonic acid (AA)

ω -6, 174

and EPA, 173

glycerides, 175

Ascending-bubble-driven flow patterns

bubble nucleation, 312–313, 313*f*

CO₂ sensor, near-IR technology

commercial champagne wine and beer,
335

description, 334

3D view, 334, 335*f*

gaseous concentrations, 335, 336*f*

pouring process, 335–336

effervescence

CO₂ concentrations, 325–326, 325*f*

ethanol concentrations, 325–326, 326*f*

experimental setup, 323–324, 324*f*

flute *vs.* coupe, 326–331

laser tomography

effect, shear stresses, 313–314, 315*f*

flute pouring, 315–317, 316*f*

optical workbench, 314–315, 316*f*

Rilsan particles, 314–315

swirling motion generators, 314–315

molecular mechanism, dissolved CO₂,
322–323, 323*f*

spontaneous self-organized 2D

convective cells, 320–322, 321*f*

stability

“bubbling environment”, 317

coupes symmetry, 319, 320*f*

time sequence, flute effervescence,
317–319, 318*f*, 319*f*

temperature, 331–334, 333*f*

Ascorbic acid, 49–50

Asteraceae family, 105

B

Bacterial pathogens

advantages and disadvantages, 255

analytical characteristics, 264–265

application, phage, 263–264

bacteriophage-host cell complex

(*see* Bacteriophage-host cell
complex, bacterial pathogens)

bacteriophage-mediated lysis

description, 272

Bacterial pathogens (*Continued*)
 intracellular metabolites, 272–273
 phage amplification assays, 273–276
Campylobacter, 217
 commercialization and governmental approvals, 256–257
C. peffringens, 218–219
 culture methods (*see* Culture methods, bacterial pathogens)
E. coli O157:H7 (*see* *E. coli* O157:H7)
 in foods, phages
 bacterial resistance evolution and phages dilution, 253–254
 electrospinning process, 254
 factors, 250
 “farm-to-fork” approach, 253
 incubation temperature, 250–251
 liquid environments, 249–250
 MOI, 250
 Salmonella phage (P7), 249–250
 food spoilage prevention, 261–262
 host specificity, 248–249
 infections, phages, 252–253
Listeria monocytogenes, 217–218
 lytic and lysogenic phages, 249
 microflora components, 252–253
 phage biocontrol (*see* Phage biocontrol)
 phage therapy, 249
 reporter phages (*see* Reporter phages, bacterial pathogens)
 safe tool, 252
Salmonella (*see* *Salmonella*)
 selection, phage, 251–252
 surface decontamination and biofilm formation, 262–263
Vibrio parahaemolyticus, 218–219
 virulent phages, 249

Bacteriophage-host cell complex, bacterial pathogens
 biosorbents, 267–269
 description, 266
 receptors, capturing agents, 269–270
 staining agents, 266–267

Bacteriophages
 bacterial pathogens
 biocontrol tools, 248–264
 detection, 264–276
 biology

environmental conditions, 243–245
 genomes, 243
 morphological structure, 243, 244f
 role, capsid, 243
 TEM image, 243, 245f
 description, life cycle, 245
 discovery, 242
 lysogenic and lytic pathways, 247–248, 248f
 lytic cycle
 adsorption, 246
 description, 245
 latent period, 246–247
 lysis/release, 247
 maturation/morphogenesis, 247
 penetration/injection, 246

Bayes’ theorem, 14

Biofilm formation
 description, 262
Listeria phage P100, 262

Bioluminescent reporter phage (BRP)
 assays, 270–271

Blending art, 294–295

BRP assays. *See* Bioluminescent reporter phage assays

Bubbles. *See* Ascending-bubble-driven flow patterns

C

CA. *See* Caffeic acid (CA)

Caffeic acid (CA)
 activities, 83–84
 defined, 83
 moieties, 92–93

Campylobacter, 217

Capillary electrophoresis (CE)
 CE-MS, 9–10, 15–16
 separation, components, 9

Carbon dioxide (CO₂) release, champagne glasses
 within bottle
 blending art, 294–295
 champagne aging, 301–302
 disgorging and corking, 297–301, 298f, 300f
 first alcoholic fermentation, 294
 second alcoholic fermentation, 295–296

- uncorking, 302–304
 - dissolved, serving
 - flute *vs.* coupe, 310–311
 - high-speed IR imaging, 307–309
 - and temperature, 304–307
 - Cardiovascular disease
 - carotenoids, 117
 - fennel, 117
 - LDLs, 116–117
 - Carotenoids
 - astaxanthin and canthaxanthin, 46
 - bixin and norbixin, 47
 - defined, 45–46
 - UV light range, 46–47
 - CE. *See* Capillary electrophoresis (CE)
 - CHA. *See* Chlorogenic acid (CHA)
 - Chain propagation, 78
 - Champagne glasses
 - ascending-bubble-driven flow patterns (*see* Ascending-bubble-driven flow patterns)
 - average composition and ionic strength, 290–291, 292*t*
 - classical flute and coupe, 293
 - CO₂ dissolved, serving
 - bottle to glass, liquid “tongue”, 304, 305*f*
 - “champagne-like” and “beer-like”, 304–305, 305*f*
 - concentrations, 306–307, 307*f*
 - description, 304
 - flute *vs.* coupe, 310–311
 - pouring step, high-speed IR imaging, 307–309, 308*f*, 309*f*
 - time sequences, 304–305, 306*f*
 - CO₂ within bottle
 - blending art, 294–295
 - disgorging and corking, 297–301
 - first alcoholic fermentation, 294
 - impact, champagne aging, 301–302, 301*f*
 - second alcoholic fermentation (*prise de mousse*), 295–296
 - uncorking, 302–304
 - ethanol, 291–293
 - hydroalcoholic systems, 290–291
 - role, effervescence, 291–293
 - VOCs and CO₂ pathways, 291
 - Champagne tasting, 291, 299, 317
 - Chlorogenic acid (CHA), 83–84
 - Chlorophyll, 43–44, 52
 - Crohn’s disease, 144–145
 - Culture methods, bacterial pathogens
 - description, 265
 - E. coli* O157:H7-specific phage (AR1), 265–266
 - host-specific bacteriophage, 265–266
 - Live/Dead BacLight bacterial viability stain, 266
 - metabolic activity and microbial growth, 265–266
 - visual observation/turbidimeters, 265
- D**
- Disgorge and corking, CO₂ caps removal, 297–299, 298*f*
 - dissolved CO₂ concentration, temperature dependence, 299, 300*f*
 - gaseous CO₂, temperature and parameters, 297–299
 - standard, magnum and half bottles, 299
 - temperature dependence, pressure *P*, 299, 300*f*
 - yeast autolysis, 297
- E**
- E. coli* O157:H7
 - E. coli* 1307 and Nissle strains, 214
 - foodborne illness, EHEC, 214
 - in vitro* cell culture models, 214–215
 - wild-type probiotics, 215
 - EHEC. *See* Enterohemorrhagic *E. coli* (EHEC)
 - Eicosapentanoic acid (EPA), 171, 173–174
 - Enterohemorrhagic *E. coli* (EHEC), 208–209, 214
 - Enteropathogenic *E. coli* (EPEC), 208–209, 214–215
 - EPA. *See* Eicosapentanoic acid (EPA)
 - EPEC. *See* Enteropathogenic *E. coli* (EPEC)
 - Ethanol release, champagne glasses. *See* Ascending-bubble-driven flow patterns
 - Extraction techniques
 - antioxidants, 86–87, 88–92
 - plant preparations, 87

F

- FAO. *See* Food and Agriculture Organization (FAO)
- “Farm-to-fork” approach, 253
- Fatty acid profile, oilseeds
 conventional, 150–156
 dietary lipids, categorization, 142–143
 genetic engineering, 172–174
 lipids
 human nutrition, 143–145
 requirements, human beings, 146–147
 sources, human consumption, 148–149
 SCOs (*see* Single-cell oils (SCOs))
 triglycerides, 141–142
 unconventional, 156–172
 unsaturated acid, 142
- ω-3 Fatty acids
 ALA, 150, 156
 EPA, 172–174
 LCPUFA, 173
 PUFA, 145, 151–155
 VLPUFA expression, 173–174
- ω-6 Fatty acids
 AA, 174
 EPA, 172–174
 LA, 155
 PUFA, 145, 151–155
 substrate specificity, 173–174
- FID. *See* Flame ionization detection (FID)
- First alcoholic fermentation
 grape cultivars, 294
 yeast contribution, 294
- Flame ionization detection (FID), 9, 10
- Flavonoids
 anthocyanins, 47–49
 quercetin, 49
 structures, photosensitive molecules, 47, 48*f*
- Flute *vs.* coupe
 carbonic anhydrase, 310
 champagne glasses, false-color time sequences, 329–330, 330*f*
 CO₂ concentrations, 326, 327*f*, 328
 CO₂ volume flux, 326–328, 328*f*
 ethanol concentration, 329, 329*f*
 false-color IR time sequences, gaseous CO₂ desorbing, 330, 331*f*
 geometrical parameters, 311*t*, 312–313
 grayscale time sequencing, 310, 313*f*
 liquid phase, bubbles, 328
 in reservoirs, 329–330
 zones, 330–331
- Food and Agriculture Organization (FAO), 195–196, 196*f*
- Foodborne pathogens
 antibiotics and bacterial resistance, 192–193
 bacteriophages, 191–192
 biological methods, 191–192
 delivery system, probiotics to gut
 alginate gels, 222–223
 chitosan, 223
 DNA-based gels, 223–224
 extrusion and emulsification technique, 222–223
 hypermellose phthalate, 223
 microencapsulation, 222–223
 PET, 222
 supplements, 222
 description, 186
 and diseases
 classification, 187–188, 189*t*
 etiologic agents, 186, 187*t*
 illnesses, hospitalizations and deaths, 186–187
 illness occurrence, 187–188
 gut health and disease prevention
 beneficial effects, probiotics, 193–194
 cocktail and bacteria, probiotics, 194
 diet *vs.* health, 193–194
 industrial production, probiotic-based functional foods, 195
 probiotic-induced enhanced butyrate production, 194
 gut microbiota *vs.* probiotics (*see* Gut microbiota *vs.* probiotics)
- lactic acid, 188–191
 microbial contamination, 191
 microbial population, guts, 192
 oils extraction, 188–191
 preharvest and postharvest interventions, 188
 probiotics (*see* Probiotics)
 safety assessments, probiotics

- decision network, SCAN, 195–196, 196*f*
 - FAO and WHO guidelines, 195–196, 197*f*
 - pathogenicity and virulence traits, 195–196
 - strain-specific characterization, 195
 - vaccine and antibody therapy, 192
 - wild-type and bioengineered probiotics (see Wild-type and bioengineered probiotics)
- Food processing. See Bacterial pathogens
- Food science. See Metabolomics, food science
- Functional foods
- components, 27
 - market, 26
 - nutritional/bioactive, 45
 - packaging selection, 27
- ## G
- Genetic engineering
- synthesis, PUFA, 173
 - VLP(U)FA, 172–174
- Ginkgoaceae family, 104–105
- GLA. See γ -Linolenic acid (GLA)
- Gut microbiota vs. probiotics
- description, 209–210
 - gastrointestinal tract components, 211
 - gene expression *in vitro*, 209–210
 - gram-positive bacteria, 209–210
 - inflammatory conditions, 211–212
 - L. casei* and *L. plantarum* administration, 211
 - metabolic pathway outcomes, 212
 - transcriptional microarrays, 211–212
- ## H
- Health effects protection, medical plants
- anticancer
 - aromatic plants, 115–116
 - research, anticarcinogens, 111–115
 - antimicrobial, 110–111, 112*t*
 - cardiovascular disease, 116–117
 - constituents, *in vivo*, 110
 - selection, medical plants, 118, 118*t*
 - uses, folk medicine, 109–110
- Henry's law, 296, 301–302
- Hurdle technology, 257
- ## I
- Infrared (IR) spectrometry
- detection, 10
 - extracted metabolites profile, 8
- IR spectrometry. See Infrared spectrometry
- Isoprene, 85
- ## L
- LA. See Linoleic acid (LA)
- Lamiaceae family
- basil, 95–96
 - common and lemon balm, 97–99
 - defined, 88
 - marjoram, 94–95
 - mint, peppermint, spearmint, 96–97
 - oregano, 93–94
 - rosemary, 88–92
 - sage, 92–93
 - thyme, 95
- LCPUFA. See Long-chain polyunsaturated fatty acids (LCPUFA)
- Light energy, food quality and packaging selection
- antioxidants, 62
 - bioactive compound, 26
 - chemical energy, 28–29, 29*f*
 - compounds, 26
 - definitions, terms, 27–28, 28*t*
 - and food molecules
 - chlorophyll, 43–44
 - defined, 33–34
 - lipids, 34–35
 - proteins, 36
 - and quality, 44–59
 - vitamins, 36–43
 - light-induced oxidation, quality, 32–33
 - photosensitizers (see Photosensitizers, food)
 - protection, 59–61
- Linoleic acid (LA), 144, 155, 173
- α -Linolenic acid (ALA)
- ω -3, 150, 156
 - and GLA, 161–162, 171
 - synthesis, PUFA, 173
- γ -Linolenic acid (GLA), 161–162, 173

- Linseed oil, 156
- Lipid hydroperoxides (LOOH)
 autoxidation, foods, 78
 formation, 79
 oxidation, 78
- Lipids
 chlorophyll, 34
 defined, 34
 fatty acids, 33–34
 human nutrition
 ω -3 and 6 fatty acids, 144–145
 dietary requirement, 144
 fats and oils, 143–144
 infant diet, 144
 lipid-derived mediators, 145
 myelin, 144
 requirements, human beings, 146–147, 147t
 sources, human consumption, 148–149, 149t
 structures, photosensitive molecules, 35, 35f
- Listeria monocytogenes*
 description, 217–218
 recombinant probiotics, 217–218
- Long-chain polyunsaturated fatty acids (LCPUFA)
 ω -3, 173
 substrate specificity, ω -6 fatty acids, 173–174
 synthesis, 174
- LOOH. *See* Lipid hydroperoxides (LOOH)
- Low-density lipoprotein (LDL)
 atherosclerosis, 116–117
 carotenoids, 117
 oxidation products, 79
- Lucerne, 164
- Lytic cycle
 adsorption, 246
 description, 245
 latent period, 246–247
 lysis/release, 247
 maturation/morphogenesis, 247
 penetration/injection, 246
- M**
- Mass spectrometers (MS)
 fingerprinting, 6
 metabolites detection, 9
- PDA, 10
- Medical plants. *See also* Antioxidants, medical plants
 antioxidants
 AA, 106–109
 carotenoids, 86
 and oxidation processes, 77–81
 phenolic compounds, 82–85
 sources, 86–106
 vitamins, 85–86
 natural and artificial exemplars, 77
 pharmaceutical industry, 76–77
 protection, health effects (*see* Health effects protection, medical plants)
 WHO, 76
- Metabolomics, food science
 analysis flowchart, 7, 7f
 components
 analysis, 9–10
 and interactions, 1–2
 compound identification, 10–11, 11f
 coupling, 17–18
 data analysis, 11–12
 definitions, 2–6
 food safety
 microbiology, 13–14
 toxicology, 12–13
 matrix components extraction, 8
 processing, 14–15
 quality, 15–16
 role, nutrition, 18
 synthesis, 18–19
 toxicity assessment, 17
- Microbiology, food, 13–14
- MS. *See* Mass spectrometers (MS)
- Myoglobin, 52–53
- Myrtaceae family, 106
- N**
- NMR. *See* Nuclear magnetic resonance (NMR)
- Nuclear magnetic resonance (NMR)
 compound identification, 10
 mango cultivars, 8
 metabolites detection, 9
 metabolomics techniques, 14–15
 noninvasive, 17

O

Oilseeds. *See also* Genetic engineering

conventional

- composition, oil, 155
- cottonseed, 155
- edible oils global production, 2010, 150, 151*t*
- fatty acid distribution, 150, 153*t*
- flaxseeds, 156
- groundnut oil, 155
- maize oil, 155
- olive, 155
- palm oil, 150
- rapeseed, 150
- sesame seed, 156
- soybean oil, 150
- sunflower seed, 151–155

unconventional

- apple seeds, 159–160
- C. amaris*, 158–159
- crude oil content and fatty acid composition, 166–167, 167*t*
- distribution, lipid, 164–165
- drumstick, 159
- extraction, fixed oil, 171–172
- fatty acid profile, black cumin crude seed oil, 165–166, 166*t*
- GLA and ALA, 161–162
- levels, PUFA, 169, 169*t*
- lipid content and fatty acid composition, 159–160, 160*t*
- lipid fractions, 168
- melon family, 159
- oleic and linoleic acids, 168
- seed oil content, fruit tree, 162–163, 162*t*
- tree seeds, 171, 172*t*
- USFA and SFA, 170
- utilization, food processing, 156–157
- vegetable seeds, 158
- wild lupin, 164

Oleaginous microorganisms, 174

Oxidation

- and antioxidants, foods
 - lipid, 78
 - LOOH, 78
- mechanisms, lipid peroxidation, 78–79
- peroxides, 79–80

- humans, antioxidants, 80–81
- light-induced effect, food quality, 32–33
- linoleic acid, 34
- photosensitized, 31
- singlet oxygen, 36, 42–43

P

Packaging, food

- films, 59–60
- materials, 59, 61
- PET, 60
- UV-permeable/impermeable, 60–61

PET. *See* Probiotic encapsulation

technology (PET)

Phage biocontrol

- animal origin, bacteria
 - Campylobacter* phages γ CP8 and γ CP34, 259–260
- foodborne pathogen, in foods, 259, 260*t*
- 5-log reduction, 259
- lytic *Listeria* phage P100, 259
- risk assessment models, 258
- Salmonella*, 259
- description, 257
- plant origin, bacteria
 - diseases, 257–258
 - in vitro* treatment, *Salmonella*, 258
 - Listeria* phage cocktails, 258
 - Xanthomonas campestris*, 257–258

Phenolic compounds

- acids, 83–84
- antioxidant properties, 82
- aromatic system, 82
- defined, 82
- flavonoids, 84–85
- intake, 82
- terpenes, 85

Phospholipid bilayer, 145

Photodiode array (PDA)

- compound
 - detection, 10
 - identification, 11
- metabolites detection, 9

Photosensitizers, food

- effect, light energy, 29–30
- energy transfer, 30

- Photosensitizers, food (*Continued*)
 structures, 30, 31^f
 transition, energy, 31–32, 32^f
- Polyunsaturated fatty acids (PUFA)
 ω -3 and 6, 145
 dry weight, adult brain, 144
 linoleic acids, 150
 microbial sources, 174
 peel lipids, 161–162
 SFA replacement, 144–145
 synthesis, 173
- Pouring step, high-speed IR imaging
 bottle-like and beer-like serving,
 307–308, 309^f
 description, 307–308
 dissolved CO₂ concentrations loss, 309,
 310^t
 gaseous CO₂ discharge, 308–309
 visualization setup, 307–308, 308^f
- Probiotic encapsulation technology (PET),
 222
- Probiotics
 antimicrobial action and cytoprotective
 effects
 bactericidal peptides and SCFAs,
 207–208
 bacteriocins and microcins, 207–208
 defensins and cathelicidins, 206–207
 description, 206–207
 EPEC and EHEC binding, 208–209
in vivo effect, bacteriocins *vs.* enteric
 pathogens, 208–209, 210^t
 barrier function
 chronic inflammation, 201–202
 enterocyte cell-cell adhesion, 201–202
 gut microflora populations, 199–201
in vitro and *in vivo* experiments, 201,
 202, 203^t
 mucus and goblet cells, 201
 pathogens and harmful agents, 199–201
 pretreatment, 202
 TLRs, 201–202
 classifications, 198
 description, 196–197, 200
 health benefits
 attributes, 199
 ideal criteria, 198–199, 199^t
 immunomodulation
 cytokines, 205–206
 effects, 205–206, 206^t
in vivo and *in vitro* studies, 204
 innate and acquired immune responses,
 204–205
 intestinal immune system, 202–204
 microbial colonization, 202–204
 mechanisms and health benefits, 199, 200^t
- Procapsids, 247
- Proteins
 collagen, 56
 disulfide bonds, 55
 structures, photosensitive molecules, 36, 36^f
- PUFA. *See* Polyunsaturated fatty acids
 (PUFA)
- ## Q
- Quality, food
 effects, light-induced oxidation, 32–33
 and light-responsive molecules
 ascorbic acid, 49–50
 carotenoids, 45–47
 chlorophyll, 52
 colorants, 53–55
 flavonoids, 47–49
 myoglobin, 52–53
 nitrogen-containing compounds, 57–59
 photoresponsive compounds, 44–45
 proteins, 55–56
 riboflavin, 50–52
 tocopherol and retinoic acid, 56–57
 metabolomics, 15–16
 packaging, protection, 59–61
- ## R
- Reactive oxygen species (ROS)
 accumulation, plastids, 85–86
 generation, 81
 oxidative processes, humans, 80
 participation, 79
- Reporter phages, bacterial pathogens
 advantages, β -galactosidase, 271
 AHLs, 271–272
 BRP assays, 270–271
 description, 270
- Riboflavin
 β -carotene, 51–52
 defined, 39

- degradation, 39–40, 50
- Havarti cheese, 51
- UV and visible light wavelengths, 50
- Rilsan[®] particles, 314–315
- ROS. *See* Reactive oxygen species (ROS)

S

- Safety, food, 12–14
- Salmonella*
 - cocktails, probiotic, 216
 - foodborne gastroenteritis, 215
 - innate and adaptive immune responses, 216–217
 - probiotic feeding, 215
- SCAN. *See* Scientific committee on animal nutrition (SCAN)
- Scientific committee on animal nutrition (SCAN), 195–196, 196f
- Second alcoholic fermentation (*prise de mousse*)
 - application, Henry's law, 296
 - Henry's law constant, 296, 297f
 - molar volume, 295–296
 - Van't Hoff-like equation, 296
 - yeast and sugar addition, 295–296
- SFE. *See* Supercritical fluid extraction (SFE)
- Single-cell oils (SCOs)
 - composition, commercial, 175, 176t
 - oleaginous microorganisms, 174
 - production, microbial oils, 174
 - safety evaluation studies, 175–177
- Soxhlet method, 159–160
- Sparkling wines
 - bars, clubs and restaurants, 304
 - kinetics, CO₂, 335–336
 - role, effervescence, 291–293
- Steam distillation and hydrodistillation
 - methods, 111
- Supercritical fluid extraction (SFE)
 - antioxidants, 86–87
 - balm, 97–99
 - rosemary extracts, 88–92
 - and steam distillation, 87

T

- TLRs. *See* Toll-like receptors (TLRs)
- Toll-like receptors (TLRs), 201–202
- Toxicology, food, 12–13

U

- Ultrasound sonification, 107
- Uncorking, CO₂
 - escaping and expanding, gaseous CO₂, 302–303
 - flute/coupe pouring, 303–304
 - time sequence, 302–303, 303f

V

- Van't Hoff-like equation, 296
 - Very-long chain polyunsaturated fatty acids (VLPUs)
 - ω -3 expression, 173–174
 - plants, 173–174
 - synthesis, 172–173
 - Vibrio parahaemolyticus*, 218–219
 - Vitamins
 - defined, 36–37
 - protection, diseases, 37
 - riboflavin, 39–40
 - vitamin A
 - carotenoids, 37
 - singlet oxygen quenching, 38–39
 - structures, photosensitive molecules, 37, 38f
 - vitamin C, 40–41
 - vitamin D, 41–42
 - vitamin E, 42–43
 - VLPUs. *See* Very-long chain polyunsaturated fatty acids (VLPUs)
 - VOCs. *See* Volatile organic compounds (VOCs)
 - Volatile organic compounds (VOCs)
 - aromatic perception, 291–293
 - ascending bubbles, 293
 - uncorking, 291
- ## W
- WHO. *See* World Health Organization (WHO)
 - Wild-type and bioengineered probiotics
 - bacterial pathogens
 - Campylobacter*, 217
 - E. coli* O157:H7, 214–215
 - L. monocytogenes*, 217–218
 - miscellaneous, 218–219

Wild-type and bioengineered probiotics

*(Continued)**Salmonella*, 215–217*vs.* foodborne pathogens, mechanisms,
213, 213*f*

toxins neutralization

aflatoxin (AFB-1), 220–222

fungal pathogens, 220

patulin and fumonisin, 220–222

probiotic strains, 220–222

viral pathogens

description, 219

lactic acid bacteria-based intervention
strategies, 219–220, 221*t*

receptor mimetics, 219–220

World Health Organization (WHO), 76,
109, 195–196, 196*f***Z**

Zingiberaceae family

ginger, 103–104

turmeric, 101–103

INDEX

Note: Page numbers followed by "f" indicate figures, and "t" indicate tables.

A

Actinidia chinensis

- A. deliciosa* and *A. setosa* complex, 21–22
- cultivars, 26–28
- scientific and horticultural literature, 22–23

Actinidia deliciosa

- A. chinensis* and *A. setosa* complex, 21–22
- cultivars, 26–28
- scientific and horticultural literature, 22–23

Actinidia species

- A. arguta* and *A. kolomikta*, 28
- A. chinensis*, *A. deliciosa* and *A. setosa* complex, 21–22
- cultivars, 26–28
- cultivation, 20
- diploid species, 20
- domestication, 25–26
- fruit diversity, 23–25
- genus revision, 19
- origin, 28
- ploidy races, 19–20
- polyploidization, 20
- scientific and horticultural literature, 22–23

Actinidin, 328–329

- Actinidia, 64–65
- applications, 67–68
- beef muscle protein-based diet, 164
- casein hydrolysis, 151–152
- catalytic activity, 66–67
- cross-reactivity, 329
- description, 328
- digestion
 - foods, 150
 - gelatin, 158
 - protein, 156
- gastrointestinal enzymes, 328
- gastrointestinal motility
 - figs, 229
 - in vivo* investigation, 228–229

- ion transport and ion channels, 229
- potential bioactivity and role, 229

kiwifruit extract (KE), 151

- occurrence, 65
- optimal pH, 158
- protease family C1A, 328–329
- severity of symptoms, 328
- structure and properties, 65–66
- upper-tract digestion, 161–163

Adaptive immunity, 302, 309

Allergens, kiwifruit

- Act d 3, 331
- actinidin (Act d 1), 328–329
- adverse food reactions, 322
- description, allergens, 326, 327t
- diagnosis, 325–326
- differences, allergenicity, 334–335
- epidemiology, 323–324
- food allergy sources, 322
- kiwellin (Act d 5), 332
- major latex protein (Act d 11), 334
- monosensitization, 323
- nsLTPs. Act d 10, 333–334
- pathogenesis-related protein (PR-10), Act d 8, 333
- pectin methylesterase (Act d 7), 333
- pectin methylesterase inhibitor (Act d 6), 332
- phytozystatin (Act d 4), 331–332
- profilin (Act d 9), 333
- sensitization, 322–323
- symptoms, 324
- TLP, Act d 2, 329–330
- treatment, 326

ANFs. *See* Antinutritional factors (ANFs)

Animal studies, vitamin C, 139–140

Antinutritional factors (ANFs), 170, 177

Antioxidants

- and cancer prevention, 296–297
- defenses, 296
- description, 295
- environmental stresses, 285–286

Antioxidants (*Continued*)

- FRAP values, 285–286, 285*t*
- in vitro* assays, 286, 286*f*, 287
- metabolic reactions, plants, 285–286
- micronutrient effects, humans
 - biomarker, 287
 - endogenous damage, 288, 291*f*
 - intervention trial, 288, 290*f*
 - placebo-controlled crossover design, 287–288
 - power calculation, 287
 - samples, 287
 - sensitivity, lymphocytes, 288, 290*f*
 - Vitamin C and lymphocytes, 287–288, 289*f*
- NER activity, 292–294, 294*f*

Ascorbate

- animals, 126
- bioavailability, 141–142
- cofactor, 128*t*
- deficiency, 129
- high concentrations, 127
- plants, 126
- supplementation, 140*t*

B

Bacteriocins, 215

Base excision repair (BER) activity

- description, 290–292
- lymphocyte, supplementation, 292, 293*f*
- measure, enzymes, 292, 293*f*
- NER activity, 292–294

BER activity. *See* Base excision repair (BER) activity

Bioavailability, vitamin C

- biological activity
 - copper-containing hydroxylases, 127
 - enzymes, cofactor, 128*t*
- chronic diseases prevention, 130–131
- content, kiwifruit
 - DHAA, 133–134
 - storage, 134
- description, 126
- dietary, 126
- food sources
 - content, 131–132, 132*t*
 - cooking, 131–132
 - meat, 131–133

kiwifruit

- animal studies, 139–140
- plasma vitamin C, 136–137
- supplementation, humans, 134–136, 135*f*
- tissue levels, 137–139
- natural *vs.* synthetic, 142–143
- plant components effect
 - AA-economizing factor, 141
 - bioflavonoids, 141–142
- plants and animals, 126
- RDI (*see* Recommended dietary intake (RDI))
- respiratory diseases
 - common cold, 131
 - pneumonia, 131
 - scurvy, 126–127
- Bristol Stool Scale, 221–222, 222*t*

C

Calcium

- apical membrane, 242
- bone mass, 235–236
- Caco-2 cell monolayers, 248, 248*f*
- pH range, 237
- pigs fed gold/green kiwifruit, 249, 249*t*
- small and large intestines, 241–242
- transcellular uptake, 242
- vitamin D, 236

Carbohydrates

- blood glucose concentrations, 262–263
- cell walls, DRR, 263
- clinical measurements, GI, 259*t*, 261
- dietary fiber, 269
- glucose diffusion, retardation, 264–265, 265*f*
- organic acids, 263
- retardation of mixing
 - dialysis experiment, 265*f*, 269
 - DRR preparations, 265–266
 - estimation, 268, 268*t*
 - measurement, 267–268, 267*f*
 - plastic tube, 266–267, 266*f*
 - soluble polysaccharide, 268–269, 268*t*
- rheological factors, 263–264
- Cardioprotective properties
 - human trials
 - antioxidant-rich diet, CVD, 279, 279*t*

- hyperlipidemia, 278
 - platelet aggregation, 276–278, 278*t*
 - supplementation period, 276–278
 - triglyceride levels, 278–279
 - in vitro* studies, 275, 276*t*, 277*f*
 - Cardiovascular disease (CVD)
 - antioxidant-rich diet, 279
 - development, blood lipids, 280
 - hyperactivity, 274
 - hypertension, 274
 - mortality, 273–274
 - platelet reactivity, 280–281
 - prevention, 279
 - risk factors, 273–274
 - Caveolae-mediated endocytosis, 189–190
 - Cell-wall polysaccharides, kiwifruit
 - cellulose, 87
 - changes
 - development and ripening, 88
 - foregut digestion, 88–89
 - hemicelluloses, 86–87
 - noncellulosic polysaccharide constituents, 83–84
 - pectic polysaccharides, 84–86
 - Clathrin-mediated endocytosis, 189–190
 - Colonic microbiota modification
 - kiwifruit carbohydrates
 - carbohydrate-degrading mechanisms, 209
 - gram-negative, cell-associated system, 210
 - gram-positive, extracellular system, 210
 - in vitro* batch fermentation system, 210–211
 - lachnospiraceogenic and bifidogenic prebiotics, 214
 - microbial fermentation, 213–214
 - NSPs, 209
 - organic acids, 207–208
 - percentage change, organic acid concentrations, 214*t*
 - prebiotics, 207–208
 - real-time quantitative PCR, 211
 - 16S rRNA pyrosequencing, 211–213, 212*f*
 - structural differences, 210
 - kiwifruit fermentation, 215
 - polyphenolic compounds
 - antimicrobial activity, 206–207
 - commercial preparations, 207
 - fluorescent bacteria adhesion assay, 207
 - vitamin C, 207, 208*f*
 - polyphenols, 206
 - Composition and nutritional value, kiwifruit
 - ADEa, ME and AE, 43*t*
 - free amino acids, amines and peptides, 53*t*
 - nutrient density and nutrient adequacy scores, 41*t*
 - nutritional composition, 36*t*
 - organic acids, 49*t*
 - sugar content, 45*t*
 - vitamin C content, 47*t*
 - vitamin E content, 48*t*
 - Constipation
 - Bristol Stool Scale, 221–222, 222*t*
 - causes, 221
 - description, 220–221
 - functional
 - definition, 221–222
 - diagnostic criteria, 221*t*
 - IBS, 222–223, 223*t*
 - kiwifruit
 - age and sex-matched case control study, 224–225
 - colonic transit, 226
 - defecation diary recording, 226
 - elderly subjects, 223–224
 - healthy subjects, 227
 - IBS-C patients, 225–226
 - laxative properties, 223
 - laxatives, 222
 - pediatric populations, 222
 - Copper
 - ceruloplasmin, 236
 - chloride ions, 243
 - homeostasis, 236–237
 - metalloproteinases, 243
 - CVD. *See* Cardiovascular disease (CVD)
- ## D
- Defining characteristics, genus *Actinidia*
 - dioecy, 17–18
 - fruit structure, 18
 - growth habit, 17
 - morphology, female flowers, 18

- Defining characteristics, genus *Actinidia*
(Continued)
natural distribution, 18–19
- Dietary fiber
classification, 187–188
composition, 82–83
definition, 82, 187–188
digestion and absorption
 components, 191, 192*t*
 dietary polysaccharides, 193
 fecal bulk, 194
 fermentation, fiber, 194
 mastication, 191–192
 SCFAs, 194
 small intestine, 193
 solubility, 192
 viscogenic soluble fibers, 192–193
functional properties (see Functional properties, kiwifruit dietary fiber)
structure, cell-wall polysaccharides
 cellulose, 87
 gold kiwifruit, 83–84
 hemicelluloses, 86–87
 pectic polysaccharides, 84–86
- Dietary minerals
ascorbic acid, 246
Caco-2 cells, 247–248, 248*f*
calcium (see Calcium)
copper, 236–237, 243
description, 234
digestive system, mineral absorption
 (see Mineral absorption)
ferritin, 246, 247*t*
iron, 240–241
magnesium, 235, 242
mineral content and percentage, RDI,
 244, 245*t*
mineral interactions, 244
mineral uptake, 234
nutritional composition, 249
pigs fed gold kiwifruit, 248–249, 249*t*
potassium, 237, 243
side effects, dietary supplements, 244
transferrin receptor, 246
- Digestion and absorption
chyme squirts, 189
clathrin-mediated and caveolae-mediated
 endocytosis, 189–190
description, 188
gastric secretions, 188–189
human gut microbiota, 190
large intestine, 190
nutrients, 189
SCFAs, 191
- Digestion, kiwifruit fiber
casein-based test diets, 195–196
in vitro and *in vivo* models, 198
in vitro digestions, 197–198
ileal organic matter digestibility, 195–196,
 196*t*
ileal protein digestibilities, 196
mean diet transit time, 197*f*
NSP content, 194–195
oxalate-soluble pectin fraction, 196
reduced gastrointestinal transit time,
 197
simulated gastric digestion, 195
water-holding capacity, kiwifruit-
 containing diets, 197
- Digestion-resistant residue (DRR)
description, 270
glucose diffusion, retardation, 264–265,
 265*f*
retardation of mixing
 measurement, 267–268, 267*f*
 plastic tube, 266–267, 266*f*
 soluble polysaccharide, 268–269, 268*t*
swollen volume, 264, 264*f*
- DNA damage and repair
antioxidants (see Antioxidants)
catalase and superoxide dismutase,
 284–285
chronic diseases, 283–284
dose, kiwifruit juice, 295
effects, kiwifruit supplementation
 BER activity (see Base excision repair
 (BER) activity)
 NER activity, 292–294, 294*f*
 phytochemicals, 297
foodmutagens, 284
fruits and vegetables, 284
gene expression, 294–295, 297
intervention trials, 295–296
supplementation trials, 295
- DRR. See Digestion-resistant residue
(DRR)

F

- Ferric reducing activity of plasma (FRAP), 285–286, 285*t*
- Flavonoids, kiwifruit, 115
- Folin-Ciocalteu method, 114
- FRAP. *See* Ferric reducing activity of plasma (FRAP)
- Functional bowel disorders, 220
- Functional properties, kiwifruit dietary fiber
 - beneficial effect, blood lipids, 89
 - foregut and hindgut, 89
 - gastrointestinal conditions, 89–90
 - hydration, 90–92
 - large bowel
 - apparent survival, 94, 95
 - fermentation, hindgut bacteria, 93
 - fiber-free diet base, 94
 - increment, fecal dry weight, 94, 95*t*
 - short-chain fatty acids, 95–96
 - retardation, 92–93
 - soluble and insoluble undigested polymer fractions, 89

G

- Gastrointestinal motility
 - actinidin and protein fractions, 228–229
 - constipation, 220–223
 - functional bowel disorders, 220
 - kiwifruit fiber
 - gut microflora, 228
 - large intestine, 227–228
 - phytochemicals, 229
- GGEs. *See* Glycemic glucose equivalents (GGEs)
- GI. *See* Glycemic index (GI)
- Global fruit bowl
 - “Chinese Gooseberry”, 2–3
 - commercialization, Zespri[®], 4
 - description, 2–3
 - exotic vine, 2
 - global health trends, 11–13
 - green-fleshed “Hayward” variety, 3
 - growing consumer demand, 10–11
 - London-based nursery firm, 1–2
 - mainstream fruit option and remains, 10
 - markets, 9, 10
 - medicinal uses, 3–4

- New Zealand-grown kiwifruit, 2–3
- novelty fruit, markets, 3
- plant and fruit, 2
- production profile
 - Europe accounts, 7
 - FAOSTAT, 6
 - major exporters, 2007–2010(%), 6–7, 7*t*
 - official statistics, 4
 - producing countries 2000, 5, 6*t*
 - producing countries 2010, 5, 5*t*
 - 1970 to 2010, 4, 5*f*
 - world value, exports, 7–8, 8*f*
- products, 3
- regular consumers, 8–9
- trade agreement, 10
- Western world, 2
- world share, major fruit groups, 8, 9*t*
- Global production
 - official statistics, 4
 - from 1970 to 2010, 4, 5*f*
- Glycemic glucose equivalents (GGEs), 259–260, 260*f*, 261
- Glycemic index (GI)
 - calculation, 258–259, 259*t*, 261
 - description, 270
 - diabetes management, 261
 - estimation, 260, 260*f*
 - GGE value, 259–260
 - vs.* glycemic impact, kiwifruit, 261, 262*f*
 - vitamin C, 261–262
- Glycemic potency
 - calculation, GI, 258–259, 259*t*
 - description, 258
 - GGEs, 259–260, 259*t*
 - glucose disposal rate, 260, 260*f*
 - in vitro* determination, 260, 260*f*
- Gut mucin production
 - chemical and physical properties
 - A. deliciosa*, 179
 - hemicellulosic polysaccharides, 178
 - insoluble needle-shaped calcium oxalate raphide crystals, 178–179
 - lignin fraction, 178
 - organic acids, 179
 - WHC, 178
 - dietary factors
 - ANFs, 177

Gut mucin production (*Continued*)

- oral administration, α -lactalbumin, 177–178
- soluble and insoluble fibers, 177
- empirical evidence
 - caco-2 cells, 179
 - goblet cells, 181
 - regression analyses, 181, 181*f*

H

Hemicelluloses

- constituent sugar and glycosyl linkage
 - analyse, 86
 - galactoglucomannan, 86
 - glycosyl linkage analysis, 86–87
 - XG, 86, 87*f*

Hydration properties, kiwifruit cell walls

- freeze-dried rehydrated kiwifruit fiber, 91*f*
- freeze drying, 91
- swelling and water retention, 90, 92*f*

Hypovitaminosis C, 127

IIBS. *See* Irritable bowel syndrome (IBS)IBS-C. *See* IBS with constipation (IBS-C)

IBS with constipation (IBS-C)

- IBS-CC and IBS-CK, 226
- natural laxative option, 226

Immune responses

- adaptive immunity, 302, 309
- carotenoids and polyphenols, 303
- description, 302

human intervention trials

- CD4 + CD8 + T cells, 315, 316*f*
- cold/flu-like illness, 315
- comparison, SIV, 315–318
- freeze-dried kiwifruit, 314
- T lymphocytes, 315, 317*f*
- upper respiratory tract infections, 313–314

inflammation, 309–310

innate immune effects (*see* Innate immune effects)

ovalbumin (OVA), 312–313

rat $\gamma\delta$ T cells

- CD25 expression, 311, 311*f*
- feed supplementation, 311–312, 312*f*

gastric degradation, 311–312

vitamins and folic acid, 303

Inflammation, 309–310

Innate immune effects

- cell proliferation assays, 308–309
- β -defensins production, 304, 305*f*, 306*f*
- direct antimicrobial activity, 303–304
- epithelial barrier integrity, 304–307
- gold and green kiwifruit fermenta, 304–307, 307*f*
- priming, rat $\gamma\delta$ T cells, 308–309, 308*f*
- type 2 immune defense mechanisms, 302

Iron

- ascorbic acid, 246
- Caco-2 cells, 247–248, 248*f*
- deficiency, 235
- duodenum, 240
- enterocyte, heme iron, 241
- ferritin, 246
- ferrous, pathway, 241
- ferroxidase, 236
- heme and nonheme, 240
- hemoglobin and myoglobin, 234–235
- paraferritin, 240–241
- supplementation, 244
- transferrin receptor, 246

Irritable bowel syndrome (IBS)

- gastrointestinal dysmotility, 222–223
- subtypes, 223, 223*t*

K

Kirola, 69

Kiwellin, 332

- definition, 63
- fragments, 68
- gold kiwifruit, proteins measurement, 61, 62*t*
- major kiwifruit proteins, nomenclature, 63*t*
- proteins measurement, green kiwifruit, 61, 62*t*

Kiwi Crush™, 164–165

Kiwifruit. *See also* Protein digestion, kiwifruit

- Actinidia deliciosa*, 258
- anthocyanidins and flavonols, 274–275
- blood lipids, 280

- carbohydrate availability
 - (see Carbohydrates)
 - cardioprotective properties, 275–279
 - chemical composition, 34–35
 - CVD (see Cardiovascular disease (CVD))
 - domestication and commercialization, 29*t*
 - enzymes characterization, 70*t*
 - fermentation
 - bacteriocins, 215
 - gut microecology, 215
 - fruit and vegetable consumption, 273–274
 - global fruit bowl (see Global fruit bowl)
 - glycemic potency (see Glycemic potency)
 - gut barrier and mucous layer significance
 - barriers, layers of defense, 171–172, 172*f*
 - dendritic cells, 171–172
 - goblet cells, 173
 - gut ecosystem, 171*f*
 - hydrophobicity, 173–174
 - intestinal goblet cells, 173
 - intestinal IgA, 171–172
 - MUC2 and MUC3 expression, 175
 - mucins, 174, 175
 - mucin turnover, 176–177, 176*f*
 - mucus degradation, 175–176
 - RELM β , 173
 - gut mucin production (see Gut mucin production)
 - “Hayward” cultivar, 102–103
 - hyperlipidemia, hypertension and hyperactivity, 274
 - macro components
 - dietary fiber, 44
 - energy, 42–43
 - lipid, 44
 - protein, 43
 - sugars, 44–45
 - minor components
 - free amino acids, amines and peptides, 53–54
 - myo-inositol, 52–53
 - modulation, gastrointestinal motility (see Gastrointestinal motility)
 - mucins (see Mucins)
 - nomenclature, 63*t*
 - nutrient density scores, 35–42
 - nutritional composition, 35
 - organic acids
 - citric, quinic and malic acid content, 49, 49*t*
 - description, 49
 - oxalate, 50
 - phytochemical content, 34
 - pigments
 - anthocyanins, 52
 - carotenoids, 50–51
 - chlorophylls, 51–52
 - platelets, 280
 - polyphenolic compounds, colonic microbiota modification, 206–207
 - proteins measurement, soluble extracts and purees, 62*t*
 - secondary metabolite components (see Secondary metabolite components, kiwifruit)
 - thrombosis prophylaxis, 280–281
 - total protein content, 60, 60*t*
 - vitamin C, 102
 - vitamins
 - folate, 49
 - vitamin C, 46–48
 - vitamin E, 48
 - Kiwifruit and mineral nutrition. See Dietary minerals
- ## M
- Magnesium
 - deficiency, 235
 - pH range, 237
 - small intestine, 242
 - vitamin D, 236
 - Major latex protein (Act d 11), 334
 - Mineral absorption
 - brush border, microvilli, 238–239, 239*f*
 - passive/active transport, 239
 - pH, 237
 - small intestine, 238, 238*f*
 - toxic levels, 239–240
 - Mucins. See also Gut mucin production
 - degradation, 175–176
 - description, 174
 - genes, 175
 - neutral, 174
 - oligosaccharide chains, 174
 - subfamilies, 175

N

- Natural *vs.* synthetic vitamin C
 bioavailability, 142
 “Ester C”, 142–143
 synthetic AA, 142
- NER activity. *See* Nucleotide excision repair (NER) activity
- Nonspecific lipid-transfer proteins (nsLTPs), 333–334
- Nonstarch polysaccharides (NSPs), 209
nsLTPs. *See* Nonspecific lipid-transfer proteins (nsLTPs)
- NSPs. *See* Nonstarch polysaccharides (NSPs)
- Nucleotide excision repair (NER) activity, 292–294, 294*f*, 297
- Nutrient density, 35–42, 41*t*
- Nutrient density enhancement, kiwifruit, 117–118
- Nutritional composition, kiwifruit, 35, 36*t*

O

- Osteogenic Disorder Shionogi (ODS) rat, 141
- Oxalate, kiwifruit
 A. chinensis, 119
 description, 118
 raphides, 118–119

P

- Pathogenesis-related protein (PR-10), 333
- Pectic polysaccharides, 192
 classification, 84–86
 RG II, 86
 structures, 85*f*
- Pectin methylesterase, 333
- Pectin methylesterase inhibitor, 332
- Phenolic acids
 aglycone, 115
 detection methods, 114
- Phloe™, 164–165
- Phytochemicals, gastrointestinal motility, 229
- Phytocystatin, 331–332
- Platelet aggregation
 ADP and collagen, 276–278, 278*t*, 280
 in vitro, 275, 277*f*
 inhibitory effects, 280

- thrombosis and arteriosclerosis, 274
 whole-blood aggregation and ACE activity, 279, 279*t*
- Platelet hyperactivity, 274, 279
- Potassium, 237, 243
- Prebiotics, definition, 207–208
- Profilin, 333
- Protein digestion, kiwifruit
 actinidin, 150
 benefits and commercial preparations
 KE, 164
 Phloe™ and Kiwi Crush™, 164–165
 small intestine
 actinidin, 161–163
 beef muscle protein, 164
 KE, 162*t*, 164
 Na-caseinate, 161–163
 11S-globulin-like protein, 163–164
 Z19 and Z22 α -zeins, 163
 stomach
 actinidin (*see* Actinidin)
 beef muscle protein, 156
 cottage cheese and yoghurt, 160
 dietary proteins classification, 150–151
 egg proteins, 161
 in vitro approach, 151–152
 in vivo studies, 152–154
 KE, gastric digestion, 152–154, 152*t*
 meat and fish proteins, 159–160
 Na-caseinate, 154–155
 nutritional homeostasis, 150
 pepsin inhibition, 150–151
 tofu, 161
 wheat gluten, 156–158
- Proteins and enzymes, kiwifruit
 actinidin (*see* Actinidin)
 1-aminocyclopropane-1-carboxylate synthase, 73
 ascorbate, 73
 digestion, 63–64
 involvement, ripening process
 cell wall metabolism, 72–73
 characterization, 69, 70*t*
 measuring activities, 69–71
 postharvest, 69
 in silico study, 69
 small amounts, 69
 starch and sugar metabolism, 71

kirola, 69
 kiwellin and fragments, 68
 major soluble proteins and patterns, 61–63
 polyphenol oxidase, 74
 protein content, 60–61
 superoxide dismutase, catalase, and peroxidase, 74
 thaumatin-like protein, 68–69
 volatile esters, formation, 73

R

RDI. *See* Recommended dietary intake (RDI)
 Recommended dietary intake (RDI)
 basal plasma levels, 129–130
 description, 129
 human studies, 129
 pharmacodynamics, 129
 toxicity, 129–130
 RELM β . *See* Resistin-like molecule beta (RELM β)
 Resistin-like molecule beta (RELM β), 173
 RG II. *See* Rhamnogalacturonan II (RG II)
 Rhamnogalacturonan II (RG II), 83–84, 86
 Ripening process
 cell wall metabolism, 72–73
 characterization, 69, 70*t*
in silico study, 69
 measuring activities, 69–71
 postharvest, 69
 small amounts, 69
 starch and sugar metabolism, 71

S

SCFAs. *See* Short-chain fatty acids (SCFAs)
 Scored human immunological vigor (SIV), 315–318
 Secondary metabolite components, kiwifruit
 carotenoids and chlorophylls, 103
 green and gold kiwifruit, 103, 104*t*
 health enhancing properties
 methods, 117
 nutrient density, 117–118
 metabolite discovery
 exact ion chromatograms (EIC), 120–122, 121*f*
 LC-MS, 120–122, 120*f*
 lipids, 120–122
 metabolomics, 119–120

negative impact, health (*see* Oxalate, kiwifruit)
 phenolics, 103–115
 vitamins
 folate/vitamin B₉, 117
 vitamin C, 115–116
 vitamin E, 116–117
 vitamin K, 117
 Short-chain fatty acids (SCFAs)
 acidification, digesta contents, 191
 butyrate, 191
in vitro fermentation models, 194
 ileal and hindgut luminal flows, 197–198
 metabolism, 190–191
 SIV. *See* Scored human immunological vigor (SIV)
 16S rRNA pyrosequencing, 211–213, 212*f*

T

TFPs. *See* Trefoil factor peptides (TFPs)
 Thaumatin-like protein (TLP)
 characterization, 329
 cross-reactivity, 330
 definition, 68–69
 description, 329
 green kiwifruit, proteins measurement, 61, 62*t*
 identification, 68–69
 major kiwifruit proteins, nomenclature, 63*t*
 proteins measurement, gold kiwifruit, 61, 62*t*
 PR-5 proteins, 330
 TLP. *See* Thaumatin-like protein (TLP)
 Trefoil factor peptides (TFPs), 173

V

Vitamin C
A. eriantha, 20
A. kolomikta, 20
 animal studies, 139–140
 bioavailability (*see* Bioavailability, vitamin C)
 concentration, 116*t*
 content, 23–25, 115–116
 glycemic index (GI), 261–262
 kiwifruit, 46–48
 and lymphocytes, 287–288, 289*f*

Vitamin C (*Continued*)

- natural *vs.* synthetic
- bioavailability, 142
- “Ester C”, 142–143
- synthetic AA, 142
- polyphenolic compounds, 207, 208*f*

Vitamin D

- calcium, 236
- magnesium, 236

Vitamin E

- composition and nutritional value, 48*t*
- kiwifruit, 48

Vitamins, secondary metabolite

- components, kiwifruit
- vitamin C, 115–116
- vitamin E, 116–117
- vitamin K, 117

W

Wild and cultivated plants, kiwifruit

- Actinidia* species (*see Actinidia* species)
- appearance, 16
- “Chinese gooseberry”, 16
- domestication and commercialization, 29, 29*t*
- genus *Actinidia*
- dioecy, 17–18
- fruit structure, 18
- growth habit, 17
- morphology, female flowers, 18
- natural distribution, 18–19
- “Hayward”, 16
- “Hort16A”, 29–30
- “mihoutao”, 16
- traded international, 16

INDEX

Note: Page numbers followed by "f" indicate figures, and "t" indicate tables.

A

- Acyl acceptor, 201
- Acyl donor, 201
- Agglomeration mechanisms
 - DA (*see* Dimensional analysis (DA))
 - description, 57–58
 - fluidized bed, 58–61
 - food powders, 57–58
 - low shear mixer, 61–73
 - powder flows and stress transmission, 75–79
 - sensors, 79–81
 - under static pressure, 73–74, 74f
 - wet, 74–75

Appetite and satiety

- eating behavior, 108, 109
- nutrients, 109–110
- peptides, 109
- psychobiological system, 108
- subjective ratings, 109

Aspergillus sp., 202

B

Bacillus sp., 202–205

Biotransformation, polyphenols

- chemical methods
 - conjugation with proteins/amino acids, 186–191
 - esterification, 191
 - miscellaneous, 192
 - polymerization, 191
- enzymatic methods
 - cellulase, 200
 - enzymes employed, 192, 193t
 - esterases and proteases, 199
 - laccase, 198–199
 - lipase, 196–197
 - peroxidase, 200
 - tannase, 197–198
 - transferases, 200

enzyme-mediated transformation

- acyl acceptor, 201

- acyl donor, 201
- solvent, 201
- temperature, 201
- water activity, 201
- improved bioavailability, 210
- increased bioactivity, 209–210
- metabolite production, 208–209
- microbes
 - bacteria, 202–205
 - fungi, 202
- plant cell cultures, 205–208
- solubility and stability in lipophilic preparations, 210–211

C

Capsicum frutescens, 207

Carbohydrates

- dietary fiber, 131–143
- digestibility, finger millet, 26–27
- foods, 30–31
- Gi, 128–131
- nutrient composition, 6, 7t
- quality and quantity measurement, 2–3

Cellulase, 200

Cereals and breads

- bacon and eggs, 138
- crushed or rolled oats, 137
- defined, 134
- β-glucans, 136–137, 138
- grain servings, 134
- lupin-kernel flour, 136
- oatmeal, 140
- rye flour, 135–136
- snacking behaviors, 139–140
- whole-grain bread consumption, 134–135, 139

Chennai Urban Rural Epidemiology Study (CURES), 4–5

Citrus paradisi, 207–208

CURES. *See* Chennai Urban Rural Epidemiology Study (CURES)

D

- DA. *See* Dimensional analysis (DA)
- Dairy powders
 spraydrying temperature, 49–50
 surface, 48–49
- Dairy products
 branched-chain amino acids (BCAA), 114–115
 “calcium appetite” theory, 115–116
 calcium intake, 115–116
 casein and whey protein, 114
 fat mass, lean body mass and waist circumference, 118
 hunger ratings, 116–117
 isoenergetic meals, 116
 milk proteins and consumption, 115
 opioid peptides, 114
 satiety, 116, 117
 weight status *vs.* dairy consumption, 117–118
- Debranning/decontamination methods, 13–15
- Degree of gelatinization (DG), 26–27, 31
- DG. *See* Degree of gelatinization (DG)
- DI. *See* Digestibility index (DI)
- Diabetes
 meal plan, *ragi*-based products, 30, 30*t*
 nutritional management, 29, 31–32
 and obesity, 27, 30
 protein glycation, 17
 type 2, 2–3, 31–32
- Dietary fiber
 breads and cereals, 134–140
 classification, 131–132
 effects, 132
 fiber from fruits, 133
 fruits and vegetables, 140–143
 gastric satiety, 132
 influence, 133
 intake, 133
- Dietary proteins
 energy expenditure, 111
 energy intake, 112
 gluconeogenesis/*de novo* synthesis, 111
 high-protein diets, 113
 legumes, 122–125
 meat, fish and eggs, 118–122
 milk and milk products, 113–118

- nuts, 125–128
 protein-induced satiety, 111
 The Recommended Dietary Allowance (RDA), 112
 thermic effect, nutrients, 110
 tryptophan, 112
 3-week crossover trial, 111–112
- Digestibility index (DI), 26–27
- Dimensional analysis (DA)
 description, 82–83
 guidelines, 91–95
 liquid atomization modeling, 86–91
 wet agglomeration process, 83–86
- Durum wheat
 agglomeration, 66*f*
 semolina, 77–79, 80, 81*f*

E

- Eleusine coracana* L. *See* Finger millet
- Energy density
 defined, 152
 high-ED diet, 153–154
 low-energy density foods, 152
 meals, 153
 selected foods, 154, 154*t*
 sugar sweetened beverages, 154
 water content, 152
- Esterases and proteases, 199
- Eucalyptus perminiana*, 207

F

- Fats
 appetite perceptions, 148–149
 bariatric surgery, 145–146
 delaying lipid digestion, 147–148
 duodenal infusion, 12-carbon fatty acids, 146–147
 energy-dense macronutrient, 149
 FA chain length, 144
 fat-soluble compounds, 144
 finger millet lipids, 10
 food texture, 143–144
 ileum exposure, 145
 infusion, triglycerides, 146
 lipases, 142
 medium chain triglycerides (MCT), 147
 OlibraT, 147–148

- palatable and unpalatable foods, 145
- Pinnothin T, 147
- Finger millet
 - calorie-restricted diet, 2–3
 - carbohydrate digestibility (*see In vitro* studies, finger millet)
 - composition, nutrient, 6–11, 7*t*
 - consumption, India, 4–5
 - CVD and type 2 diabetes, 31–32
 - dancing grain, 3–4
 - description, 2
 - domesticated plant, 4
 - GI (*see* Glycemic index (GI))
 - GR studies, 28–30
 - health beneficial properties, 17–26, 18*t*
 - low cost, 3
 - nachni*, 4
 - nutritional significance, 5
 - phytonutrients/phytochemicals, 11–12
 - whole grains and cereal fiber consumption, 2–3
- Fluidized bed agglomeration
 - agglomerate diameter evolutions, 60, 61*f*
 - amorphous components, 58–59
 - growth mechanism, 61, 63*f*
 - heat transfer zone, 60
 - isothermal zone, 60
 - liquid distribution, spray zone, 59
 - low shear device, 58
 - median diameter evolutions, 60–61, 62*f*
 - particle size distribution evolutions, 60–61, 63*f*
 - spraying and drying, 58
 - spray zone, 60
 - surface reactivity, particles, 58–59
 - thermal zones, 59–60, 59*f*
 - wetting–active zone, 60
- Food intake and body weight
 - carbohydrates (*see* Carbohydrates)
 - dietary proteins (*see* Dietary proteins)
 - energy density, 152–155
 - fats, 143–149
 - meal plans, 156–162
 - teas, caffeine and pungent foods, 149–152
- Food powders
 - agglomeration (*see* Agglomeration mechanisms)
 - characterization, physicochemistry
 - process and constraints, 48, 49*f*
 - definition, 42
 - description, 42–43
 - external stress and molecular scale, 44–45
 - hydrotextural diagram, 50–57
 - microscopy, 47
 - multiscale approach, 44, 44*f*
 - NMR microimaging experiments, 48
 - particle surface reactivity, 45–46, 46*f*
 - polarity properties and physicochemical reactivity, 44–45
 - reactivity and surface properties, 44–50
 - spectroscopy techniques, 47
 - spray-drying process, 48–50
 - surface extraction techniques, 47
 - surface sorption techniques, 47
 - water activity (a_w) and glass transition (T_g) concepts, 50
- Fruits and vegetables
 - adiposity, 143
 - annual weight change, 143
 - carrots and spinach, 141
 - consumption, dried fruit, 142
 - energy density and fiber content, 140–141
 - oranges and apples, 142
 - salads, 141–142
 - satiety, 140–141
- G**
- GI. *See* Glycemic index (GI)
- Glycemic index (GI)
 - ad libitum* reduced-GL diet, 130, 131
 - area under the curve (AUC), 128–129
 - CALERIE trial, 130
 - capillary blood glucose, 30–31
 - carbohydrate quality measurement, 2–3
 - decorticated, 29
 - and DG affects, 27
 - dietary factors, 131
 - finger millet, 29–30
 - glycemic load (GL) concept, 129
 - hepatic glucose production, 129
 - high-Gi diet, 130
 - low-Gi diets, 129
 - low to high categories, 30–31
 - meta-analysis, 130

Glycemic index (GI) (*Continued*)
 protocols, 28
roti preparations, 27
 testing, finger millet preparations, 31–32
 Glycemic responses (GRs) studies, finger

millet

capillary samples, 28
 decorticated, 29
 diabetes nutritional management, 29
 disadvantages, 29–30
 and GI, 29–30
 malting and fermentation process, 28–29
 NIDDM, 28
ragi-based products, diabetic meal plan,
 30, 30*t*

H

“High satiety” (HS) plan, 159–161, 162
 Hydrotectural diagram
 gas volume, 51
 granular media and REV, 50–51
 mapping, 56–57, 57*f*
 nuclei, agglomerate and paste states, 52,
 53*f*
 path-connected space
 fluid phases, 55–56
 solid phase, 55
 rheological states, 54–55, 54*f*
 saturated states, 53–54, 54*f*
 schematization, real porous medium and
 definition, 50–51, 51*f*
 true and apparent densities, 51, 52, 52*t*
 wet granular medium, 52–53

I

In vitro studies, finger millet
 carbohydrate digestibility and glycemic
 properties, 26–27
 cooking and cooling, 27
 DG and DI, 27
 RS, 26, 27
 starch, 26

L

Laccase, 198–199
 Legumes
 breads, 122–123
 chick peas, 123

pulses, 122, 124
 soy proteins, 123–125

Lipase, 196–197

Liquid atomization modeling, DA

aerodynamic Weber number, 86–87

air-liquid velocity, 86–87

bifluid nozzles, 88

different regimes, jet breakage, 87

droplet size, 89–91, 90*f*

mean size droplets, 86

mono- and bifluid nozzles, 86–87, 88, 89*f*

nozzle configuration, 87

physicochemical properties, 87, 88

process relationship, 88, 89

wet agglomeration process, 85–86

Low shear mixer agglomeration

bed surface, 69

fractal dimension, 71–72

granular medium, 69

heuristic model, 61, 72

hydrotectural diagram, 62–63, 65*f*

mechanical mixing conditions, 69

paste transition, 72–73, 73*f*

physical/biological systems, 72

polydispersed particle population, 69

population balance, structure, 63–64, 65*f*

porous structure, 71–72

potential barrier and grain size, 69–70

saturation degree, water content,
 69–71, 70*f*

shear stresses, blades, 69

size distribution curves and median

diameter, water content, 62–63, 64*f*

solid volume fraction and diameter,

71–72, 71*f*

wetting–mixing stage, 61–62

wetting/nucleation, 64–68

M

Malt flour, 15

Malting, 15

Meal plans

fiber content range, 156–159

“high satiety” (HS) plan, 159–161, 162

individual foods, 156–159, 156*t*

1200 kcal/day, 156–159, 158*t*

1600 kcal/day, 156–159, 158*t*

2000 kcal/day, 156–159, 160*t*

- sample menu, American diet, 159–161, 161*t*
- Micronutrients, 7*t*, 10–11
- Milling, 13
- N**
- National Nutrition Monitoring Bureau (NNMB), 4
- Near infrared (NIR) spectroscopy, 80–81, 82*f*
- NNMB. *See* National Nutrition Monitoring Bureau (NNMB)
- Nutrient composition, finger millet
 - carbohydrates, 6, 7*t*
 - fat, 7*t*, 10
 - micronutrients, 7*t*, 10–11
 - proteins, 6–10, 7*t*
- Nuts
 - almond supplementation, 126
 - consumption, 126–127
 - description, 125
 - peanuts, 126, 127
 - physical properties, 125
 - resting energy expenditure (REE), 126
 - walnuts, 125–126
- O**
- Obesity
 - description, 106–107
 - and diabetes, 27, 30
 - health hazards, 106–107
 - lifestyle modification, 107
 - longevity, 106
 - prevalence, 106
 - weight-loss dietary regimen, 107–108
- P**
- Paecilomyces variotii*, 202
- Paste transition
 - agglomerate, 72–73, 73*f*
 - median diameter growth and population balance, 72–73
 - power law exponent values, 73
- Peroxidase, 200
- Phytonutrients/phytochemicals, finger millet
 - decortication, 13–15
 - different processing techniques, 12, 13*f*
 - malting, 15
 - milling, 13
 - nutrient composition, 12, 14*t*
 - phenolic compounds, 11–12
 - popping, 15–17
 - traditional foods, 12, 12*f*
- Plant cell cultures
 - advantages, 206
 - bioconversion, polyphenols, 206, 206*t*
 - Capsicum frutescens*, 207
 - Citrus paradisi*, 207–208
 - Eucalyptus perminiana*, 207
 - glycosylation, 205–206
- Polyphenols
 - biotransformation (*see* Biotransformation, polyphenols)
 - classification, 185–186
 - description, 184
 - scavenging free radicals, 184
 - structural classification, 186, 190*t*
 - substantial daily intake, 184–185
- Popping
 - air popper device, 15–16
 - dietary fiber, 15–16
 - EDTA, 16–17
 - fermented beverages, 16–17
 - flavor and aroma, 15–16
 - fortification, 16–17
 - ready-to-eat products, 15–16
 - whole-grain product rich, 15–16
- Powder flows and stress transmission, agglomerators
 - blade and intermediate scale, 79
 - characterization elements, powder bed, 77–79
 - displacement fields and granular stresses, 77–79
 - drag forces and dissipated energy, 77–79
 - dry flowing regimes and wet-controlled, 75–76
 - frictional regime, 77–79
 - granular medium, 79
 - growth models, 76
 - intruder motion induces and particle motions, 77–79
 - mixer agglomerators and powder behavior, 76

Powder flows and stress transmission,
 agglomerators (*Continued*)
 particle impact velocity and blade tip,
 76–77
 PIV techniques, 76–77
 potential barrier and velocity gradient, 79
 quantification, granular stresses and
 displacement fields, 77–79
 semolina, vertical rise of blade, 77–79, 78f
 shear and velocities, powder bed scale, 79
 stress
 patterns, 75–76
 transmission, 76, 79
 unidirectional blade and powder bed,
 77–79
 velocity and trajectory fields, 76

Protein-rich foods
 eggs, 119–120
 essential amino acids (EAA), 118–119
 fish, 119
 meat products, 120–122
 protein synthesis, 119

R

Random close packing (RCP), 55
 RCP. *See* Random close packing (RCP)
 Representative elementary volume (REV),
 50–51
 Resistant starch (RS)
 cooking and cooling, 27
 isolation, 27
 puffing, 26
 REV. *See* Representative elementary
 volume (REV)
 RS. *See* Resistant starch (RS)

S

Satiety. *See* Appetite and satiety
 SCM. *See* Seed coat matter (SCM)
 Seed coat matter (SCM), 13–15, 31–32
 Sensors, agglomeration
 blade torque/motor power
 consumption, 80
 energy consumption measurements, 80
in situ, 79–80
 NIR spectroscopy, 80–81, 82f

physical and hydrotectural changes,
 79–80
 water addition level, 80, 81f
Streptomyces sp., 205

T

Tannase, 197–198
 Teas, caffeine and pungent foods
 c-AMP, 149–150
 capsaicin, 150–152
 EGCG-caffeine mixture, 150
 energy expenditure, 149
 methylxanthines, 150
 Transferases, 200

W

Wet agglomeration
 description, 74–75
 dimensional analysis (DA)
 fine powder recycling, 94
 food engineering tools, 84
 food materials, 83–84
 food process, 85
 key process parameters, 94
 liquid atomization mechanism, 85–86
 minor drying pilot, 91, 92f, 94
 powder characteristics, 83–84
 raw material behaviors, 84–85
 spray-drying, 91
 stochastic methods, 83
 system parameters, 91–94, 93t
 target parameter, 94
 drying stage and unit operations, 74–75
 equipment classification, 74–75
 mechanical mixing, 75
 pneumatic mixing process, 75
 Wetting/nucleation
 agglomeration, durum wheat semolina,
 64–66, 66f
 capillary bridge-building, 64–66
 drop and grain sizes, 68
 hydration, 68
 physicochemical properties, binders, 67,
 68t
 semolina, 67
 surface tension and viscosity, 66–67, 67f

INDEX

Note: Page numbers followed by "f" indicate figures, and "t" indicate tables.

A

Amino acids

glycemia

- animal-to-plant protein, 26
- blood glucose, 23
- chocolate milk, 25
- cottage cheese, 23–24
- egg white protein, 22–23
- gluconeogenesis, 24–25
- glucose and insulin responses, 25–26
- plasma glucose, 24
- source and content, 26–27
- urinary glucose, 22

insulin secretion

- alanine, 12–13
- arginine, 13
- carbohydrate, 20
- cysteine and selenocysteine, 18
- GDH, 15–16
- GIP, 20–21
- glucose homeostasis, 12
- glutamine, 18–20
- glycine, 13–14
- isoleucine, 14–15
- leucine, 15–16, 17–18
- lysine, 14
- phenylalanine, 16–17
- plasma membrane, 12
- proline, 17
- valine, 17

α -Amylase inhibitors

- chemical structures, 122, 123f
- curcumin, 124
- dicafeoyl quinic acid isomers, 124
- endo α -(1,4) glycosidic linkages, 122
- HPA and PPA, 122
- mono- and disubstituted caffeoylquinic acids, 124
- myricetin-3-O-rhamnoside and europetin-3-O-rhamnoside, 122–124
- protein-based ones and secondary metabolites, 122

tiliroside, 124

turbidity assay, 122–124

B

Barley, cereal-based ingredients

- blood glucose and HbA1c levels, 193–194
- 2 g β -glucan test meals, 194
- β -glucan, 193–194
- glucose tolerance and insulin sensitivity, 194–195
- glycemic response, food items, 194–195
- Himalaya 292, 194–195
- in vitro* starch digestibility, chapattis, 196–197
- lactic acid, 196
- postprandial glycemic response, 196–197
- prevention, diabetes, 193–194
- randomized controlled trial, 196–197
- rice, high-GI food, 194
- whole-day glucose tolerance, 194

Basal metabolic rate (BMR), 73

Blood glucose

- cereal-based ingredients, 193–202
- and chronic diseases (*see* Chronic diseases and blood glucose)
- description, 182
- diabetes-related complications, 182–183, 183t
- and dietary fiber (*see* Dietary fiber and blood glucose)
- effect, protein and fat (*see* Protein and fat, blood glucose)
- factors, GI of food (*see* Glycemic index (GI))
- fruit-based ingredients, 202–207
- legume-based ingredients, 210–213
- postprandial hyperglycemia, 183
- prediabetes, 182
- role, food (*see* Food, blood glucose)
- spices (*see* Spices, blood glucose)
- sugars and sugar alcohols, 216
- types, diabetes, 182

Blood glucose homeostasis
 concentration, 3–4
 description, 3
 dietary proteins and amino acids, 5–6
 hyperglycemia, 3
 kidney and liver, 4–5
 role, 5
 skeletal muscle and adipose sugar, 5
 BMI. *See* Body mass index (BMI)
 BMR. *See* Basal metabolic rate (BMR)
 Body mass index (BMI), 54

C

Carbohydrates and proteins, glycemia
 gelatin, 29–30
 glucagon, 27
 glucose and egg white, 27–28
 glycemic control, 29
 hydrolysate, 28–29
 insulin secretion, 27
 noninsulin-dependent diabetes, 30–31
 plasma glucose, 31
 serum insulin, 30
 Cereal-based ingredients
 barley, 193–197
 description, 193
 insoluble fibers, 193
 oats, 197–200
 rye, 200–202
 starchy foods, brown rice, 193
 Chalcones, 119–120, 119*f*

Chronic diseases and blood glucose
 ad libitum low-GI diets, 188–189
 advanced CHD, 186
 counter-regulatory hormones, 186–187
 effect of GI, health outcomes, 185–186
 hypoenergetic reduced-fat diet, 188
 hypoglycemia, 187–188
 low-GI diets, 186–187
 NEFA levels, 186–187
 reduction, gastric emptying, 188
 satiety, 187–188
 weight loss/reduction, 187–188

D

DB technique. *See* Douglas bag (DB)
 technique
 Dietary fiber and blood glucose

food characteristics, 191
 in food industry, 191–192
 food ingredients, 192–193
 gastrointestinal absorption, cholesterol,
 191
 glucomannan in Konjac, 190–191
 gum Arabic, 191–192
 physicochemical properties, 190–191
 plantago psyllium mucilage, 191–192
 viscosity properties, soluble dietary fiber,
 191
 Digesta rheology
 changes, rheological properties,
 161, 162*f*
 gastric function, 161–163
 inhibitory action, 163
 ionic interactions, starch and gum, 163
 presence of gums, 161–163
 solution viscosity, 161–163
 viscosity, cooked potatoes, 161
 Douglas bag (DB) technique, 73–74

E

Encapsulation technology, GI
 acarbose, 126–127
 anthocyanins and proanthocyanidins,
 126–127
 description, 125
 ellagitannins, 126
 functional food product formulation,
 125
 α -glucosidase and α -amylase inhibitors,
 126
 olive leaf extracts, 126
 Energy cost, children and adolescents
 BMR, 73
 compilation, physical activities,
 74, 75*t*
 DB technique, 73–74
 laboratory environments, 81
 PARs, 73
 physical activities, 81
 SWA, 80
 TEE, 72–73
 Energy expenditure (EE)
 energy intake, 53
 estimation, 74–80
 obesity, 53

- SWA, 80
TEE, 72–73
- F**
- Flavonoids, polyphenols
chemical structures, compounds 1–14,
114, 114f
isoprenylated flavanes and kazinol A. B.
116
myricetin-3-*O*-rhamnoside and
europetin-3-*O*-rhamnoside,
115–116
nongallated catechins, 114
3,5,7,3',4'-pentamethoxyflavone, 115
prenylated quercetin derivatives, 116
quercetin and isorhamnetin, 115–116
saponarin, 115
tea drink, 114
5,7,3',4'-tetramethoxyflavone, 115
5,7,4'-trimethoxyflavone, 115
vitexin and isovitexin, 115
- Food, blood glucose
carbohydrates, 183–184
defined. GI, 184
GI and GL values, 184–185
metabolic diseases, 184–185
physiological characteristics, 185
- Food matrix
addition, toppings/fillings, 163–164
alginate, 160–161
 α -amylases inhibitors, 166
commercial starch-blocking products,
166–167
compositions, 163–164
dextrin subpopulations, 165–166
dietary fiber, 167
effect, guar gum (0.5%) addition,
158–159, 159f
enzymatic digestibility, starch and
glycemic response, 157–158
enzymatic resistance, pure amylose and
lipid complexes, 165–166
extrusion cooking, 167
fatty acids complexes, 165
galactomannan-based gums, 157–158
gastric response, meal viscosity, 160–161
gluten to gluten-free flour, 163–164
hydrocolloids, 158–159
hydroxyl groups, glucose residues, 165
in vitro and *in vivo* digestibility, 160
legume crops, 166–167
phytic acid, 167
pig meals, 160
protein fractions, 163–164
reducing agents, 163–164
rheology, digesta (*see* Digesta rheology)
thermal processing methods, 167
viscous fiber, 160
water availability, 159–160
- Food microstructure and starch digestion
cell wall polymers, 140
change, cooking, 140–141
characteristics, 140–141
cultivar type, physicochemical
composition and postharvest storage,
140–141
in vitro and *in vivo*, 141
living cotyledon cells, 141
navy beans (*see* Navy beans, food
microstructure)
potato (*see* Potato, food microstructure)
raw foods, 140
- Food processing, starch digestion
cereals, 170–171
dispersed polymers, 171–172
effect, 168, 169t
extrusion cooking, 168–170
gelatinization, 171–172
irradiation and degradation, 171
microwave heating, 171
RDS, 170–171
reduction, cohesiveness, 170–171
retrogradation properties, 171–172
structure and nutritional characteristics, 168
traditional and conventional processing
methods, 168–170
in tubers and legumes, 168
water penetration and α -amylase action,
168
- Fruit-based ingredients
bioflavonoid extraction, sugar cane,
206–207
blood glucose control, healthy and type 2
diabetes subjects, 207, 207t
cranberries, 206
extracts of berries, 202–204

Fruit-based ingredients (*Continued*)

- GI, 202–204, 206
- grape products, 204–206
- healthy and diabetic subjects, 202
- white bread's glycemic response, 204–206

G

- Gastric inhibitory peptide (GIP), 20–21
- GDH. *See* Glutamate dehydrogenase (GDH)
- GI. *See* Glycemic index (GI)
- GIP. *See* Gastric inhibitory peptide (GIP)
- Global School-based Student Health Survey (GSHS), 56–57
- Glucagon secretion, 21–22
- α -Glucosidase inhibitors
 - chalcones, 119–120, 119f
 - glycomimetics, 112
 - polyacetylenes, 120, 120f
 - polyphenols (*see* Polyphenols)
 - stilbenes, 121–122, 121f
 - terpenoids (*see* Terpenoids)
- Glutamate dehydrogenase (GDH), 15–16
- Glycemia
 - alanine, 32
 - amino acids (*see* Amino acids)
 - arginine, 33
 - gelatin, 32–33
 - gluconeogenic amino acids, 31–32
 - glutamine, 35
 - insulin and glucagon, 32
 - isoleucine, 34
 - leucine, 33–34
 - lysine, 34–35
 - phenylalanine, 35
 - plasma glucagon, 35–36
 - proline, 35
 - proteins and carbohydrates
 - (*see* Carbohydrates and proteins, glycemia)
- Glycemic index (GI)
 - active compounds, 125
 - cereal grains, 189–190
 - diabetes patients, 125
 - encapsulation technology, GI, 125–127
 - factors, response to foods, 189–190, 189t
 - hyperglycemia, 125
 - response, cooking procedures, 190
 - starchy foods (*see* Starchy foods, GI)

- Glycomimetics, 112
- GSHS. *See* Global School-based Student Health Survey (GSHS)

H

- HBSC. *See* Health Behavior in School-aged Children (HBSC)
- Health Behavior in School-aged Children (HBSC), 58–59
- HPA. *See* Human pancreatic α -amylase (HPA)
- Human pancreatic α -amylase (HPA)
 - Curcuma longa*, 124
 - description, 122
 - isookanin, *Bidens bipinnata*, 122
 - and PPA, 122

I

- Insulin secretion
 - amino acids (*see* Amino acids)
 - proteins
 - amino acids, 9
 - beef meal, 10–11
 - carbohydrate meals, 10–11
 - incretin hormones, 11
 - pancreatic β -cells, 9
 - plasma amino acid levels, 9–10
- In vitro* starch digestibility
 - navy beans
 - SEMs, gastric and intestinal digestion, 155–157, 156f
 - simulated intestinal conditions, 155
 - starch granules, cotyledon cells, 154–155, 154f
 - starch hydrolysis (%), 154–155, 155f
 - potato
 - CLSM images, real-time small intestinal digestion, 150–151, 150f
 - components, 149–150
 - lower levels, hydrolysis, 149–150
 - SEMs, Agria cooked potatoes, 151–153, 151f, 152f
 - small intestinal digestion, 148–149
 - starch hydrolysis (%), 148–149, 149f
- L**
 - Legume-based ingredients
 - “atta mix” flour, 211

- leguminous and nonleguminous foods, 211–212
- low-GI effect, pulses, 212
- molasses and sugar, 212–213
- pasta products, 210–211
- postprandial glycemic response, 210–211
- types, beans, 211–212
- white kidney bean extract, phase 2, 213
- M**
- Methyl hydroxychalcone polymer (MHCP)
- active ingredient, cinnamon, 208
- polyphenol compound, 208
- MHCP. *See* Methyl hydroxychalcone polymer (MHCP)
- N**
- Navy beans, food microstructure
- cell wall xyloglucans, 153–154
- cooked, 153–154, 153*f*
- cotyledon cells, 153–154, 153*f*
- raw, 153–154, 153*f*
- starch digestion *in vitro* and digesta
 (*see In vitro* starch digestibility)
- NEFA. *See* Nonesterified fatty acid (NEFA)
- Nonesterified fatty acid (NEFA)
- adipose tissue, 186–187
- high-insulin response, 187–188
- postprandial rebounds, 186–187
- O**
- Oats, cereal-based ingredients
- bran muffins, 199
- functional food products, 198–199
- β-glucan and glucose AUC, 198–199
- glycemic response, 197–198
- healthy subjects, 199
- high fat content, 198
- intact kernels, 197–198
- size, test meals, 199–200
- starch gelatinization, food disruption, 197–198
- varieties, steel cut and rolled, 200
- Obesity
- childhood and adolescence, 51
- description, 50
- EE, 51–52, 53
- and overweight, 53–54
- PA, 52
- PF, 52–53
- prevalence rates, 51
- tropical countries, 50–51
- Overweight
- adolescents, 57–58, 57*f*
- BMI, 54
- classifications, 54
- description, 53–54
- factors, 55–56
- GSHS, 56–57
- HBSC, 58–59
- health consequences, 54–55
- prevalence, 59, 60*t*
- P**
- PA. *See* Physical activity (PA)
- PAR. *See* Physical activity ratio (PAR)
- PF. *See* Physical fitness (PF)
- Physical activity (PA)
- adolescents, 69–70
- adolescents percentage, 62, 63*f*
- Cayman Islands, 63–65
- energy cost
- body mass, 87–88
- EE, 87
- obesity, 88
- TDEE, 86–87
- walking and running, 88
- fitness components, 70
- and GSHS, 65
- and HBSC, 65
- indicators, 69–70
- male and female, 66–67
- and obesity
- adolescents, 84–85
- BMI, 83, 84*t*
- description, 82
- GSHS, 85
- sedentary behavior, 82–83
- sedentary, 63–65
- Physical activity ratio (PAR), 73
- Physical fitness (PF)
- Asian countries, 71
- children and adolescents, 71
- description, 68–69
- health-related, 69
- and obesity, 85–86
- and PA, 69–71

- Polyacetylenes, 120, 120*f*
- Polyphenols
- 1,7-bis (4-hydroxyphenyl)heptane-3, 5-diol, 117
 - bromophenol and bis(2,3-dibromo-4, 5-dihydroxybenzyl) ether, 117
 - chemical structures, compounds 15-25, 116, 117*f*
 - cis-N-p*-coumaroyltyramin, 117
 - coumestrol, dolichandroside A and aloe saponarin II, 116
 - flavonoids, 114-116
 - hispidin, hispolon and inotilone, 116
 - 6-hydroxy-2,4,7-trimethoxy-phenanthrene, 117
 - tannins, 112-114
 - trans-N-p*-coumaroyltyramine, 117
- Porcine pancreas α -amylase (PPA)
- endo-type amylase, 122
 - in vitro* digestion measurement, 122
 - noncompetitive inhibitory mechanism, 122-124
- Potato, food microstructure
- Agria potato cultivar, cooked tuber parenchyma, 142, 144*f*
 - CLSMs, 142, 144*f*
 - cooked tuber parenchyma cells, TEM, 145, 147*f*
 - microscopic and rheological techniques, 142
 - Moonlight, Agria, 142-145, 143*f*
 - Nadine, Moonlight, Red Rascal, 142, 143*f*
 - raw and cooked tuber parenchyma, 142, 143*f*
 - raw, SEM micrographs, 142, 144*f*
 - starch digestion *in vitro* and digesta (see *In vitro* starch digestibility)
 - swelling and gelatinization, starch granule, 142-145
 - TEM, raw tuber parenchyma cells, 145, 146*f*
- PPA. See Porcine pancreas α -amylase (PPA)
- Protein and fat, blood glucose
- addition, vinegar to white bread, 216
 - almond, 214
 - bread, 215
 - fermentation process, 214
 - GI values, 216
 - insulinotropic effect, 215
 - lower glycemic response, 213-214
 - milk products, 213
 - sourdough fermentation process, 215
 - starchy foods, 214-215
- Proteins
- amino acid composition, 8*t*, 9
 - blood glucose homeostasis, 3-6
 - consumption, 2-3
 - description, 2
 - glucagon secretion, 21-22
 - glucose metabolism, 3
 - glycemia, 22-36
 - insulin secretion, 9-11
 - intake, Europe and North America, 2
 - vegetable sources, 6
- R**
- Rye, cereal-based ingredients
- blood glucose control, overweight and type 2 diabetes subjects, 201-202, 205*t*
 - blood glucose, healthy subjects, 201-202, 203*t*
 - capillary and venous blood sampling methods, 201-202
 - fiber contents, 200-201
 - kernels, 201
 - low-GI values, 201-202
 - metabolic syndrome, adults, 200-201
 - types, 200-201
- S**
- SenseWear[®] Pro2 Armband (SWA), 80
- Spices, blood glucose
- cinnamon, MHCP, 208
 - fenugreek seeds, 209
 - 3 g cinnamon consumption, healthy patients, 209
 - GI, 208
 - green tea consumption, 209-210
 - hypoglycemic and hypoinsulinemic effects, 208
 - and legumes, healthy and type 2 diabetes subjects, 209-210, 211*t*
 - stimulation, insulin receptor, 209
 - use, herbal teas, 208
- Starch digestion
- composition, food matrix, 163-167

- description, 138
 - and food matrix (*see* Food matrix)
 - food processing (*see* Food processing, starch digestion)
 - lipids and proteins, 138–139
 - mammalian enzymes, 139–140
 - microstructure, natural foods (*see* Food microstructure and starch digestion)
 - polysaccharide-based gums, 138–139
 - processing, post-processing storage and composition, 138–139
 - salivary α -amylase, 139–140
 - SDS and RDS, 138
- S**
- S**tarch hydrolases inhibitors
- α -amylase (*see* α -Amylase inhibitors)
 - chromogenic molecular probes, 104–112
 - diabetes mellitus, 104
 - DNSA assay, 104–112
 - from edible plants, 104
 - enzymes catalyzation, 104
 - α -glucosidase inhibitors, botanical sources (*see* α -Glucosidase inhibitors)
 - low GI (*see* Glycemic index (GI))
 - microbial and mammal amylases, 112
 - from natural plants, 104, 105*t*
- S**tarchy foods, GI
- antidiabetic compounds, 127
 - buckwheat, 129
 - cinnamon, 127–128
 - fenugreek, 128–129
 - green tea, 129–130
 - raspberry and blueberry, 129
 - sweet potato, 127
- Stilbenes, 121–122, 121*f*
- Sugars and sugar alcohols, 216
- SWA. *See* SenseWear[®] Pro₂ Armband (SWA)
- T**
- T**annins, polyphenols
- chemical structures, hydrolyzable and condensed, 112–113, 113*f*
 - natural products, 112–113
 - oligomeric proanthocyanidins, 113–114
 - yeast α -glucosidase, 112–113
- TEE. *See* Total energy expenditure (TEE)
- Terpenoids
- arjunolic and asiatic acid, 119
 - chemical structures, compounds 26–36, 117–118, 118*f*
 - corosolic acid, 119
 - Lagerstroemia speciosa*, 119
 - Momordica charantia*, 117–118
 - momordicoside M and momordicoside A, 117–118
 - oleanolic, maslinic and 23-hydroxyursolic acids, 119
 - pistagremic acid, 118–119
 - 2,3-*seco*-20(29)-Lupene-2,3-dioic acid, 119
 - ursolic acid, 118–119
- Total energy expenditure (TEE) and BMR, 73
- and EE, 72–73
- V**
- V**iscosity
- of cooked potatoes, 161
 - dietary fiber, 167
 - enzymatic digestibility, starch and glycemic response, 157–158
 - food matrix, 138–139, 149–150
 - gastric response, 160–161
 - ionic interactions, starch and gum, 163
 - physiological processes, 160–161
 - pig meals, 160
 - soluble dietary fiber, 157–158
 - solution, 161–163
- W**
- Whey proteins, 20–21
- X**
- Xanthoangelol inhibitors, 105*t*, 119–120
- Y**
- Y**east
- α -glucosidase inhibitor with IC₅₀ values, 114
 - quercetin and isorhamnetin, 115–116
 - tannins isolation, 112–113
- Z**
- Zingiberaceae family (*Kaempferia parviflora*), 115

- SPs. *See* Sulfated polysaccharides
- Sterols
 description, 192
 health benefit activities
 antibacterial, 193–194
 anticancer, 194–195
 antidiabetic, 195
 antihypercholesterolemic, 196
 antihypertensive, 195–196
 antioxidant, 194
 marine algae, 192–193
 plant, 192
- Sulfated polymannurogluronate (SPMG),
 260–261
- Sulfated polysaccharides (SPs)
 biological activities, 393
 carrageenan, 237, 238, 392–393
 classification, 237
 fucoidan, 237, 238, 392–393
 medicinal benefits and biological
 activities
 anticancer effect, 397
 antioxidant effect, 394–395
 antiviral effect, 395–396
 immunomodulating effect, 396–397
 novel extraction and separation
 techniques, 393
 polymers, 392–393
 ulvan, 237, 238, 392–393

T

- Thrombin time (TT), 236–237
- TIMPs. *See* Tissue inhibitors of
 metalloproteinases

- Tissue inhibitors of metalloproteinases
 (TIMPs), 130
- Tororokombu (TK)
 description, 202
 and HFD, 202–203
 and NSK, inhibitory activities
 alginate, 203, 204
 alkaline-soluble fraction (AS), 203, 204
 antiobesity effects, 202–203
 pancreatic lipase activity, 203
- Transforming growth factor
 β (TGF- β), 430
- TT. *See* Thrombin time

U

- Ulvens
 applications, 62
 chemical structure, 61
 description, 218

V

- Very low density lipoprotein (VLDL), 341

W

- WAT. *See* White adipose tissue
- White adipose tissue (WAT), 119–120
- Wnt signaling components
 cell proliferation and division, 182
 expression measurement, 184
 IEC-6 cells, 184
 time-course experiment, 182